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Abstract 
 
Deciphering genetic determinants of tumorigenesis is the greatest challenge and promise 
of the present-day era of biomedical research. As extensive tumor genome characterization 
efforts of the past decade had revealed, tumor genomes harbor multiple point mutations and gene 
copy number alterations. This exquisite complexity brings forth the challenge of distinguishing 
numerous incidental alterations from those that are functionally relevant to tumorigenesis. 
During the past decade, functional genetic screens have shown their utility in identifying genetic 
changes that functionally contribute to tumor-specific hallmarks and thus hold a great potential 
for identifying promising new targets for the rational design of successful anticancer therapies. 
A key hallmark of cancer cells is their ability to escape signals that govern homeostasis 
of normal tissue. In normal epithelia, growth and survival of cells is dictated by their physical 
anchorage to the extracellular matrix, and disruption of proper cell-matrix anchorage triggers cell 
death. Tumors of epithelial origin develop ways to subvert anoikis signals, which enables both 
their uncontrollable expansion at the primary site as well as metastatic colonization of distant 
organs. Understanding the genetic determinants of matrix-independent growth of cancer cells is a 
promising approach to identify potent and selective anticancer targets. 
In the work presented in this dissertation, we use an unbiased functional genetic 
screening approach to test a large set of eight thousand human genes to identify those that are 
involved in inducing and maintaining resistance of mammary epithelial cells to matrix 
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detachment-induced cell death. We show that a cell adhesion molecule PVRL4 promotes cell 
survival in the absence of matrix anchorage in normal epithelial cells and in cancer cells. Our 
work reveals that PVRL4 promotes anchorage-independent growth by promoting cell-to-cell 
attachment and matrix-independent c-Src activation. PVRL4 is focally and frequently amplified 
in several types of solid tumors. Growth of orthotopically implanted tumors in vivo is inhibited 
by blocking PVRL4-driven cell-to-cell attachment with monoclonal antibodies, demonstrating a 
novel strategy for targeted therapy of cancer. 
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Chapter I: Introduction 
Part 1: The blueprint of an enemy 
Cancer is a unique type of a genetic disease 
Cancer is a complex and heterogeneous group of proliferative abnormalities which is 
capable of striking virtually any tissue. The uncontrollable cellular expansion characteristic for 
cancer occurs in disregard of those mechanisms which normally regiment tissue proliferation, 
attrition and differentiation. Altogether constituting the malignant phenotype, the hallmarks of 
cancer are driven by numerous genetic and epigenetic alterations carried by cancer cells. The 
critical role that these alterations play in tumor initiation and persistence warrants the 
classification of cancer as a genetic disease. 
The unique complexity of cancer as a genetic disease is that it is fueled by a combination 
of somatic alterations which are acquired in a sequential manner over the long course of tumor 
genesis. This combinatorial nature of cancer’s genetic determinants distinguishes it from the 
other known genetic diseases. Indeed, a genetic disease typically arises as a result of a single 
genetic aberration. Such aberration may be conveyed by a germline genetic alteration (for 
example, mutation of CFTR gene in cystic fibrosis [1]), or a somatic genetic alteration (for 
example, mutation of GNAS1 gene in McCune-Albright syndrome [2]). Furthermore, genetic 
aberration responsible for the disease pathology phenotype may affect not one gene but a 
contiguous stretch of genes - such as in case of Prader-Willi syndrome [3] or various trisomy 
disorders, e.g. Down syndrome [4].  
The pattern of genetic alterations seen in cancer is orders of magnitude more complex in 
that not a single alteration, but a combination of alterations scattered throughout the genome of 
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a somatic cell is causatively involved in tumorigenesis. These alterations include several types 
such as mutations, gene copy number aberrations and chromosomal translocations, and are being 
acquired by affected cells over the long course of tumor genesis, punctuated by bursts of clonal 
expansion as a consequence to the acquisition of a genetic alteration that incites unchecked 
survival and proliferation. Alterations to a cell’s genome that are deemed responsible for 
promoting malignant behavior are referred to as driver alterations or drivers. Driver alterations 
are further subdivided into two major classes with regard to their effect on gene function: 
alterations that result in a gain-of-function phenotype, represented by activation of oncogenes, 
and those that trigger a loss-of-function, represented by inactivation of tumor suppressors. 
A do-it-yourself manual or a Voynich manuscript? 
The understanding that acquired mutations are the driving force of tumorigenesis 
predates the era of molecular biology. The presence of profoundly abnormal genetic material 
in form of aberrant mitotic figures and of individual chromosomal breakages was first noted and 
characterized by Theodor Boveri in 1914 [5], who was first to suggest that genetic abnormalities 
are the driving force of tumorigenesis first to predict the clinical utility of DNA-damaging 
treatments in eradicating cancer. In 1960, the discovery that two patients with chronic 
myelogenous leukemia (CML) shared the identical, abnormally small chromosome - became 
known as a Philadelphia chromosome  - was the first demonstration that malignancies from 
different individuals can share, and potentially be driven by, the same genetic aberration [6]. 
Further supporting a causative link between mutagenesis and tumorigenesis, a wealth of 
evidence linking the exposure to mutagenic agents to increased cancer incidence has been 
accumulated by the 1950s. Despite the observed correlation, it was nonetheless clear that 
mutagenesis by itself could not be equated to carcinogenesis. As has been first demonstrated by 
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Katsusabiro Yamagiva in 1915, repeated application of coal tar to ears of rabbits caused 
squamous cell carcinoma with a 100% penetrance [7]. At the same time, a single event of an 
exposure to a strong mutagen failed to initiate carcinogenesis in animals no matter the dose [8]. 
Similarly, there was a noted delay between the carcinogen exposure and onset of cancer in 
humans, such as a 5-year delay in the onset of leukemias and a 10-year delay in the onset of solid 
tumors seen in the aftermath of atomic bombings of Hiroshima and Nagasaki [9].  
Even in cases that could not be clearly traced to carcinogen exposure, a marked increase 
of cancer incidence with age was observed. In 1956, Carl O. Nordling estimated from the rate of 
increase in cancer diagnoses with age that it may require, on average, seven mutations in order 
for normal cell to develop into a malignant tumor [10]. More recent estimates suggested that for 
a solid tumor, five to ten genetic ‘hits’ may be needed in order for a normal cell to progress to 
clinically detectable cancer [11]. In agreement with these estimates, a pattern of a progression 
through a series of four to six, histopathologically distinct, stages has been documented - first, 
for colorectal carcinoma [12] and later, for other tumor types. Taken together, epidemiology and 
histopathology of human cancers provided further support to a multistep theory of tumor 
progression. 
Supported by sound correlative evidence, the idea of cancer as a genetic disease, 
however, lacked veritable experimental proof. The discovery of first viral oncogene, v-src from 
Rous sarcoma virus (RSV), followed by its cellular analog, c-src, had all but revolutionized the 
understanding of tumorigenesis. For decades, the RSV tumor isolate was known of turning 
normal chicken fibroblasts into cells with characteristic sarcomatous morphology and behavior, 
thus inducing a readily identifiable phenotypic change, aptly named transformation [13]. In 
1976, aided by the discovery of reverse transcriptase and development of subtractive 
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hybridization technique, the cDNA copies of RSV-encoded sequences responsible for 
transforming normal fibroblasts into sarcoma-like cells has been, unexpectedly, found to 
hybridize with the normal genomic DNA of several bird species [14]. As Peter Vogt reminisces, 
the publication describing the finding of a human gene inside a viral genome has been, at first, 
ridiculed by the research community [15] – and yet soon the cancer-inducing power of other 
tumor viruses was similarly found to be attributed to sequences that were ‘borrowed’ from the 
genomes of their respective hosts.  Up to a 40 other viral oncogenes as well as their cellular 
counterparts were discovered from a variety of transmissible avian and rodent tumors [16, 17], as 
well as through transfection of genomic DNA of human tumors of non-viral genesis [18, 19]. 
Taken together, these discoveries provided strong empirical proof of not only cancers harboring 
aberrant versions of human genes, but also that non-cancerous cells can become transformed by 
introducing such aberrant genes exogenously. 
Importantly, introduction of a single oncogene, such as Ras, led to transformation of 
immortalized fibroblasts, such as the NIH-3T3 line, but insufficient for transformation of 
primary cells [20], whereas a combination of two oncogenic events, namely, Ras and Myc, 
readily transformed primary embryo fibroblasts [21]. Similarly, in genetically engineered mouse 
models of cancer, germline expression of Ras only rarely gave rise to tumors, but did so with a 
markedly increased penetrance when combined with Myc [22]. Aided by the development of 
targeted gene deletion technology, a variety of mouse models of tumorigenesis have been created 
(reviewed in [23]). Importantly, the timing of tumor onset, clonality of tumors as well as 
recapitulation of a multistep character of cancer progression indicates that for a tumor to form, 
sporadic acquisition of extra genetic perturbations is necessary. 
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In addition to oncogene discovery via fibroblast transformation assay, methods of 
cytogenetic analysis and comparative genomic hybridization were instrumental for identification 
of recurrent genetic deletions, amplifications and translocations in human tumors. In particular, 
profiling of allelic deletions in tumors and adjacent normal tissues via restriction fragment length 
polymorphism analysis has been instrumental for the discovery of frequent losses on 
chromosomes 5, 17 and 18 in colorectal cancer, paving the way to the discovery of tumor 
suppressors APC, p53 and DCC, respectively [24]. Furthermore, implementation of a PCR-based 
representational difference analysis assay made possible cloning of key tumor suppressors PTEN 
[25, 26] and BRCA2 [27, 28]. In 2004, a census of cancer genes has been compiled, into which 
291 genes with casual implications in tumorigenesis have been included [29].  
Two events prompted the explosion of knowledge about genomic alterations harbored by 
tumors: the completion of the human genome sequence in 2001 [30, 31] and technological 
advances in microarray hybridization and DNA sequencing, the latter including the development 
of automated Sanger sequencing, and more recently, invention of massively parallel (“next-
generation”) sequencing technology. With the first studies reporting on the systematic exome 
resequencing and studies performing high-resolution copy number variation analyses of tumor 
genomes allowed appreciating the extent of the alterations suffered by individual tumor 
genomes. 
The data from cancer genome analyses has revealed that the load of genomic alterations 
carried by tumors is strikingly complex. In particular, numbers of somatic substitutions ranged 
from 1,000 to 10,000 per tumor. The somatic substitution count in those types of cancers that 
arise as a result of mutagen exposure, such as melanoma or smoking-related lung cancer, is an 
order of magnitude higher, reaching up to 100,000 substitutions [32]. Furthermore, catalogues of 
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tumor-specific copy number alterations reveal extensive amounts of deletions and amplifications 
of chromosomal regions of varying lengths. For example, across recently characterized lung 
cancer genomes, 26 out of 39 autosomal arms have been affected by large-scale copy number 
gains or losses, but only 6 out of 31 copy number alterations that were recurrently identified had 
genes in them that were known to be involved in driving tumorigenesis [33].  
It is conceivable that the vast majority of genes altered in cancers likely bear no 
consequence on tumorigenesis as they are merely a byproduct of a decade-long shaping of a 
clinically detectable tumor and of catastrophically unstable genomes of cancer cells. A large 
fraction of alterations can therefore be regarded as passenger alterations. The task of separating 
drivers from passengers appears to be especially complex when copy number alterations are 
considered, as they more often than not span large chromosomal areas and encompass multiple 
of genes. To narrow down the spectrum of genes recurrently affected by copy number 
alterations, statistical methods have been developed. Thus, in a comprehensive study of 3,131 
tumors of various lineages, 76 focal amplification peak regions and 82 focal deletion peak 
regions, containing a median of 6.5 and 7 genes, respectively, have been identified through a 
statistical approach termed GISTIC [34]. 
Importantly, recent insights into functional significance of individual genes within 
chromosomal regions recurrently affected by copy number gain or loss in tumors reveal that 
copy number alterations may benefit tumor growth in a manner that is driven not by a single 
gene embedded within an amplified or hemizygously deleted region, but rather, by a cumulative 
effect of multiple genes. For example, functional interrogation of a frequently amplified in 
hepatocellular carcinoma 11q13.3 chromosomal region revealed that in addition to a known 
oncogene CCND1, another gene within that region, FGF19, also strongly contributed to 
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transformation [35]. Furthermore, genes that negatively affected proliferation rates of 
immortalized human mammary epithelial cells were found to be statistically overrepresented 
inside chromosomal regions which are recurrently deleted in cancer, elegantly demonstrating that 
hemizygous deletions are likely to be targeting not one gene, but rather, blocks of aptly named 
“STOP” genes, thus having a cumulative effect on the cancer cell’s fitness [36]. As a result, such 
polygenic alterations are likely to be selected for due to their cumulative effect on a proliferative 
potential of cancer cells. In further agreement with this demonstration, four genes within a 
recurrently deleted 8p22 were found to have an additive tumor-promoting effect [37]. Taken 
together, this evidence strongly suggests that genetic alterations selected during the process of 
tumorigenesis may have a higher order of complexity than has been previously appreciated.  
Cancer in time and space – new dimensions to genetic complexity  
As a consequence of a high proliferative capacity of cancer cells and their marked 
genome instability, novel genomic alterations are continuously acquired and those of 
functionally advantageous consequence to a tumor are being selected for. An important 
complication in isolating driver alterations that stems from this is that a profile of genomic 
alterations harbored by a tumor at the time when a biopsy is performed reflects a history of all 
alterations suffered by it. Thus, some alterations that once were essential for tumor initiation may 
have become less important at a later stage of tumorigenesis. In other words, a driver alteration 
responsible for placing the cell on the road to eventual cancer development could become later 
substituted by alterations that are analogous in function and yet convey a pro-tumorigenic 
advantage more strongly. In support of that, tumors often harbor multiple alterations converging 
upon the same pathway, such as those exemplified by the co-existence of PTEN loss or 
mutations in PIK3CA with the amplification of HER2 in breast cancer. Another such example is 
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overexpression of EGFR in early stages of pancreatic interstitial neoplasia, which has been 
shown to be required for a KRAS
V12
-dependent progression to PDAC but is dispensable at the 
invasive stage, which is when pancreatic tumors are diagnosed [38, 39]. Thus, the information 
about how and when particular alterations are acquired and which ones are actively contributing 
to the tumor as a clinically dangerous entity may be missed by whole-genome characterizations 
of clinically advanced tumors; however, attempts such as ultra-deep sequencing of cancer 
genomes to trace the clonal evolution of a tumor demonstrate ways of how this problem may be 
circumvented [40].  
In-depth characterization of individual tumor genomes has brought the issue of tumor 
heterogeneity into a sharp focus, revealing that within the confines of a single tumor, multiple 
subpopulations may be coexisting, each harboring distinct genetic alterations. A prominent 
demonstration of such spatial heterogeneity is a recent analysis of twelve biopsies of the same 
primary pancreatic tumor which were sequenced along with seven metastases of various organ 
tropisms, all spawned by the primary tumor. The comparison of mutation spectra harbored by 
these samples revealed that even though metastases contained some mutations that were not 
uniformly present throughout the bulk of a primary tumor, they still existed within a primary 
tumor as minor subpopulations [41]. In another striking example, a brain tumor composed of 
three subpopulations derived from the common ancestor – each one bearing a high grade 
amplification of a distinct receptor tyrosine kinase EGFR, MET and PDGFRA – has been 
identified [42]. Since most of the cancer genome characterization studies are performed using a 
single biopsy specimen as a source of genetic information, such studies may fall short of 
capturing the full spectrum of tumor-specific driver alterations, especially those involved in 
enabling metastatic colonization.  
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In conclusion, whole-genome characterizations of cancer-specific alterations reveal that 
large and complex sets of gain- and loss-of-function alterations are accumulated by cancer 
genomes over the course of disease progression. Some of these alterations are purely incidental; 
while others act in concert to bestow the malignant phenotype upon the affected cell. In addition 
to functional consequences of alterations to gene-containing regions of the genome, which only 
account for 1% of the human genome, massively parallel sequencing will undoubtedly reveal 
tumor-specific alterations in non-coding RNAs, some which had been already demonstrated to 
profoundly affect tumorigenesis. Furthermore, tumor-specific alterations of the epigenetic 
landscape of a cell add a whole other layer of complexity to the picture. The altered genomic 
milieu of cancer cells elicits profound changes in transcriptional and translational profiles, 
posttranslational modifications and rates of protein degradation, altogether contributing to tumor 
expansion. Finally, germline polymorphisms, as well as aspects of the whole-body physiology, 
such as obesity and chronic inflammation, have a likely strong and as of now underappreciated 
influence on induction and maintenance of the malignant state as well. 
With deeper and more extensive sequencing and copy number analyses underway, the 
exhaustive catalogue of all alterations seen in human cancer will be completed in the foreseeable 
future. In addition to providing extensive characterization of cancer landscapes, tumor 
sequencing has revealed that the spectra of cancer-driving alterations are more complex than has 
been previously appreciated.  All things considered, the task of interpreting cancer genomic data, 
deciphering molecular networks which fuel tumorigenesis and isolating its weaknesses, which 
could be exploited for a new generation of cancer therapeutics, remains far from being 
completed. 
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Precision warfare 
The goal of anticancer therapies is to selectively eradicate malignant cells while sparing 
the healthy tissue. Prior to the discovery of oncogenes, successful cancer therapies were guided 
by clinically evident aspects of cancer pathology. For instance, use of classic cytotoxic 
treatments, such as gamma-irradiation, DNA alkylating agents and mitotic poisons, was based on 
the difference in the extent of the deleterious effect they had on rapidly dividing cell types 
compared to slowly dividing or non-dividing majority of cells of the body. In another instance, 
the discovery of sex steroids and their role in driving proliferation of reproductive tissues led to 
the development of hormone-ablation as a therapy for breast cancer – first by oophroectomy, and 
since 1970s, by specific estrogen receptor antagonists [43]. In yet another classical example of 
pathophysiology guiding therapy, low levels of folic acid in children with acute lymphoblastic 
leukemia led Sidney Farber to propose that leukemia cells may be exquisitely reliant on folic 
acid [44]. The design and implementation of antifolate therapy led to remarkable remissions, 
predating the discovery of its target, dihydrofolate reductase (DHFR) and the role played in 
producing intermediates for nucleotide synthesis, in high demand for leukemic blasts [45]. 
The discovery of the genetic basis of tumorigenesis had revolutionized the understanding 
of the tumorigenic process on a molecular level. Cancer-specific genetic alterations, while 
influencing activities of individual proteins, were demonstrated to profoundly affect pathways 
and networks which are implicated in fueling various aspects of cancer cell’s aberrant 
physiology, as well as the physiology of its surrounding microenvironment. The demonstration 
that malignant behavior is driven by alterations to individual components of growth and survival 
pathways via mutation or a change in a level of expression has made targeting these pathways a 
priority. Multiple oncogene-targeted drugs have shown their efficacy in a clinical setting. Thus, 
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with less than a two-decade delay after the discovery of the genetic identity of the Philadelphia 
chromosome [46], a staggering success of imatinib (Gleevec, Novartis), the inhibitor of c-Abl 
kinase, in producing stable remissions in 90% of CML patients with BCR-ABL fusions has been 
achieved [47]. In the same year that the report of a remarkable efficacy of Gleevec in CML was 
released, use of a humanized monoclonal antibody trastuzumab (Herceptin, Genentech) in 
HER2-positive metastatic breast cancer patients became another targeted therapy success story 
[48]. 
These clinical successes described above provided a proof-of-principle to the concept of 
oncogene addiction [49]. This principle states that tumors become exquisitely dependent on 
driver alterations that fuel their hyperactive pro-growth and pro-survival signaling. Such 
oncogene dependencies therefore allow a unique window of opportunity for a rationally designed 
therapeutic which is exclusively targeted against cancer cells. This principle has been validated 
by studies in genetically engineered animals, where oncogene-driven tumors (c-Myc [50, 51], 
BCR-ABL [52] and Ras [53]) were all but extinguished by an acute genetic shutdown of 
oncogene expression. In addition, restoration of p53 in a genetically engineered mouse model of 
lung cancer provided yet another dramatic demonstration of the addiction principle [54], thus 
extending the addiction principle to the loss-of-function alterations as well.  
However, even when a dominant oncogene is clearly present, incomplete responses, as 
well as development of drug resistance, is often seen in clinic. One explanation of the difference 
between animal models of oncogene addiction and cancer in humans is that in animal models, 
introduction of potent driver alterations - such as activated Ras allele and loss of p53 – bypasses 
the tortuous process of shaping tumor-specific networks, accumulation of layers of redundancies 
among network activators and allowing fine-tuning of negative and positive feedback loops, 
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driving a remarkable resilience of tumors to chemicals that target individual prosurvival and 
proliferative signaling pathways. Furthermore, presence of substantial intratumoral heterogeneity 
allows the outgrowth of drug-resistant subclones, and a variety of molecular mechanisms for 
development of resistance to specific therapies has been described [55].  
Another challenge to the targeted therapy paradigm is that dominant driver alterations 
have only been identified for a fraction of tumor subtypes, while for some others no clear driver 
oncogenes have been assigned. For example, in the most recent whole-genome characterization 
of 183 cases of lung adenocarcinoma, only 47% of tumors contained mutations in a known driver 
oncogene, and only 55% had amplifications of known proliferation-sustaining genes [56]. 
Therefore, for half of the cases a potential therapeutic target cannot be readily identified. 
Moreover, whole classes of tumors, such as triple-negative breast cancers, pancreatic cancers and 
glioblastomas, essentially lack known targets that are easily druggable. Additional tumor 
genomes may need to be sequenced to increase the statistical power of discovery of recurrent 
driver alterations. In addition, the lack of recurrently identified oncogenic perturbations in some 
cancers also suggests that whereas some cancers may be fueled by clearly identifiable dominant 
oncogenes, such as HER2 amplification in 30% of breast cancers, others may be instead driven 
by highly redundant networks of alterations - and may be, ostensibly, harder to treat.  
In conclusion, besides rare exceptions, targeted therapies in cancer are not curative and 
more often than not produce only transient remissions in patients, with the inevitable emergence 
of a drug-resistant tumor. Thus, a new anticancer drug that receive FDA approval may be 
prolonging the patient median survival by a measure of two months [57]. Alarmingly, phase II 
trial success rates for novel therapeutics dropped from 28% in 2006-2007 to 18% in 2008-2010 
[58]. A more comprehensive understanding of how cancer-specific genetic alterations are fueling 
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various aspects of aberrant cellular physiology and a search for novel therapeutic targets, as well 
as the development of novel therapeutic strategies against presently “non-druggable” classes of 
targets, are urgently needed. 
How to spot a perpetrator in a genetic lineup  
The expected benefit of a comprehensive characterization of cancer genomes lies in 
providing a complete map of gain- and loss-of-function alterations that are responsible for cancer 
being cancer. Identifying those genetic elements that bear functional significance to a cancer cell 
can then be used to develop novel targeted therapeutics and combination therapeutic strategies. 
However, as has been discussed above, the problem of separating driver events from passenger 
alterations severely complicates this task. Moreover, up to 40% of genes in the human genome 
have no known function and many more have been only cursorily described [59]. As a result, 
assessment of their potential for functional contribution to cancer is challenging. Finally, some 
clinically successful treatments, such as proteasome inhibitor bortezomib (Velcade) are targeted 
towards proteins and pathways that are not altered in cancer themselves, instead being 
components of stress-response networks upon which cancer cells become dependent as a 
consequence of harboring certain oncogenic alterations. These potential targets will be altogether 
missed by mining cancer genome alone. 
In support of these concerns, even with significant efforts directed towards tumor genome 
characterization, the discovery of clinically-validated therapeutic targets through this approach 
alone, has been infrequent. Notable exceptions include a discovery of transforming EML4-ALK 
fusions in a subset of lung carcinomas [60], which led to a rapid adoption and successful 
application in clinic of an ALK-specific inhibitor crizotinib (Xalkori) [61-63]. Another 
prominent example of exome-sequencing-led discovery was identification of gain-of-function 
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mutations in catalytic domains of IDH1 and 2 proteins (isocitrate dehydrogenase) in a large 
subset of glioblastomas, and the development of specific small molecule inhibitors is currently 
underway [64]. 
To address the functional validation problem, several function discovery-oriented 
approaches have been developed and displayed their utility in isolating critical genetic alterations 
that directly contribute to the various aspects of tumor biology. Two of the most prominent 
among such approaches are (a) comparative oncogenomics in genetically engineered mouse 
models of cancer and (b) in vitro and in vivo genetic screening approaches. 
Comparative oncogenomics takes advantage of genetically engineered mouse models of 
cancer, profiling tumor-specific copy number alterations to identify those that foster the 
formation of either a primary tumor [65] or acquisition of metastatic ability [66] in the context of 
specific driver oncogenes. Some drawbacks of this approach are that it does not faithfully model 
the sequential mode of acquisition of individual oncogenic lesions and the extent of genomic 
instability seen in human cancer. Engineering mice which replicate the extent of genomic 
instability which is seen in human tumors has shown a potential to overcome this problem [67].  
Genetic screening approaches, on the other hand, allows a direct assessment of hyper- (or 
hypo-) active states of individual gene products in a setting that models cancer-specific 
phenotypes either in vitro or in vivo. Two prominent screening technologies that are applied to 
identify causative perturbations in cancer include (i) insertional mutagenesis screens and (ii) 
library-based screens. As an example, insertional mutagenesis screens, such as one based on 
the action of Sleeping Beauty transposase has been successfully used to identify novel genes 
that, when disrupted, contribute to the colorectal cancer initiation [68].  
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Among functional genomics approaches aimed at profiling cancer-relevant genes, library-
based screens had arguably been the most widely used, having been adapted to the assessment of 
a wide range of cancer-specific phenotypes. It was the advent of new methods of constructing 
large-scale libraries of genetic elements, which include gain-of-function libraries of open reading 
frames, and RNAi-based loss-of-function libraries, that opened new opportunities to address 
what just two decades ago seemed to be an insurmountable task in cancer biology.  
Functional genetics in cultured cells becomes a reality  
Until recently, functional genetics has been the realm of researchers who worked with 
model organisms in which sexual reproduction was possible - and feasible - such as S. 
cerevisiae, D. melanogaster and C. elegans. In S. cerevisiae in particular, performing targeted 
gene deletions has made reverse genetics a tool of great utility. Cultured mammalian cells were 
challenging for use as a geneticist’s tool due to their somatic nature, which complicated the task 
of positional cloning of genes. 
When the first oncogenes were discovered, not only the conceptual understanding of 
cancer was enriched, but so was the arsenal of cancer biology methods. First, studies of avian 
and rodent transmissible oncogenes provided a set of assays by which to identify and measure 
cancer phenotypes in cultured tissue. Most notable of these assays were methylcellulose colony 
formation assay [69] and contact inhibition assay [70]. In the latter, chicken fibroblasts 
infected with a single copy of RSV were found to acquire a capability of increasing cell numbers 
even when grown in a fully confluent monolayer culture, forming macroscopically visible foci of 
multiple layers of small rounded cells. Use of contact inhibition assay in NIH-3T3 line further 
led to the phenotype-driven discovery of other oncogenes, including neu and ras [18, 19] from 
the genomic DNA of human tumors of non-viral origin.  
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Another important contribution of cancer virology to the emerging field of mammalian 
cell genetics was that oncogene-carrying viruses became prototype for designing retrovirus-
based cDNA expression vectors [71]. Similarly to transfectable plasmids, viral genome 
sequences were encoded on a plasmid that contained a bacterial origin of replication and 
therefore could be propagated in E. coli. However, retrovirus-based vectors had several 
advantages over transfectable plasmids as they (a) allowed introducing a gene of choice into 
virtually any cell line expressing a suitable receptor, (b) could be stably integrated into 
mammalian cell genome, which allowed stable expression of genes and assessment of a potential 
phenotype over an extended period of time, (c) could be integrated into the host genome at a 
single copy per cell, allowing gene expression levels to be closer to those seen in the context of 
normal cell physiology. 
In addition to studying the action of individual genes at a level of expression which more 
closely replicate the physiological expression levels than a plasmid transfection, another 
advantage of a single-copy mode of integration of virus into cell genome was that they permitted 
introduction of complex expression libraries of cDNAs into cultured cells [72]. Infections with 
such libraries can be performed in a manner so that a complex mix of clonal cell populations – in 
which a single cell carried just one copy of a virus and therefore just one cDNA - are created. 
The resulting library-infected populations of cells can then be assayed in a pooled, massively 
parallel format, with a potential of using a wide variety of biological phenotypes as a potential 
readout. Genetic screens with tumor-derived cDNA libraries had soon proven their superiority in 
discovery of novel cancer-relevant genes. For example, a NIH-3T3 focus formation assay screen 
with a neuroblastoma cDNA library yielded three previously described oncogenes as well as nine 
previously unknown ones [73]. In a set of two further examples, screens for genes conferring 
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resistance to c-myc-induced apoptosis and to TGFβ-induced growth arrest identified Twist1 [74] 
and Mdm2 [75], respectively. 
A drawback of using cDNA libraries as a screening tool is that they only represent a 
snapshot of a cell’s transcriptome at a time point at which cDNA is obtained. Since any given 
cell has only a fraction of its mRNAs expressed, and the relative abundance of cDNAs in the 
library is reflective of the levels of expression in the cell from which the library is obtained, the 
coverage of such type of library is far from comprehensive and highly expressed transcripts are 
overrepresented in it. The sequencing of human and mouse genome has simplified the task of 
cloning of individual genes, making possible the creation of a new generation of expression 
libraries of open reading frames (ORFs). Thus, creation of the ORFeome library, encompassing 
8,000 human open reading frames in 2004 [76] and expanded to over 16,000 ORFs in 2011 [77] 
became an important step forward towards creating a whole-genome tool for performing gain-of-
function genetic screens in mammalian systems. 
Last but not least, the discovery of RNA interference (RNAi) [78] fostered the creation of 
loss-of-function libraries – either in an arrayed format of transfectable siRNAs for performing 
well-by-well screens or in a format of retrovirus-encoded short hairpin RNA sequences 
(shRNAs) for stable expression in cell populations [79-81]. RNAi libraries allowed efficient 
downregulation of individual genes in genomes of mammalian cells, providing highly effective 
means of conducting loss-of-function screens in mammalian cells. 
Logical frameworks are guiding the design of genetic screens 
Newly available tools of functional genomics made possible a high-throughput, unbiased 
assessment of relative functional consequences of hyper- or hypoactivation of individual 
mammalian genes. In the past decade, mammalian genetic screens have proven their utility as a 
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tool of systematic interrogation of a wide range of phenotypes pertaining to cancer cells. The 
versatility of library-based genetic screening technology is arguably one of its key advantages. 
Indeed, virus-encoded libraries can be introduced into a wide spectrum of cell lines which can be 
pre-modified with additional genetic elements and exposed to a variety of conditions. 
Furthermore, diverse cancer-relevant phenotypes can be assayed in cultured cells in vitro. The 
variety of cancer-specific hallmarks and the obvious complexity of networks that contribute to 
the establishment and maintenance of the tumorigenic state highlight the importance of using 
rigorous logic when designing genetic screens. Several of such frameworks could be isolated 
among those emerged in the past decade, all successfully adapted to use with the genetic 
screening technology.  
A majority of recurrent perturbations seen in tumors drive the aberrant flux though 
pathways that stimulate proliferation and most of currently approved targeted therapeutics are 
inhibitors of such pathways. Genetic screens can be readily used for a systematic profiling of 
genes for their relative contribution to cell proliferation rates. Both pooled [36, 82-84] and well-
by-well approaches [85] have been implemented to systematically assess cell proliferation. In 
vivo screens for regulators of xenograft growth in immunocompromised mice have also been 
carried out. The limitation faced with in vivo screens is the sizes of libraries that are needed to 
interrogate whole genomes - especially sizes of shRNA libraries. However, separation of 
libraries into sub-pools [86], use of focused libraries that target genes of specific function [87] or 
genes that are frequently altered in cancer [88] can be used to circumvent this problem. 
Another important application of in vitro genetic screens is modeling the emergence of 
resistant states of tumors to targeted therapies. Screens that address the problem of resistance of 
cancer cells to therapeutics such as anti-HER2 antibody trastuzumab (Herceptin) [89] and BRAF 
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inhibitor vemurafenib (Zelboraf) [90] are examples of this approach. The limitation of genetic 
screening as a tool for the discovery of drivers of drug resistance is that only those resistance 
mechanisms driven by a single genetic change can be discovered. Nevertheless, insights gained 
from these types of screens can help designing combinatorial therapy approaches for a 
preventative targeting of both the original oncogene as well as the likely resistance mechanism.  
A majority of targeted therapies approved for use in clinic are designed to target drivers 
of abnormally fast cellular proliferation. However, alternative approaches to target selection are 
gaining ground as well. Such alternative approaches address the existence of cancer-specific 
phenotypes other than abnormal proliferative index and could be further subdivided into (a) 
those targeting unique tumor-specific stress states, created as a direct consequence to the genetic 
aberrations carried by tumors and (b) those designed to reinstate the normal cellular/tissue 
homeostasis through inhibiting tumor-specific adaptations developed to circumvent it or via 
recruiting existing homeostatic mechanisms.  
Existence of a set of distinct stress states that tumors are burdened with to a greater 
extent than normal tissues is the foundation of the principle of non-oncogene addiction [91]. 
Several distinct types of stresses – including genomic instability, as well as mitotic, proteotoxic, 
metabolic and oxidative stresses – are experienced by cancer cells as a result of acquired genetic 
alterations and cell physiology changes stemming from these alterations. The presence of such 
vulnerabilities, or at a more likely scenario, the extent of such vulnerabilities creates a unique 
therapeutic window with a great potential for specificity, as targeted therapeutics designed to 
inhibit appropriate stress relief pathways will preferentially affect cancer cells over normal cells. 
Importantly, stress response pathways themselves may not themselves be genetically perturbed 
in tumors and therefore will be altogether missed by cancer genome data mining alone. 
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Examples of the therapeutics that are successfully employing this principle are a agents 
disrupting protein folding (HSP90 inhibitor geldanamycin [92]), protein degradation (proteasome 
inhibitor bortezomib [93]) and DNA repair in BRCA-deficient tumors (PARP inhibitor olaparib 
[94]). The principle of non-oncogene addiction is readily applicable to functional interrogation 
with library-based screens and several screens aimed at isolating vulnerability points that are 
specific to various oncogenes have been successful in identifying novel synthetically lethal 
interactions [95-97].  
Cancer develops from normal cells which, via genetic and epigenetic alterations, lose 
sensitivity to cellular and tissue homeostasis signals. These include intrinsic signals, such as 
entry into a senescent state in response to oncogene activation, as well as diverse extrinsic 
signals. Extrinsic signals may be specific to the tissue of origin, such as differentiation-inducing 
action of retinoic acid in neurons or programmed cell death triggered by the detachment from the 
basement membrane in epithelia, which will be discussed in detail in the next section. A distinct 
set of hallmarks involves acquisition of privileges that are normally reserved for other cell types, 
or other developmental stages. These examples include (a) epithelial-to-mesenchymal transition, 
which correlates with metastatic phenotype in epithelial cancers and allows cells to develop 
abilities to modify and invade the surrounding environment, and (b) heightened ability to induce 
de novo growth of blood capillaries.  
Genetic determinants of various aspects of cancer cells’ faulty homeostasis can be readily 
interrogated via in vitro genetic screening. Successful genetic screens for determinants of 
phenotypes such as matrix anchorage-independent growth [98-101], changes in balance between 
stemness and differentiation [102, 103], bypass of cellular senescence [104, 105], as well as cell 
motility and invasiveness [106, 107] have been performed, representing examples of how 
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library-based screens can be used to interrogate the genetic basis of corrupt homeostasis 
mechanisms.  
In conclusion, gain- and loss-of-function genetic screening approaches allow deciphering 
genetic determinants of a wide spectrum of abnormal behaviors characteristic for tumors. 
Furthermore, application of a target discovery-minded logic to the design of genetic screens 
allows not only evaluating contributions (or lack thereof) of individual gene products to cancer, 
but isolating potential drug targets. Combining genetic screening data with evidence from 
recurrent cancer-specific genetic alterations further fosters development of novel therapeutic 
ideas. Finally, the integration of knowledge produced by independent logical frameworks can 
assist the development of combinatorial therapies that approach the problem of eradicating 
cancer from different angles and may be have a greater success in clinic in the long run.  
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Part 2: Adherence to principles  
The epithelium – matrix connection: the declaration of dependence 
Epithelia are found in a wide variety of organs where they provide inner lining of hollow 
structures and carry out a variety of secretory, barrier or mixed functions specific to the demands 
of a site of residence. A distinct characteristic of epithelia is their unique two-dimensional 
pattern of growth in a form of organized monolayers. Even though epithelia account for a meager 
1% of total mass of tissue in the human body, they give rise to a disproportionately large fraction 
of adult tumors. Thus, in 2012, 82% of all adult cancers diagnosed in the United States were of 
epithelial origin; furthermore, epithelial cancers accounted for 77% of cancer-related deaths 
[108]. Cancers that arise from epithelial tissues are termed carcinomas. Carcinomas are further 
subdivided into adenocarcinomas – those arising from cells involved in secretory functions, 
such those residing in lumens of breast, prostate and stomach, and squamous cell carcinomas, 
which originate from epithelia serving the barrier function, such as epithelial layers of skin, oral 
cavity and uterine cervix.  
The functions served by epithelial tissues in the body require a strict maintenance of the 
geometrically constrained pattern of growth and a prompt removal of cells that fail to conform to 
that pattern. This, in turn, requires a set of exquisitely complex quality-control mechanisms 
which serve to maintain tissue homeostasis. Several important growth constraints are being 
imparted upon epithelia, altogether enforcing the maintenance of monolayer pattern. First, 
survival and proliferation of epithelial cells is dictated by their physical anchorage on the 
basement membrane, an organizing acellular substratum composed of a mix of proteglycans, 
such as heparan sulfate, and extracellular matrix (ECM) molecules, such as fibronectin, 
vitronectin, laminin and various types of collagen [109]. Physical attachment to ECM is carried 
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out through a family of integrin receptors, activation of which is dependent on their ligation to 
specific components of ECM. In addition to inducing activating conformational changes in 
individual integrin molecules, adhesion to a contiguous stretch of matrix induces clustering of 
individual activated integrins, thereby enhancing the avidity of binding and the strength of the 
intracellular signal [110]. When activated, integrins influence intracellular signaling [111]. 
Diverse intracellular signaling cascades downstream of integrins are triggered via ECM-
dependent recruitment of a number of integrin-associated tyrosine kinases such as p125
FAK 
[112], 
ILK [113], as well as members of Src family of kinases [114]. A variety of downstream 
pathways become activated upon integrin-ECM ligation (reviewed in [115]), including those 
affecting proliferation (such as MAPK [116]), survival (such as PI3K [117]) and cytoskeletal 
remodeling (such as Rho, Rac and Cdc42 [118]). In addition, some integrins directly associate 
with receptor tyrosine kinases and thereby enhance growth factor-dependent signaling as well 
[119]. Specific integrins display selectivity in their affinity to particular ECM molecules, which 
ensures that not only a complete ECM deprivation, but also alterations to the molecular 
composition of ECM can profoundly affect integrin-dependent signaling. Taken together, 
dependence of epithelial cells on ECM-mediated signaling ensures their growth as monolayers 
and prevents improper colonization of other microenvironments.  
Second, the monolayer growth pattern is enforced by the requirement for individual 
epithelial cells for having a particular geometric shape. In a set of elegant experiments, this was 
demonstrated by seeding cells onto ECM-coated micropatterned islands. Remarkably, cellular 
fate was determined by the number of islands that each cell was stretched across, and not by the 
cumulative area of ECM that a cell was occupying [120]. Mechanistically, changes in geometric 
shape of cell were shown to affect activation of RhoA and modulate protein levels of p27
Kip1
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CDK inhibitor, thus directly governing proliferation [121]. Thus, changes in cell shape following 
complete or partial loss of anchorage can affect cellular proliferation independently from integrin 
engagement. 
Third, besides providing the physical substratum enabling cell spreading and specific 
integrin engagement, heparin and heparin sulfate proteoglycans within ECM bind and 
accumulate a variety of growth factors, making them available to epithelial cells, and as a result, 
stimulating pro-growth and survival signaling [122]. Such capture and accumulation of 
growth factor molecules further ensures a close association of epithelial cells with the 
underlying matrix. In addition, epithelial cells are forced to stay in close proximity to the 
basement membrane due to the avascular nature of epithelia, which makes them dependent on 
diffusion of nutrients, oxygen and hormones across the basement membrane.  
A stark sense of detachment 
As summarized above, growth and survival of epithelial cells is governed by interactions 
with the ECM. The requirement for in vitro growth of epithelium-derived cells on glass or 
treated plastic substratum has been described in 1968 and given the term anchorage dependence 
[69]. Importantly, tumor-derived cell lines or cell lines transformed in vitro by oncogenic viruses 
or chemical carcinogens[123] did not have a similar substratum attachment dependency, thus 
they were characterized as having had acquired anchorage independence. Solidifying the 
functional link between anchorage independence and tumorigenesis, a cell line’s ability to 
proliferate in the absence of anchorage was demonstrated to be the best predictor of an ability to 
grow in a form of xenografts in immunocompromised mice when compared to other cancer-
specific phenotypes – among these, resistance to serum deprivation, contact inhibition or 
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presence of chromosomal aberrations [124, 125]. In addition, anchorage independence correlated 
with the metastatic character of cancer cell lines derived from patients [126]. 
However, it was not until 1994 when two groups independently discovered that cell death 
in the absence of attachment is not merely a process of passive cell attrition, but is, in fact, a type 
of a programmed cell death [127, 128]. Indeed, in a manner similar to apoptosis, substratum-
deprived cells were shown to display the characteristic nuclear morphology and fragmentation of 
genomic DNA. The apoptosis-like response to substratum deprivation in cultured normal 
epithelial cells was termed anoikis, or “homelessness”, derived from the Greek an- (lack of) and 
oikos (home). Furthermore, ectopic expression of a known anti-apoptotic protein Bcl-2 potently 
inhibited the execution of anoikis. Similarly, ectopic expression of viral oncogenes such as v-Src 
and v-Ha-Ras, prevented anoikis, providing a direct demonstration of how anoikis can be 
circumvented by cancer cells. 
Further insights into signaling events that are associated with the execution of the anoikis 
program have demonstrated that it consists of intrinsic and extrinsic components (reviewed in 
[129]). Thus, the intrinsic anoikis pathway is driven by the pro-apoptotic protein Bim, which 
triggers cytochrome c release from mitochondria and activates the caspase cascade. As a 
consequence of ECM detachment and concomitant cytoskeletal remodeling, Bim becomes 
displaced from the cytoskeleton, where it is normally sequestered. In addition, disengagement 
from ECM results in accumulation of total Bim consequential to the reduced flux through PI3K 
and MAPK pathways, which normally phosphorylate Bim and target it for proteasomal 
degradation. Extrinsic anoikis pathway is carried out through increased expression of Fas and 
TNF receptor as well as their respective ligands, also contributing to the initiation of the caspase 
cascade.  
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The Hippo/YAP pathway has recently emerged as a novel sensor of cell anchorage. 
Specifically, loss of ECM attachment and concomitant changes in cytoskeletal arrangement has 
been shown to trigger YAP protein inactivation and cytoplasmic retention, thus inhibiting Hippo 
pathway-driven transcription of a number of pro-growth and survival genes [130].  
Another prominent consequence of ECM deprivation, in addition to abrogation of 
proliferative and survival signaling and initiation of cell death program is a profound defect in 
cellular metabolism [131]. In particular, ECM-deprived mammary epithelial cells had profound 
defects in glucose uptake, fatty acid oxidation and production of antioxidants through pentose 
phosphate pathway, all of which were rescued by expressing a breast cancer oncogene HER2 or 
by exogenous antioxidant supplementation. As a result, metabolic deficiencies contribute to 
cessation of cell proliferation, cooperating with other anoikis mechanisms. Taken together, the 
cell death response to ECM disengagement displayed by epithelial cells is not a passive 
phenomenon, but rather, a process of active sensing of specific microenvironmental cues and 
acting upon them. 
Hematopoietic cells and fibroblasts share tips on staying protected 
One way of getting a perspective on some of the possible ways of how a cell can avoid 
the consequences of anchorage loss is to consider cell types that are constitutively protected from 
anoikis and examine some of the possible ways of how (and why) their requirements for matrix 
anchorage are less stringent than those of epithelial cells. Cells of different lineages and 
specializations display varying degrees of dependence on ECM anchorage. On the end of the 
spectrum opposite from epithelial cells are cells of hematopoietic system, which are entirely 
anchorage-independent in their mature state. This is thought to be a consequence of expression 
of a diverse array of ITAM (immunoreceptor tyrosine-based activation motifs)-containing 
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transmembrane proteins, as well as various cytokine receptors [132]. As a result, a constitutively 
high flux through pro-survival and pro-growth pathways is maintained, which prevents the 
induction of pro-apoptotic proteins like Bim. Intriguingly, ectopic expression of ITAM-
containing fusions is sufficient for the induction of anchorage-independence in mouse mammary 
epithelial cells [133]. 
In the middle of the anchorage requirement spectrum are fibroblasts, which populate 
stromal compartments of various organs. Fibroblasts specialize in de novo synthesis of matrix 
and express a wide spectrum of integrins, which allows a degree of flexibility in modifying and 
using the surrounding ECM environment. Furthermore, motility and invasiveness of fibroblasts, 
reflected in their key role in tissue repair, is associated with a greater sensitivity to growth 
factor signaling pathways [134]. On the far end of the anchorage dependency spectrum are 
epithelial cells  - they express only a limited set of integrins and therefore require a matrix 
composed of specific ECM proteins, plus growth factor signaling in them are strictly regulated. 
A de novo acquisition of changes reminiscent of those that underlie partial (displayed by 
fibroblasts) or complete (displayed by hematopoietic cells) autonomy from matrix anchorage can 
similarly enable anchorage-independent growth of cancer cells of epithelial origin. One well-
described way that cancer cells use to withstand the lack of matrix-dependent signaling is 
through acquisition of genetic changes which result in permanently increased flux through 
survival and growth signaling pathways (reviewed in [135]). In carcinomas, such changes may 
be represented by amplification or mutation of receptor tyrosine kinases, such as EGFR, HER2 
or c-Met, or activation of key downstream effectors, such as K- and H-Ras and PI-3 kinase. 
Alternatively, increases in pro-growth and pro-survival signals may be achieved via inactivation 
of various tumor suppressors, such as PTEN, INPP4B or NF1. A second set of means through 
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which cancer cells bypass the anchorage requirement is through integrin-dependent mechanisms, 
such as the integrin switch. For instance, whereas normal mammary epithelial cells express 
integrins specific for laminin and fibronectin, the molecules that basement membranes within 
mammary gland are composed of, breast cancer metastasis to the bone is facilitated via the de 
novo expression of αVβ5 integrin, which allows survival on bone-specific ECM sialoproteins 
[136]. Similarly, in melanoma, inappropriate expression of αVβ3 integrin permits cell survival 
on dermal collagen, which is abundantly present in the stroma, thus facilitating melanoma 
transdermal invasion [137]. 
A switch to a fibroblastoid cellular state, such as what is seen in epithelial-to-
mesenchymal transition (EMT) further allows cells to survive in the absence of proper ECM. 
Governed by TGF-β signaling and transcriptional regulators such as Twist, Snail and Slug, EMT 
initiates a profound change in cellular state, which involves driving pro-survival signaling 
through upregulation of c-Met and NF-κB, increasing cellular motility and upregulating de novo 
synthesis of extracellular matrix.  
Finally, upregulation of de novo synthesis of individual ECM molecules can lead to 
anoikis protection outside of the context of EMT phenomenon. For example, secretion of 
laminin-5, a ligand of α6β4 integrin, by cancer cells was shown to mediate their survival in the 
absence of anchorage [138]. Similarly, collagen XXIII production was shown to be essential for 
metastasis and anoikis protection in another breast cancer cell line as well [139]. 
Different tissues, different signals 
The precise nature of a cellular response to attachment deprivation is tissue-specific. 
For example, normal mammary epithelial cells undergo apoptosis-like death when cultured in the 
absence of attachment [140]. At the same time, keratinocytes that become deprived of ECM 
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attachment enter a state of terminal differentiation, or cornification [141]. Interestingly, some 
interchangeability is seen between various responses to ECM deprivation. For example, 
mammary epithelial cells that are deficient in pro-apoptotic protein Bim, instead of cell death 
undergo growth arrest and begin expressing markers characteristic for terminal differentiation of 
keratinocytes [142].  
Anoikis and related cellular responses play a pivotal role in growth and remodeling of 
normal tissue. In the context of the mammary gland, anoikis allows fast and precise molding of 
the glandular architecture of trees of milk-producing alveolae and ducts, triggered by pregnancy 
and lactation [143]. In skin regeneration, a time-delayed onset of detachment-induced terminal 
differentiation maintains the stratified organization of skin epidermis. Thus, the suprabasal 
layers, by virtue of losing the attachment to the basement membrane are subjected to a gradual 
onset of differentiation, which culminates with cornification and a non-apoptotic cell death of the 
outermost layer of the skin [144]. Thus, anoikis does not only maintain the status quo but is 
actively involved in tissue and organ morphogenesis. 
Increased anoikis plays a key role in a number of pathologic conditions. For example, in 
cardiovascular disease, matrix-degrading enzyme elastase, secreted by macrophages, triggers the 
degradation of the basement membrane and anoikis of cardiomyocytes and smooth muscle cells, 
thereby exacerbating cardiac damage [145]. In diabetes, chronic hyperglycemia promotes 
excessive glycation of extracellular matrix proteins, thus disrupting the integrity of extracellular 
matrix and triggering anoikis in endothelial cells, which results in a widespread vasculopathy as 
a consequence [146]. Finally, a variety of snake venoms, such as acurhagin [147] and jararhagin 
[148] act as integrin inhibitors and induce hemorrhage by triggering massive levels of anoikis in 
the endothelium. 
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In summary, anoikis and related responses represent a set of critical quality-control 
mechanisms which are operational in epithelial tissues throughout an organism. Importantly, 
such mechanisms play a role in both normal and pathological histology contexts.  
Once a drifter, always a drifter – resistance to anoikis in a context of multistep 
tumorigenesis 
While excessive anoikis underlies pathologic states seen in cardiovascular disease and 
diabetes, insufficient anoikis is a hallmark state of epithelial tumorigenesis. The 
histopathological progression of ductal breast carcinoma is a classical example of how, at all 
stages of tumor genesis, insufficient anoikis contributes to the uncontrollable expansion of the 
abnormal tissue. Breast glandular tissue is shaped in a form of a tree, multiple branched ducts of 
which end with terminal ductal-lobular units (TDLUs), where, in their differentiated state, milk 
is produced. TDLUs are composed of the two monolayers of distinctly specialized cell types - (a) 
luminal, which are lining the lumens of ducts and lobules, and (b) myoepithelial, which are 
facing the basement membrane, which, in turn, separates the mammary tree from the surrounding 
stroma (reviewed in [149]). The myoepithelial layer is fenestrated so that even though luminal 
cells are not resting on the 
basement membrane directly, 
they nevertheless maintain 
physical contacts with it via 
specialized protrusions (Figure 1, 
adapted from [149]). 
  
Figure 1. Cellular architecture of a terminal ductal-
lobular unit. 
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Breast cancer originates predominantly not from myoepithelial but from luminal cells, of 
which 80% are of ductal subtype and up to 10% of lobular, while the rest are of the mixed origin 
(reviewed in [150]). The earliest described (but not universal) precursor of breast ductal 
carcinoma is FEA (flat epithelial atypia), represented by an enlarged lobule and atypically 
small columnar epithelial cells lining the lumen. ADH (atypical ductal hyperplasia) is a first 
stage at which the lining of a lobular unit becomes thickened due to a local cellular 
hyperproliferation distinctly shaped into such structures as micropapillae, trabeculae and Roman 
arches. Thus, the emergence of ADH in breast is the first stage where three-dimensional manner 
of transformed cell proliferation becomes evident. Atypical ductal hyperplasia further proceeds 
to becoming a DCIS lesion (ductal carcinoma in situ), which is characterized by (a) a complete 
filling of the lumen with cells (solid DCIS), (b) formation of multiple lumens at a site of lesion 
(cribiform DCIS) or (c) a maintenance of ADH-like multilayered luminal cell outgrowth in 
which cells remain attached to each other while becoming progressively necrotic in the center 
(comedo DCIS). Thus, being acquired early, defective luminal clearance is a prominent hallmark 
of the preinvasive stage of breast cancer evolution.  
Furthermore, as cancer progresses towards becoming invasive ductal carcinoma, tumor 
cells begin to traverse through the stroma located underneath the basement membrane in a form 
of sheets and cords of interconnected cells or as individual cells [151]. Even though stroma itself 
is rich in extracellular matrix, the molecular composition of it is markedly different of that in the 
basement membrane, composed mostly of collagen for which epithelial cells lack integrin 
receptors. Next, to disseminate and form metastases, cells must travel through blood and 
lymphatic circulation, thus having to withstand the state of a complete matrix deprivation. At 
last, seeding and expansion of cancer cells within lymph nodes and in distant organs such as 
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brain, lung or bone requires not only tolerance for a distinct matrix composition but also ability 
for clonogenic growth. In conclusion, anchorage-independent growth ability plays critical 
adaptive role in all stages of cancer progression, making possible both the uncontrollable tissue 
expansion at a site of a primary tumor as well as metastatic colonization of distant tissues. 
Foci, colonies and spheroids - anchorage-independence in a dish 
First experimental observations of oncogene-induced disturbances in cellular monolayer 
pattern were obtained from studies of Rous sarcoma virus-transformed cells. Having been 
independently described by Adams and Groupe [70] and by Temin and Rubin [13], infection of 
cultured chicken fibroblasts with RSV infection triggered formation of distinct cellular foci 
which consisted of small, round, tightly-packed cells that did not cease proliferating even when 
cellular confluency was reached. When limiting dilutions of the virus were applied to fibroblasts, 
the number of resulting foci was reduced proportionally, suggesting that cells within such foci 
represented the progeny of a cell infected with a single viral particle. Facilitating the discovery of 
the first viral oncogene v-src, as well as its human homologue c-src, the focus formation assay 
was further utilized for identification of dozens of other viral oncogenes as well as of cellular 
oncogenes derived directly from human tumors.  
The focus-forming phenomenon has been regarded as a manifestation of a so-called loss 
of contact inhibition. As discussed in the previous section, not only the degree of integrin 
engagement, but also the degree of cell stretch on the substratum, together comprising a set of 
cues that epithelial cells receive from their contact (or absence thereof) with ECM. Thus, even 
though cells in a focus-formation assay remain attached to the substratum, they nevertheless 
experience changes in cell shape as a result of local cell crowding and progressive reduction of 
the surface area of cell-substratum interaction. A focus formation assay provides demonstration 
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that for transformed cells, a much lesser amount of cell attachment to the substratum can be 
tolerated without halting cell proliferation, so that a focus can be formed. 
Another important in vitro assay of cellular transformation is colony formation in semi-
solid medium. Adoption of this assay was based on the observation that tumor-derived, but not 
normal, cells could be subjected to a cloning technique borrowed from the study of 
hematopoietic cells. In this method, cells are seeded at a clonal density into a so-called semi-
solid medium to which an inert thickening agent, such as soft agar [152] or methylcellulose [69], 
has been added. The presence of a thickening agent prevents attachment of cells to the plastic 
substratum as well as associations of cells with one another. Resulting clonally-derived colonies 
are later isolated. Curiously, it was found that only tumor-derived cells, but not cells obtained 
from normal tissues, were amenable to this method of cell cloning. In addition, normal cells that 
were transformed in culture with either oncogenic viruses or chemical carcinogens were found to 
acquire the colony-forming ability de novo. Importantly, a colony-formation assay is a measure 
of not only an ability of a cell to sustain anchorage-independent growth, but also its ability to 
generate a multicellular colony from a single cell when seeded at a clonal density. Thus, colony 
formation in the semi-solid matrix can be also regarded as recapitulating the metastatic 
outgrowth or of stem-cell like pluripotency. The latter property forms a rationale for a 
mammosphere formation assay, which bears similarities to colony formation assay [153]. In a 
mammosphere assay, which is used to measure the percentage of cells with stem-like 
characteristics, cells are introduced into suspension conditions at a clonal density and assayed for 
a number of resulting spheric organoids which replicate the in vivo mammary architecture. The 
mammosphere formation assays brings forth an important connection between a cellular state of 
pluripotency and insensitivity to anchorage deprivation. 
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A three-dimensional morphogenesis assay is another in vitro assay that has been 
developed to study the phenomenon of anchorage dependence in mammary epithelial cells. In 
this assay, cells are seeded into a three-dimensional matrix composed of a complex mixture of 
extracellular matrix molecules (such as Matrigel, bovine collagen or a combination of the two), 
which serves to recapitulate aspects of breast microenvironment that orchestrate glandular 
expansion and differentiation [154, 155]. When introduced into three-dimensional matrix, 
normal epithelial cells undergo morphological differentiation and form so-called acini, which are 
hollow spheroids morphologically reminiscent of lobular units within a mammary gland. 
Importantly, cells that become displaced into the lumen in the process of acinar formation 
undergo anoikis, and the hollow architecture is maintained. Furthermore, in dramatic contrast to 
normal mammary epithelial cells, various cancer cells as well as cells ectopically induced to 
express oncogenes, display cancer-like aberrations of acinar growth, including filling of lumens, 
formation of multilobular structures or disordered, invasive growth in the matrix. 
In summary, detachment from proper ECM triggers downregulation of matrix-dependent 
integrin signaling. Besides compromised flux through c-Src, PI3K-AKT and MAPK pathways, 
stresses of anchorage loss include defects nutrient utilization and antioxidant production and 
defects in maintaining the proper cytoskeletal tension. To tolerate absent or inadequate 
anchorage, cancer cells must undergo adaptive changes that allow them to proliferate and survive 
independently of anchorage. The multifaceted nature of stresses associated with anchorage loss 
highlights it as an important node of therapeutic intervention. As the histopathologic progression 
of breast ductal adenocarcinoma illustrates, some degree of ability to tolerate ECM deprivation 
often must be acquired early in the course of cancer development. Even a localized hyperplasia 
within an epithelial surface theoretically cannot arise without cells developing at least some 
35 
 
degree of resistance to anoikis. At the same time, anchorage independence phenotype continues 
to be important and, ostensibly, increases in its importance, throughout all the stages of multistep 
tumorigenesis. Therefore, regardless the disease stage, cancer cells should display sensitivity to 
therapies that are designed to target the mechanism of anchorage-independence. As has been 
reviewed above, ways of circumventing the anchorage requirement are remarkably complex – 
and many more likely remain to be discovered. 
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Chapter II: A genetic screen for drivers of anchorage-
independence in human mammary epithelial cells 
Background and Rationale 
In vitro transformation of normal human cells 
The first cancer genes were isolated from oncogenic viruses and from genomic DNA 
derived from human tumors or chemically mutagenized mouse cells. When introduced into 
recipient cell lines, such as cultured chicken fibroblasts or mouse embryonic fibroblasts (MEFs), 
oncogenes like v-src and Ha-ras induced a distinct phenotype described as transformation, or 
ability to form foci. At the same time, fibroblasts that were freshly derived from animal tissues 
failed to undergo transformation upon introduction of an oncogene, entering a distinct state of 
growth arrest instead. Contrary to established fibroblast cell lines, achieving transformation in 
primary fibroblasts required introducing additional oncogenic elements, such as adenoviral E1A 
[20, 156]. The difference between freshly isolated and culture-adapted fibroblasts was found to 
be due to a spontaneous immortalization that fibroblasts underwent upon continued passaging, 
through, most often, a spontaneous inactivation of the p53 gene [157].  
Human cultured cells posed an even bigger problem with regard to transformation in 
culture. In a stark difference to mouse cells, human cells failed to immortalize spontaneously and 
entered a state of irreversible growth arrest after a number of passages in culture. For example, 
human fetal fibroblasts enter a state of irreversible “degeneration”, or “senescence” by the 50th 
passage [158], whereas normal adult cells sustained even fewer passages. Human mammary 
epithelial cells (HMECs), in particular, were able to sustain proliferation for only 10-20 passages 
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[159]. Replicative senescence in both fibroblasts and epithelial cells could be bypassed through 
exogenous inactivation of Rb and p53 tumor suppressors by expressing Large T antigen of SV40 
or a combination of E7 and E6 antigens of human papillomavirus; however, it did not prevent 
them from entering an eventual state of “crisis” [160], in which massive genome instability, 
fusion of chromosomal ends and cell death was observed.  
For human cells, the bypass of replicative senescence appeared to have fewer 
requirements in epithelial cells than it did in fibroblasts. Indeed, human fibroblasts required both 
E6 and E7 HPV proteins for immortalization, whereas E7 protein appeared to be dispensable for 
immortalization of HMECs [161]. Furthermore, breast epithelial cells, but not breast stromal 
fibroblasts, isolated from a patient with a germline p53 mutation due to Li-Fraumeni syndrome, 
were able to spontaneously bypass senescence in culture [162]. The bypass of Rb inactivation 
requirement in HMECs was found to occur via outgrowth of rare clones (up to 0.01% of the 
HMEC population) that silenced p16
INK4A
 gene expression [163] as a consequence of p16 
promoter methylation [164]. HMECs that lost p16 expression continued proliferating past the 
initial “stasis” stage, eventually reaching the second state of growth arrest, or “agonescence”. 
Interestingly, culturing HMECs on feeder cells [165] or on treated plastic that mimicked the 
natural ECM [166] permitted cells to avoid the induction of p16 altogether, suggesting that the 
state of “stasis” may be a consequence of stress associated with the absence of proper 
microenvironmental factors in culture. Similarly to human fibroblasts, “agonescence” could be 
bypassed with the exogenous inactivation of p53 [167], only to reach the third state which 
involved massive cell death from a so-called “crisis”. This third barrier to HMEC 
immortalization could not be spontaneously bypassed. 
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The death of cells from “crisis” in human fibroblasts and epithelial cells was discovered 
to be the consequence of massive DNA damage response to critical shortening of telomeres 
[168]. In a stark contrast to mouse cells, which had a sustained expression of telomerase enzyme 
component TERT, normal human cells lacked its expression [169]. When human TERT was 
ectopically introduced, the “crisis” state in human fibroblasts and epithelial cells has been 
avoided, so that cells became fully immortal [170, 171]. 
Exogenous immortalization with hTERT made it possible to introduce oncogenes into 
cells of human origin and thus model the emergence of the transformed state. For example, a 
combination of three ectopically introduced elements: (i) hTERT, (ii) the early region of SV40 
and (iii) Ha-Ras
V12
 transformed a variety of human cells - fibroblasts, embryonic kidney cells, 
small airway epithelial cells and HMECs without apparent need for further clonal selection [172, 
173]. Even though the early region of SV40 was originally thought to contain only the Large T 
antigen, subsequent studies had shown that it also contained a small t antigen, an inhibitor of a 
widely-acting serine/threonine phosphatase PP2A, and that both Large T and small t were 
required for transformation [174, 175].  
Extended passaging of hTERT-immortalized HMECs selects for subpopulations of cells 
with increased levels of c-myc [176]. In addition, the outgrowth of cell populations with the 
genomic amplification of c-myc locus, through events such as trisomy of chromosome 8 or 
unbalanced translocation of the region of chromosome 8 that contained c-myc, was seen 
following the transforming combination of SV40 and Ha-Ras
V12
 transgenes. This brought forth 
an important caveat that both prolonged passaging and transformation may be selecting not only 
for c-myc, but for additional genes in the vicinity of c-myc locus as well [177]. Importantly, c-
myc activity itself is positively regulated by Ras. In agreement with this, in late-passage hTERT-
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HMECs or in early-passage hTERT-HMECs in which c-myc was ectopically expressed, Ha-
Ras
V12
 was no longer required for in vitro anchorage independence and Large T and small t 
expression was sufficient. However, c-myc could not substitute for all actions downstream of Ha-
Ras
V12
, because Ras was still required for in vivo xenograft growth [178].  
PP2A phosphatase, a target of a small t antigen, acts upon a wide range of proteins within 
growth and survival pathways, some of which overlap with those stimulated by c-myc [179]. 
Further dissection of the requirements for in vitro anchorage-independence of hTERT-HMECs 
revealed that myristoylated catalytic subunit of PI-3 kinase (myr-p110-PI3K) or a combination of 
its constitutively active effector mutants, myr-Akt and Rac1
V12
, can substitute for small t in both 
late-passage and early-passage/c-myc-expressing hTERT-HMECs [178].  
In addition to potentiating anchorage-independent colony formation, ectopic expression 
of a small t antigen, or myr-p110-PI3K, or a combination of myr-Akt and Rac1
V12
 also enabled 
HMEC proliferation in conditions where growth factor concentration was reduced to 0.5% of 
standard amount, yet these oncogenic perturbations had no effect on HMEC proliferation rates in 
regular media [178]. Thus, a constitutively active PI-3 kinase pathway is sufficient to mitigate 
the proliferation-suppressing effects of both anchorage deprivation as well as growth factor 
deprivation. This illustrates the concept that the flux through PI-3 kinase pathway in adherent 
cells is potentiated through a combined effect of growth factor signaling pathways and integrin 
signaling. The added effect on PI-3 kinase flux is that reducing the stimulation through either of 
the two inputs – growth factor starvation in the first instance and culturing in the absence of 
attachment in the second – compromises cellular growth. Along these lines, it is conceivable that 
increasing growth factor stimulation in conditions of anchorage deprivation may partially bypass 
the integrin requirement and promote colony formation. 
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In vitro screens for determinants of anchorage-independence phenotype 
Anchorage-independence is a hallmark phenotype of epithelial cancers that has been 
found to be a best predictor for xenograft growth in vivo, and it has been used extensively as a 
tool of oncogene discovery. An important technical challenge of testing of an ability of a gene-
of-interest to induce anchorage-independence in vitro is that it involves formation of either a 
macroscopic focus or an anchorage-independent colony by a progeny of an individual cell, a 
recipient of a tested gene. Therefore, unless the expression is only necessary for the survival of a 
founding cell, a stable expression of the gene in question is required. 
First functional screens for oncogenes involved transfecting fragmented genomic DNA 
from human cancers, or from cells mutagenized with chemical carcinogens [19, 180]. However, 
stable genomic integration events are extremely rare with this method of gene transfer. The 
development of retrovirus-based expression vectors allowed, for the first time, increasing the 
number of successful stable integration events into genomes of recipient cells by orders of 
magnitude and, in addition, allowed easy recovery of integrated sequences. Thus, a retroviral 
vector-mediated introduction of a neuroblastoma-derived cDNA library into NIH-3T3 MEFs 
yielded 19 independent cDNAs that induced foci formation, which included raf, lck and ect2 - 
previously known oncogenes, and 16 that were novel, including a cDNA for β-catenin [73]. This 
screening method was further applied to identification of genes capable of suppressing anoikis in 
anoikis-sensitive rat intestinal epithelial cells (RIE cells). Screening a mouse embryo-derived 
cDNA library for sequences that were able to induce anchorage-independence in RIE cells 
identified NTRK3/TrkB receptor tyrosine kinase as a novel transforming gene with strong ties to 
cancer [181]. 
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The demonstration that cells derived from normal human tissues could be transformed 
though introducing a small number of defined genetic elements had opened new possibilities for 
functional genomics-based oncogene discovery - this time, in the context of cultured human 
cells. In addition, creating libraries of shRNAs targeted against thousands of human genes has 
made loss-of-function screens a reality, facilitating the discovery of not only potential oncogenes 
but tumor suppressors as well.  
Thus, taking advantage of the modular nature of late-passage hTERT/Large T HMEC 
model (TL-HMEC model), a library of shRNAs sequences has been screened for those shRNAs 
that could substitute for the small t as enablers of anchorage-independent colony growth. This 
screen identified a novel tumor suppressor REST, a frequent target of mutation in colon cancers 
[98]. A similar loss-of-function screen was performed with a human BJ fibroblast cell line, in 
which a combination of hTERT, small t, RAS
V12
 and shRNAs against p53 and p16
INK4A
 triggered 
transformation. Screening an shRNA library of 4,000 shRNAs targeting human genes in this 
model identified that an shRNA against PITX1, a putative suppressor of RAS, was able to induce 
anchorage-independent growth in the absence of RAS [100]. 
Genetic screens aimed at the discovery of regulators of anchorage-independence had also 
been performed with focused libraries of ORFs and shRNAs which were designed to cover 
functionally-related groups of genes. Thus, screening a library of shRNAs targeting human 
kinases and phosphatases in TL-HMEC model allowed identification of a tumor suppressive 
function of PTPN12 phosphatase, which is a target of frequent deletion in triple-negative breast 
cancer [99]. Also, a gain-of-function screen in human embryonic kidney cells which expressed 
hTERT and dominant-negative p53 with a library of 354 myristoylated kinase ORFs identified a 
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transforming activity of IKBKE kinase, an upstream activator of NF-κB pathway and a target of 
focal amplification in breast cancer [83].  
To summarize, genetic screens in human epithelial cell lines have been successfully 
performed with both loss-of-function RNAi libraries or with focused libraries of ORFs encoding 
genes of specific function. Large-scale screens for positive regulators of anchorage independence 
in systems like TL-HMEC have not yet been performed. An effort aimed at cloning of human 
ORFs led to a creation of a human ORFeome library which consisted of 8,000 genes and could 
be readily shuttled between different types of expression vectors using Gateway recombination 
[76]. Taking advantage of this library, we set out to perform a screen with the ORFeome library 
to identify novel transformation-inducing ORFs in TL-HMEC system, without the inherent 
limitation of using libraries of genes with certain function only. In addition, we performed key 
modifications to TL-HMEC system and the anchorage-independence protocol to improve the 
signal-to-noise ratio to facilitate discovery of novel oncogenes and tumor suppressors as well as 
their subsequent study. 
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Results 
Anchorage-independence screen with the ORFeome library 
To identify novel genes that promote transformation of epithelial cells, we performed a 
genetic screen for anchorage-independent colony formation in methylcellulose, using a TL-
HMEC system in which late passage hTERT-immortalized human mammary epithelial cells 
induced to express Large T antigen of SV40. TL-HMECs fail to form colonies in semi-solid 
medium, such as methylcellulose, when deprived of attachment. However, ectopic expression of 
oncogenic H-RAS
V12
, myristoylated catalytic subunit of PI3K [178] or shRNA against PTEN 
[98] readily induces formation of macroscopic colonies. We introduced a pROLES retroviral 
vector-encoded library of 8,000 human open reading frames (ORFeome v1.1) [76] into TL-
HMECs and selected successful integrants with puromycin (for the workflow schematic, see 
Figure 2). Expression of ORFs was driven by a CMV promoter. To avoid potential positional 
effects of provirus integration on proliferation or transformation of individual clones, the 
ORFeome library infection and the subsequent screening was performed in two independent 
replicates. In addition, we took care to avoid introducing multiple ORFs into the same cell by 
performing the viral infection at a multiplicity of infection of 0.2. This way, the number of 
recipient cells exceeded the number of viral particles by a factor of 5, ensuring that viruses were 
not present in excess. Furthermore, we continued to maintain the representation of the library at a 
200-fold magnitude throughout the process of a pre-screen cell culture as well as during seeding 
the cells for the anchorage-independence screen. This was done to ensure that each ORF is 
sufficiently represented in the resulting polyclonal population of TL-HMECs to further reduce 
stochastic effects on cell viability and growth. 
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Library-transduced cell populations were seeded into methylcellulose medium at a clonal 
density and formation of macroscopic colonies was observed three weeks post-seeding. 
Methylcellulose is superior to soft agar for performing genetic screens in that it does not solidify 
like agar does and therefore allows easy recovery of anchorage-independent clones. We have 
isolated individual colonies from methylcellulose and re-adapted them to adherent growth by 
culturing each one individually in wells of 96-well plates. A total of 732 colonies have been 
isolated from the screen with a 100% recovery rate. Once all the clones reached confluency, we 
proceeded to isolate the genomic DNA and recover proviral integrations by PCR amplification. 
A pair of primers used for PCR was designed to target common sequences outside the ORF 
insert, and successful PCR amplification has been verified by agarose gel electrophoresis. 
By this method, we were able to successfully recover ORF inserts from 83% of colonies. 
From 68% of total colonies, a unique ORF has been recovered from each colony, 15% of 
colonies contained two ORFs integrated into them, and two clones had each three integrated 
ORFs. This shows that even with a 5-fold excess of recipient cells over viral particles, double 
Figure 2. A genetic screen for drivers of anchorage-independent growth in human 
mammary epithelial cells. A total of 200x8,000=1,600,000 cells was plated per replicate as to 
maintain the 200-fold library coverage.  
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integrations of a provirus do occur with a substantial frequency, which could be reflective of 
aggregation of individual viral particles or of selection of cells containing two copies of a 
puromycin resistance gene during the process of antibiotic selection. This does not rule out the 
possibility that in some double integrants, both ORFs contribute to anchorage-independence 
phenotype; therefore, it would be of further interest to compare the rate of double integrations 
among isolated colonies to that of the starting cell population. 
The identity of ORFs recovered by PCR was determined by sequencing, yielding the total 
of 646 unique ORFs. Since we have performed our screen in two independent replicates, we 
reasoned that ORFs identified in both replicates will be enriched for those with bona fide 
transforming sequences. A total of 40 ORFs were identified in both screen replicates and were 
selected for individual cloning into pROLES retroviral vector for further validation of the 
phenotype (see Appendix II for the list of candidate ORFs).  
Modifications to TL-HMECs system to facilitate further studies of transformation 
We saw that with the increasing passage number of TL-HMEC cells, the number of 
anchorage independent colonies in an empty vector-transduced population, that is, the 
background level of colony formation, was increasing. This phenomenon caused the reduction of 
the dynamic range of TL-HMEC transformation assay and made the system less effective for 
studying moderate transformation phenotypes.  
Thus, we set out to improve the dynamic range of TL-HMEC transformation system and 
employed two strategies for it: (1) isolation of individual clones from TL-HMEC line and 
characterization of them with respect to a fold change in a number of anchorage-independent 
colonies induced by an oncogenic perturbation compared to control population; (2) modifications 
to the culture medium composition to increase the assay stringency. 
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We reasoned that the observed reduction in signal-to-noise ratio may be due to a 
polyclonal nature of the TL-HMEC line. One may hypothesize that, as a result of specific genetic 
and epigenetic differences, which could be both original or accumulated in culture, some of the 
clones may have a higher proliferation index than others. If this is the case, the fraction of such 
clones in the total population is bound to increase with each passage. Furthermore, if these 
hyperproliferative clones are also spontaneously transformed, then the presence of such clones 
may explain the decreasing dynamic range of transformation assay that we consistently 
observed.  
To ask directly if this is indeed the case and to obtain clones of TL-HMECs with a 
dynamic range superior of that of the parental population, we have isolated six TL-HMEC 
clones, expanded them and transduced with an shRNA against PTEN tumor suppressor or a 
control shRNA which targeted firefly luciferase gene (FF2). Resulting clones were then seeded 
into methylcellulose medium and anchorage-independent colony formation was monitored. 
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Strikingly, we 
found that four out of six 
clones failed to form 
colonies regardless of 
whether they expressed a 
control FF2 shRNA or an 
shRNA against PTEN. 
Furthermore, one clone 
(clone A7) yielded a 
massive number of 
colonies when transduced 
by FF2 shRNA, and only a two-fold increase in colony number was seen with PTEN shRNA in 
it. Finally, one clone (clone F7) had a low background rate of colony formation and had a 10-
fold increase in colony formation in presence of PTEN shRNA (Figure 3). Thus, a great 
heterogeneity with respect to clones’ ability to form anchorage-independent colonies was seen 
across individual clones of TL-HMEC line. First of all, only two out of six clones became 
transformed by PTEN shRNA. Strongly supporting our original hypothesis about the presence of 
hyperproliferative, spontaneously transformed clones, we indeed found that clone A7 was a 
spontaneously transformed clone. In addition, during the process of clone isolation, we noticed 
that A7 clone occupied an area on the dish approximately five times larger than the rest of the 
clones. Because all six clones were isolated at the same time and individual cell sizes did not 
vary across individual clones, this may be indicative of an increased proliferation rate of A7 
clone, or, alternatively, of a decreased rate of cell death. We have decided to use F7 clone for our 
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Figure 3. Spontaneous and PTEN shRNA-induced anchorage-
independent colony formation by individual TL-HMEC 
clones. 
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future experiments, as it exhibited a superior dynamic range in colony numbers between positive 
and negative control. 
The origins of the striking heterogeneity between individual clones from TL-HMEC line 
that we observed are not entirely clear. First of all, HMECs are isolated from human mammary 
tissue which is a polyclonal mix of cells of at least two lineages – luminal and myoepithelial 
cells, and may contain tissue stem cells as well. HMECs are further transduced with two separate 
viral constructs – hTERT and Large T, and positional effects from provirus integration events 
may influence expression of transduced genes and genes in the vicinity of the genomic 
integration as well. Finally, HMECs exhibit some degree of genomic instability – for example 
events such as a trisomy of chromosome 8, as well as presence of unbalanced translocations have 
been observed. The heterogeneity with regard to alterations to gene copy numbers could further 
contribute to differences in proliferation rates and anchorage-independence phenotype across 
individual TL-HMEC clones.  
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In addition to isolating 
a clonal population from TL-
HMECs, we asked whether we 
can further improve the system 
by modifying the anchorage-
independent growth conditions. 
As was previously shown, 
transducing TL-HMECs with a 
small t antigen, myr-PI3K or a 
combination of myr-Akt and 
RAC1
V12
 not only facilitated 
anchorage independence, but 
also made cells less sensitive to 
reductions of growth factor 
concentrations in culture 
medium. Indeed, PI3K 
pathway activation in adherent 
cells is maintained via two 
crucial inputs: growth factor 
stimulation and signaling 
downstream of activated integrins. In agreement with this, ectopic hyperactivation of PI3K 
pathway makes cells insensitive to the absence of either of the two stimuli. We reasoned that TL-
HMECs may be partially able to tolerate anchorage-independence conditions through receiving 
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the non-cell-autonomous prosurvival signaling input via growth factors. Therefore, we 
hypothesized that reducing growth factors concentration in methylcellulose medium may reduce 
the background colony formation and further improve the dynamic range, thereby facilitating the 
discovery of more moderate phenotypes. HMEC growth medium is a semi-defined culture 
medium, which contains two defined growth factors - insulin at 10 μg/mL and EGF at 5 μg/mL - 
as well as bovine pituitary extract at 2% v/v, which is a mixture of various growth factors, 
predominantly basic FGF. To test how changes in growth factor concentrations will affect 
anchorage-independence assay performance, we prepared methylcellulose medium containing 
100%, 75%, 50%, 25% or 0% of normal growth factor concentration and seeded TL-HMECs 
expressing either empty vector or one of the validated candidate ORFs, PVRL4, in these 
conditions. In addition, we also plated cells at three different cell densities to simultaneously 
assess the paracrine stimulatory effects on transformation from cells themselves.  
We have indeed observed that reducing the concentration of growth supplements in the 
culture medium produced a very strong effect on the dynamic range of our assay (Figure 4). 
Seeding cells in 100% and 75% growth factor medium resulted in an average of a five-fold 
increase in anchorage-independent colony formation of PVRL4 ORF-expressing cells over 
empty vector, but when cells were seeded in 50% or 25% growth factor medium, a dramatic 
increase in dynamic range was observed. Similar effects were further observed with other 
transforming sequences such as PTEN shRNA (not shown). Based on these onservations, we 
decided to modify our assay protocol and prepare methylcellulose medium with 50% growth 
factors for future studies. 
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Validation of anchorage-independence screen candidates 
We have introduced 40 ORFs that were indentified in both replicates of the 
transformation screen into F7 clone of TL-HMECs by viral transduction and assayed resulting 
lines for ability to form anchorage-independent colonies under reduced growth factor conditions 
(Figure 5). We have found that 11 out of 40 ORFs potently induced TL-HMECs colony 
formation (5-fold increase over background), and another 8 ORFs produced a moderate 
phenotype (2-5-fold increase over background). 
 
Figure 5. Validation of screen candidates. ORFs recovered from two independent screen 
replicates were individually transduced into TL-HMECs and plated into semi-solid medium. 
Colonies were counted and colony numbers were normalized to an empty vector-transduced 
sample. Asterisks denote strongly validated ORFs that localize to focal amplification peaks in at 
least one tumor subtype. Assays were performed in triplicate (error bars ± SD).  
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Next, we searched publicly available datasets of recurrent copy number alterations in 
cancers to find whether transforming ORFs that we recovered were frequently targeted for 
amplification in human tumors. According to comprehensive copy number variation analysis 
across more than 3,000 cancers, encompassing a variety of tumor types [34], 8 out of 11 ORFs 
Gene 
Symbol 
Genomic 
Location 
Cancer 
Subset 
Amplification 
Peak 
Number 
of 
Genes 
in Peak 
Q 
Value 
Fraction 
Amplified 
Fraction 
Focally 
Amplified 
ADCK5 
chr8:14556853
8-145589261 
all_cancers 
chr8:14048059
3-146264218 
97 0.000 0.3548 0.0843 
DCLRE1B 
chr1:11424956
0-114258217 
Lung SC 
chr1:44531979
-143798352 
450 0.184 0.375 0.175 
GPR172A 
chr8:14555303
2-145555754 
all_cancers 
chr8:14048059
3-146264218 
97 0.000 0.3548 0.0843 
MRPS28 
chr8:80993649
-81105061 
Lung NSC 
chr8:80901900
-82348486 
7 0.000 0.4243 0.0955 
NPM1 
chr5:17074740
2-170770493 
Lung NSC 
chr5:16504204
6-180624927 
126 0.006 0.2333 0.0928 
PVRL4 
chr1:15930811
9-159325966 
all_cancers 
chr1:15832689
6-159953449 
52 0.000 0.3526 0.0782 
TAGLN2 
chr1:15815452
6-158161908 
all_hemat. 
cancers 
chr1:15549805
2-161098015 
112 0.060 0.0801 0.0143 
TMEM65 
chr8:12539233
9-125454121 
Lung NSC 
chr8:11631908
4-125488036 
37 0.000 0.5321 0.1501 
Table 1. Strongly validated ORFs located in recurrently amplified genomic regions. 
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that potently induced anchorage-independent colony formation in our system, were localized to 
statistically defined peaks of focal amplification in at least one tumor subtype (p=0.009, Fisher’s 
exact test), further suggesting that our screen identified genes that are under positive selection in 
cancer (Table 1). 
Among the list of positively validated ORFs identified by our screens were those 
corresponding to genes for which survival-promoting function in cancer cells has been 
previously described. One of such genes is SULF2 (sulfatase 2) [182], which functions by 
remodeling heparin sulfate matrix components. This, in turn, mobilizes various growth factors, 
making them available for binding to corresponding receptor tyrosine kinases. The second gene 
previously involved in prosurvival signaling is NPM1 (nucleophosmin 1). Indeed, in addition to 
its function in the nucleolus, the non-canonical role of nucleophosmin in potentiating PDGF 
receptor signaling has been described [183]. This suggests that our screen identified a number of 
transformation-inducing genes with a strong functional and genomic relevance to the process of 
tumorigenesis. 
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Materials and Methods 
Constructs and virus production. For screen candidate validation, ORFs from isolated 
colonies were subcloned into pROLES retroviral vector (provided by W. Harper). For negative 
and positive transformation controls, TL-HMECs were transduced with pMSCV-mir30-FF2 or 
pMSCV-mir30-PTEN shRNA constructs. Retro- and lentiviral supernatants were generated by 
transient transfection of 293T cells following Mirus Bio's TransIT transfection protocol and 
harvested 48 hrs later. 
Cell Culture. TL-HMECs expressing hTERT and SV40 Large T antigen [178] were 
cultured in MEGM (Lonza). 293T cells were cultured in DMEM (Invitrogen), supplemented 
with 10% FBS. Retroviral infections were performed in presence of 8 ug/mL of polybrene 
(Sigma). Successful viral integrants were selected with puromycin (2 ug/mL) or Geneticin (200 
ug/mL). 
Anchorage-independent colony formation assay. Anchorage-independent colony 
formation assays were performed as previously described[98] with minor modifications. Briefly, 
cells were suspended in reduced growth factor MEGM (containing 50% of kit-supplied BPA, 
Insulin, EGF and hydrocortisone) with 2% methylcellulose (Sigma) and plated on tissue culture 
dishes precoated with 0.6% Noble Agar (Sigma) in MEM (Invitrogen). For assays performed in 
6 cm dishes, 4.5 x 10
4
 cells per dish were plated. For assays performed in 6-well plates, 1.2 x 10
4
 
cells per well were plated. Colonies were counted after three weeks of growth. For each assay, 
except for those in Figures 3 and 4, an average of three replicates +/- SD is shown. 
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Chapter III: The investigation of PVRL4–driven anchorage-
independence: the role of cell-cell contacts 
Background and Rationale 
Is cancer a sticky business? 
Whereas the prosurvival role of cell-ECM contacts has been extensively described, the 
role of cell-cell contacts and individual cell adhesion molecules (CAMs) in driving epithelial cell 
survival and the process of tumorigenesis is considerably less well understood. On one hand, 
development of invasive tumors is associated with the loss of normal cell-cell adhesions and 
facilitation of cellular motility, yet other studies demonstrate that in many solid tumors, cell-cell 
contacts are preserved even at advanced stages of disease and may be serving a critical 
prosurvival role. 
The study of how cell-cell adhesiveness contributes to tumorigenesis is complicated by a 
remarkable variety of molecular mechanisms that mediate cell-to-cell attachment. Indeed, 
mammalian genomes have over two hundred described cell adhesion molecules (CAMs), which 
are involved in stable as well as transient types of cell-cell interactions and serve a variety of 
physiological roles. Thus, various CAMs function in maintaining tissue integrity, governing 
tissue morphogenesis and relaying cell-to-cell signals between immune system components. 
Normal epithelial cells possess three types of cell-cell junctions which altogether constitute the 
junctional complex: adherens junctions and desmosomes, which are built by E-cadherin and 
other tissue-specific cadherins and tight junctions, built by claudins. In addition to cadherins and 
claudins, which promote stable intercellular interactions, three other classes of cell adhesion 
56 
 
molecules are involved in facilitating more transient cell-cell contacts. These include integrins, 
which can potentiate cell-to-cell adhesion in addition to their role in cell-to-ECM adhesion, 
selectins, which mediate adhesion of leukocytes to endothelial cells via various sialoproteins 
[184], and a diverse family of immunoglobulin-like CAMs (IgCAMs). Extracellular regions of 
IgCAMs contain from 1 to 5 immunoglobulin-like folds and, sometimes, fibronectin-type III 
domains. IgCAMs form cell-cell contacts through trans-interacting with other IgCAMs in a 
homotypic or heterotypic manner, or with integrins, thus facilitating the cell-cell adhesive 
function of the latter. The role of IgCAMs in mediating cell-to-cell signaling in the immune 
system is best described [185], however various IgCAMs - such as nectins - are involved in 
carrying out other functions as well, such as guiding neural and epithelial tissue morphogenesis. 
Histopathological analysis of invasive tumors often reveals a characteristic appearance of 
individualized cancer cells or small cell clusters at the invasive front of a tumor, a phenomenon 
termed “cell budding”, which is associated with a more adverse prognosis. Concomitantly, loss 
of junctional complexes characteristic for normal cells is a hallmark of a transition from a 
benign to a more aggressive disease stage. Both whole-genome tumor analysis and 
immunohistochemical analysis show that invasive carcinomas frequently attenuate the 
expression of E-cadherin. Loss of E-cadherin, a major structural component of normal cell-cell 
junctions, can occur via events such as loss-of-function mutations [186], epigenetic silencing 
[187] and transcriptional downregulation during the process of epithelial-to-mesenchymal 
transition (EMT) (reviewed in [188]). Importantly, loss of E-cadherin is an independent predictor 
of a poor disease outcome [189]. Functional studies support the significance of E-cadherin loss 
to the onset of invasion: indeed, ectopic re-expression of E-cadherin reduces in vitro 
invasiveness [190]. In addition, it blocks the transition from adenoma to invasive carcinoma in a 
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mouse model of pancreatic tumorigenesis, whereas a dominant-negative mutant of E-cadherin 
accelerates this transition [191]. On a signaling level, E-cadherin sequesters critical signaling 
modulators β-catenin and p120-catenin, preventing their participation in activating Wnt-
dependent signaling [192] and small GTPase activation [193], respectively. In support of the 
critical role of the cytoplasmic region of E-cadherin in mediating its growth-suppressive 
functions, expression of a membrane-tethered cytoplasmic region of E-cadherin was sufficient 
for the inhibition of cell transformation, thus demonstrating that growth suppressive function of 
E-cadherin is functionally distinct from its role in mediating cell-cell adhesion [192]. 
The prevalence and even relevance of EMT as being an obligatory step towards 
metastatic disease has been hotly debated in the field [194, 195]. One possibility is that rather 
than being an irreversible transdifferentiation process, EMT is a transient phenomenon driven by 
the contact between tumor cells and the underlying stroma, whereas once seeded in a distant 
organ, cells revert back to the epithelial morphology [196]. This theory is supported by the 
immunohistochemical analysis of carcinoma metastases, the majority of which display epithelial 
differentiation [197]. Unexpectedly, cancer cells can seed inside the bone marrow as early as at 
the in situ stage of a primary breast carcinoma, and progression to invasive disease does little to 
affect the number of individual tumor cells that reach bone marrow [198]. Furthermore, rather 
than being a universal mechanism of metastasis, EMT may represent just one of the modes of 
cellular invasion. In support of that, an alternative mode of invasion, termed collective invasion, 
whereby cancer cells invade the surrounding stroma as large groups, shaped as cords or sheets, 
where individual cells remain connected to each other, has been observed both in vitro [199] and 
is seen routinely on histopathological examinations of various types of carcinomas as well. 
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While there is a tendency for the loss of tight and adherens junctions in tumors, some 
CAMs are on the contrary, upregulated in cancer and are functionally involved in promoting 
survival and invasiveness. Thus, N-cadherin, a less adhesive mesenchymal cadherin, becomes 
upregulated during the EMT process and acts to promote prosurvival signaling and invasiveness; 
furthermore, monoclonal antibodies against N-cadherin inhibit prostate cancer cell line growth in 
vivo [200]. Mechanistically, N-cadherin associates in cis with FGFR, enhancing its downstream 
signaling [201]. In addition, intracellular domain of N-cadherin can be cleaved and translocated 
to the nucleus where it enhances CREB-dependent gene expression [202]. Both of these 
signaling mechanisms appear to be independent of cell-to-cell adhesion. Some IgCAMs are 
upregulated in cancers and are involved in facilitating invasion and growth. These include 
L1CAM [203], EpCAM [204] and NrCAM [205]. The function of EpCAM is thought to be 
carried out though translocation of its intracellular domain to the nucleus, whereas NrCAM and 
L1CAM potentiate integrin activation via cleaved extracellular regions, binding to their 
respective integrin counter-receptors and promoting invasion. This evidence taken together, 
some of the functions of CAMs in tumors may occur independently from their role in cell-cell 
contact formation.  
In addition, several lines of evidence support the notion that enhanced cell-to-cell 
adhesion may have a pro-survival role and be selected for during tumorigenesis. Cells in which 
junctions are preserved display resistance to anoikis [206]. Among cancer cell lines, aggregate 
formation in oral squamous carcinoma cultured under anchorage-independent conditions 
promotes their survival through an EGFR-dependent mechanism [207], whereas preventing cell-
cell aggregation with antibodies against E-cadherin induces anoikis [208]. One caveat is that oral 
squamous carcinoma is a type of cancer where E-cadherin expression is not typically lost [209], 
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which may not be the case in other cancer types such as breast cancer, where loss of E-cadherin 
at the invasive stage is a frequent event.  
Correlative evidence suggests that aggressive cancer cells display higher propensity for 
self-aggregation than their less aggressive counterparts or than normal cells. Thus, the 
multicellular aggregate-forming propensity of virus- and chemically-transformed cell lines 
correlates with anchorage-independent colony formation phenotype and xenograft growth in vivo 
[210]. Furthermore, renal carcinoma-derived subclones selected for greater metastatic capacity in 
vivo display increased self-aggregation in vitro [211]. Reciprocally, melanoma cell line-derived 
subclones selected for increased in vitro aggregate formation were shown to be more metastatic 
in mice [212].  
Whereas early studies on correlations between cell-cell adhesiveness and tumor 
phenotypes were largely performed in established cell lines, the advent of technologies for 
isolation and characterization of circulating tumor cells (CTCs) from patients further hints at the 
pro-tumorigenic role of cell-cell aggregation. Indeed, among CTCs from the blood of patients 
with breast, colorectal, prostate and lung cancers, as well as in mouse tumor models, there is a 
noted preference for multicellular cluster formation [213-215], with one study detecting as many 
as 50% of all CTCs from the blood of breast and lung cancer patients to be residing in 
multicellular clusters [216]. Importantly, clusters of CTCs, named circulating tumor microemboli 
(CTMs) were shown to display reduced levels of apoptotic markers compared to isolated CTCs, 
although the possibility that isolated CTCs become separated from CTM clusters as a result of 
their apoptosis, cannot be ruled out  [213]. Circulating tumor microemboli are associated with 
poor prognosis and are a frequent cause of death in patients with invasive cancers [217]. In 
inflammatory breast carcinoma, numerous microemboli tend to accumulate within the lymphatic 
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vasculature [218]. Tumor clumps released by a primary tumor are detected in venous outflow in 
a third of a cohort of patients with clear cell renal carcinoma [219]. In one striking 
demonstration, when mutant allele frequencies of 48 point mutations and small indels were 
assessed by deep sequencing in the primary tumor and the metastatic lesion from the same 
patient, the mutant allele frequency for 26 mutations was the same in the metastatic lesion and 
the primary tumor, while 20 mutations displayed an increase and yet another two – a decrease in 
the metastatic lesion, suggesting that the metastasis originated not from one but from at least 
three initiating cells [220]. Furthermore, an ex vivo microscopy study provided a direct 
demonstration that intravascular CTMs can initiate metastatic colonies directly inside micro 
capillary lumens, bypassing the extravasation step altogether [221]. 
Finally, the increase in adhesive behavior of cancer cells is not limited to self-
aggregation, and interactions with a variety of other cell types were shown to be essential for 
dissemination of cancer cells and subsequent metastatic colonization. Thus, de novo expression 
of ligands for E- and P-selectins on the surface of cancer cells facilitates their adhesion to 
endothelial cells within target organ microvasculature and promotes intravasation and metastatic 
lesion formation, and are associated with the worse disease outcome [222]. Moreover, signaling 
elicited by physical association of cancer cells with platelets [223] and macrophages [224] have 
been demonstrated to be essential for successful seeding and metastatic outgrowth.  
Taken together, several lines of evidence suggest that increased cell-to-cell adhesiveness 
may protect cells from anoikis and is under positive selection during tumorigenesis, and is a 
prominent phenomenon during cancer cell dissemination by through vasculature. Despite that, 
specific drivers of cell-cell aggregation exhibited by cancer cells and mechanisms of their action 
are not well understood. 
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PVRL (nectin) family of cell adhesion molecules 
Having screened a library of 8,000 open reading frames (ORFs) to identify ORFs that are 
able to promote anchorage-independence in TL-HMECs, we recovered 11 potent inducers of this 
phenotype. In particular, one ORF that consistently tested as strongest in our dataset 
corresponded to a full-length PVRL4 gene (poliovirus receptor-like 4), also known as Nectin-4. 
Together with PVRL1, PVRL2 and PVRL3, it comprises a family of four calcium-independent 
cell adhesion molecules (reviewed in [225, 226]). Nectins belong to IgCAM superfamily and 
play a prominent role in morphogenesis of various tissues through the formation of heterotypic 
types of cell-cell contacts. All four family members have a sequence homology to the poliovirus 
receptor (PVR), and three of the nectin family members were demonstrated to act as viral 
receptors themselves. Thus, PVRL1 and PVRL2 have been originally cloned as receptors for 
herpesvirus α [227, 228], and PVRL4 is a receptor for measles virus [229, 230]. 
Nectins mediate cell-cell adhesion between a wide variety of cell types, including 
epithelial cells, fibroblasts and neurons. A prototypical nectin is a single-pass transmembrane 
protein with three immunoglobulin-like domains in the extracellular part, a transmembrane 
domain and a short cytoplasmic tail containing no known domains. The exception is a E/A-x-Y-
V motif at the C-terminus of nectins, which has been characterized as a PDZ-domain-interacting 
sequence [231]. Notably, PVRL4 is the only nectin that does not contain this motif but is 
nevertheless capable of interacting with PDZ-containing proteins [232].  
Nectin-mediated cell-cell attachments take place at early stages of adherens and tight 
junction formation, but nectins are also capable of mediating less stable cell-cell interactions in a 
manner that is autonomous from other junctional structures. For a contact to form, nectins first 
form a cis-homodimer on the surface of one cell, which then trans-interacts with a cis-
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homodimer on a cell juxtaposed to it, thus forming a heterotetramer. Cell-cell contacts formed by 
nectins share two distinguishing characteristics. First, different nectins exhibit a specific 
preference for a trans-interacting partner. In vitro binding studies have demonstrated that PVRL1 
preferentially interacts with PVRL3 and PVRL4 [232, 233], whereas PVRL2 interacts only with 
PVRL3. Some nectins also interact with other IgCAM classes. For example, a trans-interaction 
of PVRL3 with PVR in MDCK cells has been described [234], and PVRL2 was shown to 
interact with NK-cell specific receptor TIGIT, which inhibits NK cell activation [235].  
Second, a trans-interaction of nectin dimers at a site of a cell-cell contact has been 
proposed to trigger the formation of nectin polymers at the site of contact. In particular, crystal 
structure analysis of individual PVRL1 and PVRL3 cis- and trans-dimers [236] suggests that the 
mode of interaction in which two cis-homodimers bind in trans- can triggers formation of long 
chains of alternating cis- homodimers at the extracellular interaction interface between two cells, 
thus increasing the avidity of nectin-based contacts dramatically. 
The heterotypic nature of nectin-driven cell-cell interactions is reflected in the role 
various nectins play in facilitating interactions between two distinct cell types; in which cells of 
different types express two different nectins with preferential affinity for trans-interacting with 
one another. A wide variety of such inter-cell type interactions have been described, including 
the following: (a) in the hippocampus, between axon-containing neurons (PVRL1) and dendrite-
containing neurons (PVRL3) [237] (b) in the hindbrain, between commissural axons (PVRL1) 
and floor plate cells (PVRL3) [238], (c) in the ciliary body of an eye, between pigment (PVRL1) 
and non-pigment epithelial cells (PVRL3) [239]; (d) in the testis, between Sertoli cells (PVRL2) 
and spermatid cells (PVRL3) [240] and (e) in the developing tooth, between ameloblasts and 
cells of stratum intermedium [241]. Furthermore, the trans-interacting nature of nectins drives 
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formation of some unique cellular arrangements, such as a checkerboard-like pattern of auditory 
epithelium within the organ of Corti [242].  
PVRL4 and its function in mammalian tissue patterning remains the least studied. While 
other members of the family are expressed in wide spectra of tissues and cell types, PVRL4 is 
expressed in only a limited number of tissues [243], namely, skin epidermis and hair follicles, 
teeth, cornea, trachea and placenta. In particular, expression of PVRL4 in stratified epithelia of 
skin and hair follicles is restricted to intermediate layers of skin and hair epithelia, whereas both 
topmost, terminally differentiated (cornified) layer and the basal layer, which consists of cells 
directly anchored on the basement membrane are negative for PVRL4 staining [244].  
Recently, mutations of PVRL4 and PVRL1 have been identified in patients with 
ectodermal dysplasia syndrome [244-247]. Ectodermal dysplasia can be caused by multiple 
genes and the severity of symptoms, which affect a variety of tissues, including skin, teeth, nails, 
sweat glands and hair, vary greatly [248]. Whereas patients with PVRL1 mutations that disrupt 
its ability to trans-interact with other nectins exhibit severe craniofacial abnormalities such as 
cleft palate, patients with loss-of-function PVRL4 mutations are characterized with milder 
symptoms, namely, sparse brittle hair and distinctly small teeth. These are consistent with some 
but not all sites where PVRL4 is known to be expressed, and suggest that other nectins or other 
functionally related CAMs may have some functions that are redundant with PVRL4. 
In addition to their role as “intercellular glue”, nectins interact with various cytoplasmic 
proteins through their PDZ-binding C-terminal sequences and with other membrane proteins 
through a lateral cis-interaction. Among proteins shown to be recruited to C-termini of nectins 
are afadin (AF6) [249] and PAR-3 [250]. The functional consequences of afadin interaction with 
nectins in MDCK cells are well studied. Specifically, it triggers the assembly of 
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afadin/Rap1/p120
ctn
 complex, which positively regulates membrane retention of E-cadherin, 
further assisting in adherens junction (AJ) formation in MDCK cells [251]. 
In addition to interactions with PDZ-containing proteins via their C-termini, two 
instances in which nectins engage in lateral interactions with other transmembrane proteins have 
been described. In particular, through their extracellular regions, PVRL1 and PVRL3 recruit an 
activated form of αVβ3 integrin to sites of adherens junctions, which also serves to potentiate 
downstream signaling [252]. After an adherens junction is established, PVRL3 further acts to 
recruit a PTPμ phosphatase via C-terminal region. This phosphatase then inhibits interaction of 
αVβ3 integrin with talin, dampening the level of integrin-dependent downstream signaling [253]. 
Another known example of nectin cis-interacting with other membrane-localized proteins is a 
recruitment of PDGF receptor by PVRL3-PVR interaction to sites of cell-cell contact in 
embryoid bodies which results in the potentiation of PDGF ligand-stimulated downstream 
signaling of PRGF receptor, which was shown to be afadin-dependent [254].  
To summarize, nectins play roles in promoting contact formation between cells of same 
as well as of distinct identity, which is made possible as a result of preferential heterotypic 
affinities between different nectins. Nectins are involved in guiding morphogenic processes in 
various tissues. Devoid of catalytic domains themselves, nectins recruit other signaling and 
scaffold proteins either through their cytoplasmic C-termini or laterally through their 
extracellular regions. In addition, it has been proposed that trans-interacting nectin cis-dimers 
self-organize into supramolecular structures at a site of cell-cell contact. Whereas other nectins 
are ubiquitously expressed, PVRL4 (nectin-4) has a limited pattern of tissue expression and is 
the least studied member of nectin family. 
PVRL4 is overexpressed in several types of solid tumors 
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Our initial analysis of the list of validated candidates has shown that 8 out of 11 ORFs, 
including PVRL4, corresponded to genes that localized to regions of focal amplification in 
tumors, according to a publicly available dataset [34]. In breast tumors in particular, PVRL4 
localizes to a statistically defined peak of focal amplification containing only 12 other genes, 
none of which known oncogenes, according to the Cancer Gene Census [29]. This peak of focal 
amplification was shared by 8% of all breast tumors in the dataset; furthermore, the PVRL4 
locus was gained without being focally amplified in another 30% of breast tumors. 
In addition to genomic evidence, expression of PVRL4 protein has been detected in large 
subsets of breast ductal adenocarcinoma [255], non-small cell lung adenocarcinoma [256] and 
ovarian serous carcinoma [257]. In particular, immunohistochemical analysis of breast ductal 
adenocarcinomas revealed that 62% of analyzed samples were positive for PVRL4, whereas its 
expression was absent in normal mammary epithelia [255], suggesting that PVRL4 expression 
can be upregulated through mechanisms other than focal amplification. In addition, PVRL4-
positive tumors were strongly associated with the poor five-year prognosis, and this striking 
correlation held true for patients with breast cancer (p<0.0001, [258]) and patients with non-
small cell lung cancer (p<0.0001, [256]). 
In summary, PVRL4 is strongly overexpressed and amplified in several types of cancers 
and is a predictor of poor outcome. The utility of PVRL4 as a potential tumor marker has been 
proposed; however, its functional involvement in transformation remains unclear. As discussed 
above, the investigation of the contribution of specific mediators of cell-cell adhesion in 
tumorigenesis is a conceptually intriguing problem. Thus, we set out to investigate whether 
PVRL4 promotes cell-to-cell attachment in TL-HMECs and if so, whether (and how) these 
contacts play a role in anchorage-independence phenotype.  
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Results 
The cytoplasmic region of PVRL4 is dispensable for anchorage-independent growth 
We focused our attention on the top scoring candidate identified in the screen, PVRL4 
(poliovirus receptor-like 4). To identify regions of PVRL4 responsible for driving anchorage-
independent colony formation, we created a series of PVRL4 deletion constructs, stably 
transduced them into TL-HMECs and verified their expression by Western blot (Figure 6a, b). 
Importantly, the endogenous expression of PVRL4 was not detectable in TL-HMECs (Figure 
6b), which is consistent with the absence of its expression in normal mammary gland by 
immunohistochemical analysis [255]. 
Ectopic expression of a full-length PVRL4 strongly induced anchorage-independent 
colony formation. Remarkably, deletion of the afadin-binding region of PVRL4, or of entire 
cytoplasmic region of PVRL4 did not affect its ability to promote anchorage-independent colony 
formation in TL-HMECs (Figure 6c). 
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The methylcellulose colony formation assay measures not only cell survival in the 
absence of attachment but also clonogenic potential of individual cells. We next asked whether 
cell viability in the absence of attachment will be enhanced by PVRL4 in the absence of the 
clonogenic growth requirement - thus, in conditions less stringent than those of the 
transformation assay - we cultured a population of TL-HMECs in suspension (as described in 
Methods section) and measured their ATP content by CellTiterGLO assay. Both the full-length 
Figure 6. PVRL4-induced anchorage-independent colony formation is carried out 
through its extracellular region. a, b, A series of PVRL4 deletion constructs were designed 
and their expression confirmed by Western blot. c, PVRL4 mutants from (a) were tested for 
their ability to induce ECM-independent colony formation in triplicate (error bars ± SD). 
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PVRL4 and its cytoplasmic deletion mutant promoted cell viability, further verifying that 
PVRL4 promotes cell survival in the absence of attachment (Figure 7a). 
Interestingly, when cultured in attachment-deprived conditions, non-transformed 
mammary epithelial cells are known to enter an alternative mode of detachment-triggered cell 
death, characterized with a robust induction of terminal squamous differentiation markers. This 
was previously described in hTERT-immortalized HMECs and MCF10A cells [142], and 
Figure 7. PVRL4 promotes cell viability and blocks the initiation of squamous 
differentiation of TL-HMECs is suspension. a, Cells with full-length PVRL4 or the 
cytoplasmic region deletion mutant were assayed for viability under conditions of ECM 
deprivation by measuring total ATP content in cells cultured on ultra-low attachment plates for 
72 hours. Values were normalized to empty vector-transduced sample. Assays were performed 
in triplicate (error bars ± SD). b, TL-HMECs expressing empty vector, full-length PVRL4 or 
cytoplasmic region deletion mutant containing cells were cultured on tissue culture-treated 
(adherent) or ultra-low attachment (suspension) dishes for 72 hours. RNA was isolated and 
mRNA levels of Transglutaminase 1, a marker of squamous differentiation, were measured by 
RT-qPCR. Transcript levels were normalized to β-Actin. qPCR was performed in quadruplicate 
(error bars ± SD). 
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parallels the response of keratinocytes to ECM deprivation [259]; a phenomenon that is perhaps 
best explained by a common epidermal lineage that these two cell types belong to. In agreement 
with what was seen in other non-transformed mammary epithelial cell lines,  suspension-cultured 
TL-HMECs did not undergo apoptosis in response to anchorage deprivation, yet they potently 
induce squamous differentiation markers, such as transglutaminase TGM1 (Figure 7b), keratin 
6A and involucrin (not shown). Notably, expressing full-length PVRL4 or its cytoplasmic region 
deletion mutant attenuated TGM1 induction. These data demonstrate that PVRL4 protects TL-
HMECs from the attachment deprivation-associated differentiation and allows proliferation in 
attachment-free conditions. Furthermore, this phenotype is facilitated by the extracellular part of 
PVRL4 rather than by its intracellular region. 
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PVRL4 facilitates cell-cell contact assembly which is required for anchorage-independent 
growth 
To verify experimentally whether PVRL4 can promote cell-to-cell attachment in TL-
HMECs, we performed aggregate formation assays with PVRL4-expressing and control cells. 
We observed that while TL-HMECs do not readily form aggregates in suspension by themselves, 
expression of PVRL4 drives rapid association of TL-HMECs into multicellular clusters within a 
short time span of 0.5-1 hour (Figure 8a, b). 
We sought to rule out the possibility 
that anchorage-independent colony formation 
that we observed in PVRL4-expressing TL-
HMECs was simply a result of a tissue 
culture artifact associated with either 
incomplete dissociation of cells prior to 
seeding into semi-solid medium or a potential 
de novo association of cells during growth in 
anchorage-independent conditions. To 
address this, we mixed equal numbers of 
dsRed- and GFP-labeled TL-HMECs 
transduced with PVRL4 and (i) seeded them 
into methylcellulose; or (ii) co-cultured the 
mixed population on adherent surface, 
subsequently seeding them into 
methylcellulose. Examining the colors of 
Figure 8. PVRL4 promotes cell clustering 
of TL-HMECs. a, Cells were dissociated off 
the tissue culture surface with trypsin-free 
cell dissociation buffer and kept in 
suspension for 1 h. b, small (3-5 cells) and 
large (>5 cells) cell clusters per field of view 
were counted, n = 3 (error bars ± SD). 
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resulting anchorage-independent colonies revealed that out of 56 colonies from the sample (i), all 
56 were single-color colonies, whereas in the sample (ii), 39 out of 40 colonies were single-
color, and only one colony contained both GFP and dsRed-positive cells (Figure 9a). The rarity 
of doubly-colored colonies demonstrates that PVRL4-induced colonies originate predominantly 
from individual cells. Consistent with this observation, passing cells through a 35 μm cell 
Figure 9. PVRL4-induced ECM-independent colonies originate from single cells. a, 
PVRL4 expressing TL-HMECs were stably transduced with dsRed or GFP and mixed in equal 
proportions, followed by (i) immediate plating into semi-solid medium, or (ii) co-culturing on 
adherent surface for 2 days, followed by plating into semi-solid medium. Resulting colonies 
were visualized under a fluorescent microscope and each colony was assessed for presence of 
red and green fluorescence. Representative phase-contrast and fluorescent images (red and 
green channel) are shown. b, Colony formation efficiency of TL-HMECs transduced with 
empty vector or vector expressing PVRL4 was compared  between cell suspensions that were 
filtered through a 35 μm nylon mesh strainer prior to plating into methylcellulose, or left 
unfiltered. ECM-independent colony formation assays were performed in triplicate (error bars 
± SD). 
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strainer immediately prior to being plated in anchorage-independent conditions did not affect 
colony numbers (Figure 9b), further confirming that PVRL4-induced colonies are clonal and that 
the observed increase in anchorage-free growth is not a result of pre-existing multicellular 
clusters having a survival advantage over single cells when grown in conditions of matrix loss. 
The extracellular region of 
PVRL4 exhibits preferential affinity 
for trans-interacting with its counter-
receptor PVRL1 [232] which is 
endogenously expressed in TL-
HMECs. To test whether PVRL1 
was necessary for PVRL4-driven 
cell-cell adhesion in TL-HMECs, we 
used an shRNA to stably deplete the 
PVRL1 transcript in a dsRed-labeled 
population of TL-HMECs and 
allowed cells to aggregate with 
PVRL4-expressing GFP-labeled TL-
HMECs. PVRL1 depletion resulted in exclusion of dsRed-labeled cells from multicellular 
clusters, whereas control shRNA-expressing cells were readily incorporated (Figure 10), 
confirming that PVRL4-mediated cell-cell contacts are carried out through its interaction with a 
counter-receptor PVRL1. 
 
Figure 10. PVRL4-driven cell-cell clustering is 
dependent on its putative trans-interaction partner 
PVRL1. GFP-labeled PVRL4-expressing TL-HMECs 
were allowed to aggregate with dsRed-labeled cells 
expressing either a PVRL1-targeting shRNA or a 
control shRNA. Representative phase-contrast and 
fluorescent images (red and green channels 
superimposed) are shown. 
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We then asked whether disrupting PVRL4-driven cell-cell contact formation via stably 
depleting its trans-interacting partner PVRL1 affects the ability of PVRL4 to promote colony 
formation in the absence of anchorage. To address this, we stably depleted PVRL1 transcript 
with two independent shRNA constructs and verified the degree of depletion by qPCR (Figure 
11a). Seeding PVRL1 shRNA- or control shRNA-transduced PVRL4-expressing TL-HMECs 
revealed that anchorage-independent colony formation was abolished by PVRL1 depletion 
(Figure 11b). This result paralleled the effect of PVRL1 depletion on PVRL4-driven cell-cell 
clustering and strongly implicated PVRL4/PVRL1-dependent cell-cell contacts in driving 
anchorage-independent growth. 
Figure 11. PVRL4-driven anchorage independence requires PVRL1. a, Efficiency of 
shRNA-mediated PVRL1 mRNA depletion was measured by RT-qPCR. PVRL1 transcript 
abundance was normalized to β-Actin. qPCR was performed in quadruplicate (error bars ± SD). 
b, PVRL4 was co-expressed with the indicated shRNAs and ECM-independent colony 
formation in TL-HMECs was assayed. Values were normalized to empty vector-transduced 
sample. Assays were performed in triplicate (error bars ± SD). 
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To further assess the involvement of PVRL4-PVRL1 trans-interaction on juxtaposed 
cells in driving anchorage-independent colony formation, we sought a physical means by which 
to disrupt PVRL4-induced cell-cell contacts to examine its effects on colony formation. 
Specifically, we asked whether antibodies directed towards the extracellular domain of PVRL4 
could block PVRL4-induced cell clustering and anchorage-independent growth. Indeed, cell 
clustering was completely abrogated in presence of three independent PVRL4 antibodies, 
whereas control IgG or a blocking antibody against E-cadherin (DECMA-1) did not produce 
such an effect (Figure 12a, b). In addition, an antibody targeting the extracellular region of 
PVRL1 also inhibited PVRL4-induced cell clustering (Figure 12c). Next, we tested whether a 
monoclonal antibody against PVRL4 affects anchorage-independent growth induced by it. 
Indeed, PVRL4-driven colony formation was inhibited to almost a basal level in the presence of 
a monoclonal antibody targeting the extracellular region of PVRL4, but no such effect was 
observed on colonies formed by cells transduced with PTEN shRNA, another transforming 
construct (Figure 12d), demonstrating that the observed inhibition is due to a PVRL4-specific 
effect of an antibody and not due to nonspecific effects. Taken together, our data indicate that 
PVRL4 enables anchorage-independent cell growth in a manner which is dependent on the 
assembly of PVRL4-PVRL1 cell-cell contacts, suggesting that these contacts may be providing a 
survival benefit in the context of the absence of anchorage. 
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Figure 12. Antibodies directed against the extracellular region of PVRL4 disrupt PVRL4-
driven cell-cell clustering and anchorage-independent growth. a-c, PVRL4-expressing TL-
HMECs were allowed to aggregate in presence of the indicated antibodies or isotype controls. 
Representative images are shown. Cell clusters were quantified as before. d, Anchorage-
independent growth induced by PVRL4 or an shRNA against PTEN was assayed in the presence 
of PVRL4-targeting antibody or control IgG. Colony numbers were normalized to control sample. 
Anchorage-independent colony formation assays were performed in triplicate (error bars ± SD). 
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The transmembrane and cytoplasmic regions of both PVRL4 and PVRL1 are dispensable 
for cell-to-cell attachment and anchorage-independent growth 
To further probe the functional link between PVRL4-driven cell-cell contact assembly 
and anchorage-independent growth, we asked whether the PVRL4-PVRL1-mediated cell surface 
interaction alone is sufficient for driving this phenotype. To address this question, we created 
chimeric constructs in which extracellular regions of PVRL1 and PVRL4 were fused to 
transmembrane regions of an unrelated transmembrane molecule, CD8 (Figure 13a), while the 
cytoplasmic regions of each of the two molecules were deleted. We first introduced PVRL4-
CD8tm into TL-HMECs, concomitantly depleting endogenous PVRL1 by RNAi (Figure 13d). 
Membrane localization of the chimeric construct was verified by immunofluorescence (Figure 
13f). Expression of PVRL4-CD8tm induced both cell clustering and ECM-independent colony 
formation, and both phenotypes were suppressed by stable depletion of endogenous PVRL1 
(Figure 13b, c). Importantly, clustering was restored when two populations of clustering-
incompetent cells - PVRL4-CD8tm expressing, PVRL1-depleted cells (PVRL4
+
; PVRL1
-
) and 
control cells (PVRL4
-
; PVRL1
+
) - were mixed together, independently verifying that such cell 
contacts assemble through formation of a PVRL4-PVRL1 trans-interacting module (Figure 13e). 
Finally, both cell clustering and colony formation defects induced by PVRL1 shRNA were 
rescued by expression of the shRNA-resistant PVRL1-CD8tm construct (Figure 13b, c). These 
data indicate an on-target nature of PVRL1 depletion phenotype and demonstrate that ability to 
withstand altered ECM environment is driven by the PVRL4-PVRL1 cell-surface trans-
interaction and not by intracellular or transmembrane regions of either molecule. 
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Figure 13. Expression of extracellular regions of PVRL4 and PVRL1 on the cell surface 
is sufficient for ECM-independent growth. a, Schematics representation of chimeric 
constructs consisting of extracellular domains of PVRL4 or an shRNA-resistant version of 
PVRL1 fused to the transmembrane domain of CD8 (blue). b, c TL-HMECs were stably 
transduced with the indicated combinations of expression constructs and assayed for 
anchorage-independent growth (b) and clustering (c). Anchorage-independent colony 
numbers were normalized to control sample. Anchorage-independent colony formation 
assays were performed in triplicate (error bars ± SD). d, Expression levels of endogenous and 
chimeric proteins were verified by Western blot. e, Clustering assays were performed with 
TL-HMECs expressing the following transgenes: (i) empty vector/control shRNA; (ii) 
PVRL4-CD8tm/control shRNA; (iii) PVRL4-CD8tm/anti-PVRL1 shRNA; (iv) 1:1 mixture 
of (iii) and (i). f, TL-HMEC cells infected with PVRL4-CD8tm or empty vector were fixed 
with methanol and stained with goat polyclonal anti-PVRL4 antibody followed by anti-goat 
Alexa Fluor 488 secondary antibody. 
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Figure 13 (Continued). 
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Multiple oncogenic perturbations converge upon cell-cell clustering phenotype 
We have shown that PVRL4-driven anchorage-independence is dependent on its ability 
to induce cell-cell contacts, suggesting that in conditions of an altered extracellular matrix, 
certain types of intercellular interactions may act to enable matrix-independent survival. We 
hypothesized that other oncogenic perturbations may also promotes cell-cell contact formation in 
TL-HMECs (Figure 14a), and that such contacts may play a role in anchorage-free survival. 
Strikingly, mutant Ras
V12
, myristoylated catalytic subunit of PI3K (Figure 14b), and shRNA-
mediated depletion of PTEN (Figure 14c, d) all promoted cell-cell clustering in TL-HMECs. 
None of the perturbations induced endogenous PVRL4 expression, as measured by FACS (not 
shown), which suggests that cell-cell attachment was mediated by other adhesion mechanisms. 
Mixing PTEN shRNA-expressing GFP-labeled cells with control shRNA-expressing dsRed-
labeled cells triggered formation of multicellular clusters that contained both GFP- and dsRed-
labeled cells (Figure 14e), showing that, in a manner similar to PVRL4, PTEN-depleted cells can 
heterotypically attach to other cells. Our experiment reveals that increased cell-to-cell attachment 
is a phenotype that multiple oncogenic perturbations converge upon, and it would be of interest 
to investigate further, what drives the increased adhesiveness in each of these settings. 
Taken together, our findings reveal a new mechanism which potentiates anchorage-
independent survival that may be operational in tumors. PVRL4-driven anchorage-independent 
growth is carried out in a manner dependent on cell attaching to one another and is readily 
blocked by antibodies that disrupt this attachment, hinting at it being a node for a potential 
therapeutic intervention. In addition, exploring whether increased cell-to-cell attachment in 
oncogene-transformed cells contributes to the prosurvival effect can further shed light on how 
various types of cell-cell adhesions contribute to tumorigenesis. 
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Figure 14. Clustering phenotypes are induced by various oncogenic perturbations. a, TL-
HMECs transduced with the indicated constructs were assayed for ability to promote anchorage-
independent colony formation in triplicate (error bars ± SD). b, TL-HMECs were stably transduced 
with indicated constructs and assayed for cell-cell clustering and colony formation in the absence 
of attachment. Representative clustering assay images are shown. c, TL-HMECs expressing two 
independent PTEN shRNAs or control shRNA were assayed for cell-cell clustering. Representative 
images are shown. d, Efficiency of PTEN mRNA depletion was measured by RT-qPCR. PTEN 
transcript abundance was normalized to β-Actin. qPCR was performed in quadruplicate (error bars 
± SD). e, GFP-labeled PTEN-depleted TL-HMECs were allowed to aggregate with dsRed-labeled 
control shRNA-expressing cells. Images were taken and processed as before. 
81 
 
Materials and Methods 
Constructs and virus production. For PVRL4 structure-function analysis, full-length 
ORF (accession number BC010423, aa 1-510) or indicated fragments (Supplementary Table 1) 
were generated by PCR and subcloned into pQCXIN retroviral vector (Clontech). PVRL4-CD8 
and PVRL1-CD8 chimeric fusions were created the following way: extracellular region of 
PVRL4 (accession number BC010423, aa 1-342) or PVRL1 (accession number BC113471, aa 1-
354) was amplified by PCR using a reverse primer containing a sequence for a 28-aa-long 
transmembrane domain of CD8A gene (accession number NM_001768, 543-626 bp), followed 
by a STOP codon. The resulting PCR product was subcloned into pQCXIN vector. To create an 
shRNA-resistant PVRL1-CD8 construct, silent mutations were introduced via site-directed 
mutagenesis with the following primers: sh3ResFW 5’-
CCAGGCGTCCACAGTCAAGTTGTGCAAGTCAATGACTCCATGTATG-3’ and sh3ResRV 5’-
CATACATGGAGTCATTGACTTGCACAACTTGACTGTGGACGCCTGG-3’ using QuikChange II Site-
directed mutagenesis kit (Agilent). Stable RNAi-mediated depletion was performed with 
shRNAs expressed in either pMSCV-PM or pGIPZ vector in miR-30 context that were either 
picked from the Hannon-Elledge shRNA library (Open Biosystems) or designed de novo (design 
and cloning protocol described in [260]). 21-nt sense sequences of shRNAs used in this study are 
listed in Supplementary Table 2. For stable labeling with fluorescent markers, cells were 
transduced with pHAGE-dsRed and pMSCV-CMV-GFP viruses. For assaying cell clustering in 
presence of oncogenes, TL-HMECs were transduced with pWZL-myr-p110-PI3K-Neo or empty 
pWZL-neo, and pBABE-H-RAS
V12
-puro or empty pBABE-puro. Retro- and lentiviral 
supernatants were generated by transient transfection of 293T cells following Mirus Bio's 
TransIT transfection protocol and harvested 48 hrs later. 
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Cell Culture. TL-HMECs expressing hTERT and SV40 Large T antigen [178] were 
cultured in MEGM (Lonza). Retroviral infections were performed in presence of 8 ug/mL of 
polybrene (Sigma). Successful viral integrants were selected with puromycin (2 ug/mL) or 
Geneticin (200 ug/mL). 
ECM-independent colony formation and anoikis assays. ECM-independent colony 
formation assays were performed as previously described [98] with minor modifications. Briefly, 
cells were suspended in reduced growth factor MEGM (containing 50% of kit-supplied BPA, 
Insulin, EGF and hydrocortisone) with 2% methylcellulose (Sigma) and plated on tissue culture 
dishes precoated with 0.6% Noble Agar (Sigma) in MEM (Invitrogen). For assays performed in 
6 cm dishes, 4.5 x 10
4
 cells per dish were plated. For assays performed in 6-well plates, 1.2 x 10
4
 
cells per well were plated. Colonies were counted after three weeks of growth. For each assay, an 
average of three replicates +/- SD is shown. For ECM-independent colony formation assays in 
presence of antibodies, the following antibodies were used: normal mouse IgG (MAB004, R&D 
Systems), mouse anti-human PVRL4 IgG2B (MAB2659, R&D Systems) at 4 μg/mL. For 
anoikis assays, cells were seeded on ultra-low attachment dishes (Corning) in reduced growth 
factor MEGM with 1% methylcellulose. For assays performed in 10 cm dishes, 1.4 x 10
5
 cells 
were plated; for assays performed in 6-well dishes, 2.0 x 10
4
 cells per well were plated. Total 
ATP measurements were performed using CellTiterGLO reagent (Promega) according to the 
manufacturer’s protocol after 72 hours of growth in suspension, and luminescence values were 
read with Victor X5 plate reader. For isolation of RNA or protein lysates, cell pellets were 
harvested after 72 hours of growth in suspension and washed with cold PBS prior to lysis. 
Clustering Assays. Cells were gently detached off the tissue culture surface with 
enzyme-free cell dissociation buffer (Invitrogen) and washed once with complete medium. 1.0 x 
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10
5
 cells were allowed to aggregate in 1 mL of complete medium in a 15-mL conical tube at 
room temperature. Tubes were gently flicked in the process to visually assess the progression of 
clustering. After 1-1.5 hr of incubation, cell suspension was poured into wells of 12-well dishes 
and allowed to attach to the bottom of the dish for 5-10 minutes. Cells were promptly visualized 
and photographed under phase contrast and fluorescent filters using AxioVert inverted 
microscope. When clustering assays were performed in the presence of antibodies, following 
antibodies were used: normal mouse IgG (MAB004, R&D Systems), normal goat IgG (AB-108-
1C, R&D Systems), mouse anti-human PVRL4 IgG2A (MAB26591, R&D Systems), mouse 
anti-human PVRL4 IgG2B (MAB2659, R&D Systems), goat anti-human PVRL4 (AF2659, 
R&D Systems), goat anti-human PVRL1 (AF2880, R&D Systems), DECMA-1 (anti-human E-
Cadherin, ab11512, Abcam). All antibodies were used at a concentration of 4 μg/mL. For short-
term culture of TL-HMECs in suspension, 4.0 x 10
5
 cells were allowed to aggregate in 1 mL of 
complete medium in a 15-mL conical tube at room temperature, mixed with 5 mL of 0.5% 
methylcellulose in reduced growth factor MEGM and incubated in wells of a 6-well ultra-low 
attachment dish (2 wells per sample) for indicated periods of time. 
RT-qPCR. Total RNA was isolated from cells using RNAeasy Plus kit (QIAgen). cDNA 
was synthesized from 1 μg of total RNA, using Superscript III Reverse Transcriptase 
(Invitrogen) and Oligo-dT primer (Invitrogen), following the manufacturer’s protocol. 
Quantitative PCR was performed with the Platinum SYBR Green qPCR Supermix-UDG kit 
(Invitrogen) on Applied Biosystems 7500 Fast Real Time PCR machine. Gene-specific primers 
were designed using Universal Probe Library (Roche Applied Science). PCR reactions were 
carried out in triplicates or quadruplicates. For each value, an average of at least three technical 
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replicates +/- SD is shown. Sequences of gene-specific primers used for qPCR are listed in 
Supplementary Table 3. 
Immunofluorescence. TL-HMEC cells were cultured on chamber slides (BD 
Biosciences), fixed with cold methanol following by blocking in blocking buffer containing BSA 
and cold water fish gelatin (Sigma-Aldrich). Cells were incubated with primary goat anti-PVRL4 
antibody (AF2659, R&D Systems), at 1:500 dilution at 4C overnight, followed by 1 hour 
incubation with chicken anti-goat Alexa-Fluor 488 secondary antibody (Invitrogen) at 1:2500 
dilution. Cells were mounted in Vectashield mounting medium with DAPI (Vector Labs) and 
visualized under a fluorescent microscope. 
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Chapter IV: Genetic and pharmacological validation of 
PVRL4 as a drug target 
Background and Rationale 
Antibody-based cancer therapeutics 
The proverbial “magic bullets” against cancer, monoclonal antibodies are arguably 
among the safest and most potent kinds of cancer therapeutics. Therapeutic antibodies are 
selected so that an antigen specifically overexpressed on the surface of cancer cells is targeted. 
This creates a wide therapeutic window which largely allows sparing healthy tissues from the 
antibody-elicited adverse effects. In addition, antibodies are highly efficacious as antitumor 
agents due to the multipronged nature of their attack on a tumor cell. Finally, a variety of 
chemical and genetic approaches can be used to modify antibodies and further enhance their 
tumor-killing capabilities. 
There are two distinct ways by which antibodies act to suppress tumor growth. First, 
antibody binding can result in direct inhibition of the function of an oncogene to which tumor 
cells display “addiction” to. Antibody binding to its antigen may directly inhibit its function via, 
for example, blocking its dimerization, assumption of an active conformation or interactions with 
ligands. In addition, antibody-antigen binding can trigger internalization of the receptor and thus 
cessation of signaling associated with it. A second mechanism of anti-tumor action of therapeutic 
antibodies is carried out via coating or opsonization of tumor cells by antibodies, which triggers 
the recruitment of a number of native immune system components. Such recruitment is 
mediated through interactions of the Fc region of an antibody and Fc receptors which are 
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expressed by several types of immune effector cells. Importantly, for opsonization to trigger 
immune effector cell recruitment, the concentration of antigen molecules on the cell surface must 
be sufficiently high, which further widens the therapeutic window between tumor and healthy 
tissue. 
The two major classes of immune cells that become recruited to tumor cells via their Fc 
receptors are (a) natural killer (NK) cells, which elicit a so-called antibody-dependent cellular 
cytotoxicity (ADCC) by releasing perforin which compromises cell membrane integrity and 
granzyme which initiates the apoptotic cascade, and (b) macrophages, which carry out the 
antibody-dependent cellular phagocytosis (ADCP). In addition to cell-based immune responses, 
antibodies attached to tumor cells trigger activation of immune complement, which also 
compromises cellular membrane integrity via assembly of a membrane attack complex (MAC). 
This mode of antibody-triggered cell killing is termed complement-dependent cytotoxicity 
(CDC).  
The specificity of an antibody molecule is mediated by two relatively compact 
complementarity-determining regions (CDRs) which are situated on Fab regions of the molecule. 
This property makes antibodies highly modular as therapeutic agents and their safety and 
efficacy can be further enhanced in a number of distinct ways. Thus, the humanization of 
mouse monoclonal antibodies, a process in which all of the antibody sequences with the 
exception of those that are engaged in antigen recognition are substituted with human sequences 
using recombinant DNA technology, greatly reduces the non-specific immune response to 
antibody infusion and permits their safe use in patients [261]. In addition, the modular nature of 
antibody molecules fosters the creation of newer generations of antibody-based therapeutics. A 
prominent example of antibody engineering to enhance their therapeutic potential is the creation 
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of bispecific antibodies where one of the two Fab regions targets the tumor-specific antigen and 
another is directed towards a CD3 receptor. A molecular design of this type allows a 
simultaneous recruitment of both the native immune system components via Fc region, as well as 
CD3-expressing cytotoxic T lymphocytes through anti-CD3 Fab entity. As a successful example, 
anti-EpCAM/anti-CD3 bispecific antibody catumaxomab is efficacious in treating malignant 
ascites (tumor cells that invade into peritoneum) [262]. Yet another direction is creation of 
antibodies that are chemically conjugated to chemotherapeutics, bacterial toxins and 
radionuclides, which allows using antibodies as vehicles for delivery of toxic “payloads” 
directly to tumor cells. This short overview covers just some of the examples of the great 
versatility of antibody-based therapeutics. 
As a next step of this study, we sought to verify, in a preclinical setting, whether PVRL4 
can have a potential utility as a target for antibody-based therapy against cancer. Indeed, we have 
already shown that PVRL4-driven anchorage-independent growth is dependent on cell-cell 
contact formation, and can be directly inhibited by monoclonal antibodies targeted against its 
extracellular region. In addition, PVRL4 becomes overexpressed in at least three types of solid 
tumors whereas in corresponding normal tissues its expression is not detected. Taken together, 
this suggests a potential applicability of PVRL4 as a therapeutic target. As a next step, we sought 
to validate whether cancer cells that overexpress PVRL4 endogenously also require it for the 
maintenance of transformed phenotype in vitro and in vivo. Moreover, we directly tested the 
proposed therapy hypothesis by asking whether PVRL4-driven xenograft growth in vivo can be 
suppressed by antibodies targeted towards its extracellular region.  
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Table 2. The prevalence of PVRL4 amplifications across breast cancer subtypes. The 
fourth column represents how many tumors in each subtype are expected to have PVRL4 
amplification if there was no correlation between tumor subtype and PVRL4 amplification. 
Results 
PVRL4 is essential for the transformed phenotype of breast cancer cells in vitro 
Having shown that PVRL4 enables the escape of epithelial cells from the growth 
restriction associated with the lack of proper ECM, we next wanted to test its functional 
relevance to breast tumor-derived lines. We have analyzed a publicly available dataset of copy 
number alterations from 541 breast tumors [263] and identified high-level amplifications of 
PVRL4 in 6.5% of samples (Table 2). Importantly, high-level amplifications of PVRL4 were 
statistically significantly overrepresented in breast tumors with basal-like expression profile 
compared to the rest of subtypes classified by PAM50 qPCR assay [264]. 
 
  
Expression 
subtype 
Total samples 
in database 
Samples with 
PVRL4 
amplification 
Expected by 
random chance 
P value (Z-
score statistic) 
Luminal A 235 6 16.5 0.004 
Luminal B 133 8 9.3 0.33 
HER2-enriched 58 5 4 0.32 
Basal 99 16 7 0.0002 
Claudin-low 8 0 0.6 0.22 
Normal-like 8 0 0.6 0.22 
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In particular, a high-level copy number amplification was detected in 16% of all basal-
like tumors (Figure 15a), thus strongly implicating PVRL4 in the pathogenesis of a particularly 
aggressive breast cancer subtype. A particularly strong focal amplification (~50 kb) of a genomic 
region which included PVRL4 was harbored by an inflammatory breast cancer cell line SUM190 
(Figure 15b) [34]. This region of focal amplification contained a total of just five genes - none of 
them with known roles in tumorigenesis, which raised a possibility that the amplification of this 
locus was due to a potential survival advantage that PVRL4 provides to cells. 
SUM190 cells exhibited a strong propensity for cluster formation when incubated in 
suspension for 0.5-1 hours. Importantly - and in parallel with the effect seen in TL-HMECs - 
anti-PVRL4 antibodies (Figure 16a), as well as an shRNA against PVRL4 (Figure 16b) 
completely abrogated clustering of SUM190 cells. Because PVRL4-driven cell contacts are 
Figure 15. Amplification of PVRL4 in breast cancer. a, PVRL4-amplified samples are 
overrepresented in breast tumors with basal-like expression signatures. b, A view from the 
Integrated Genome Viewer program showing focal amplification of PVRL4 locus in SUM190 
(HER2-amplified) cell line. The degree of amplification is denoted by the intensity of the color. 
90 
 
assembled via PVRL4 interaction with PVRL1, PVRL4 can potentially facilitate cell adhesion to 
any PVRL1-expressing cell type. Clustering phenotype is prominent in circulating tumor cells 
and is associated with greater metastatic capacity in mouse models. In addition, adhesion of 
CTCs to the endothelium can facilitate extravasation and metastatic seeding. To test this in vitro, 
we asked whether SUM190 can adhere to HMVEC-Ls, a primary microvascular endothelial cell 
line from human lung, which is a target organ for breast cancer metastasis. Indeed, we have 
observed heterotypic clustering of SUM190 and HMVEC-L cells, and just like self-self SUM190 
clustering, SUM190-to-HMVEC-L clustering was abrogated by anti-PVRL4 antibody (Figure 
16c) as well as by an shRNA against PVRL4 (Figure 16d). 
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Figure 16. SUM190 cell clustering is PVRL4-driven. a, b, SUM190 cells were assayed for cell 
clustering in presence of the indicated antibodies (a) or shRNAs (b). c, d, GFP-labeled SUM190 
cells were assayed for heterotypic clustering with dsRed-labeled HMVEC-L cells in presence of 
antibodies (c) or shRNAs (d). 
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We next asked whether PVRL4 is functionally involved in driving transformation of 
SUM190 cells. To test this, we stably expressed four independent shRNAs against PVRL4 in 
SUM190 cells, confirming the extent of the transcript depletion by RT-qPCR. In agreement with 
the phenotype seen with PVRL4 overproduction in TL-HMEC line, RNAi against PVRL4 
potently reduced anchorage-independent colony formation as well as clonogenic survival of 
adherent SUM190 cells, indicating that PVRL4 plays an important prosurvival role in breast 
cancer cells. Importantly, observed effects correlated with the degree of RNAi-mediated mRNA 
depletion (Figure 17). 
  
Figure 17. PVRL4 is essential for the transformation of SUM190 breast cancer cells. PVRL4 
mRNA was stably depleted from SUM190 cells by four independent shRNAs. Transcript levels 
were measured by RT-qPCR and normalized to β-actin. qPCR was performed in quadruplicate 
(error bars ± SD). PVRL4-depleted and control cells were assayed for clonogenic survival and 
anchorage-independent colony formation. Assays were performed in triplicate (error bars ± SD). 
All values were normalized to uninfected control sample. 
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To confirm that the 
observed phenotype was 
specific for PVRL4 
depletion, we used a 
PVRL4-CD8tm construct 
to rescue the colony 
formation defect. 
Coexpression of PVRL4-
CD8tm in presence of 
PVRL4-targeting shRNAs 
alleviated the clonogenic 
survival defect, confirming 
its on-target nature (Figure 
18a, b). In addition, this 
result demonstrates that the 
prosurvival function of 
PVRL4 is carried out via its 
extracellular region in 
breast cancer cells, which is 
consistent with the ability of PVRL4-CD8tm construct to enable colony formation in conditions 
of anchorage independence in TL-HMECs. 
  
Figure 18. Transforming phenotype of PVRL4 in SUM190 
cells is carried out through its extracellular region. a, The 
PVRL4-CD8 chimeric construct was used to rescue the defect in 
clonogenic survival observed with RNAi-mediated PVRL4 
depletion. Assays were performed in triplicate (error bars ± SD). 
Colony numbers were normalized to the control shRNA sample. 
b, Expression levels of endogenous and chimeric proteins were 
verified by Western blot. 
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Targeting PVRL4 inhibits tumor growth in vivo 
To determine whether growth inhibition observed with PVRL4 depletion in vitro was 
also relevant for growth of breast cancer cell 
lines in vivo, we stably transduced SUM190 cells 
with a control shRNA or shRNA targeting 
PVRL4, and orthotopically implanted them into 
mammary fat pads of nude mice. Depletion of 
PVRL4 by RNAi from SUM190 resulted in a 
significantly reduced xenograft growth as 
compared to control shRNA (Figure 19a, b), 
demonstrating that PVRL4 is an important 
determinant of cancer cell growth in vivo as well 
as in vitro. A similar effect was achieved with a 
triple-negative breast cancer line SUM185, 
transduced with an anti-PVRL4 shRNA (Figure 
19c), demonstrating that the observed effect is 
not limited to an isolated cell line. 
  
Figure 19. RNAi-mediated suppression of 
PVRL4 inhibits xenograft growth. a, b, Female 
nude mice were injected into mammary fat pads 
with SUM190 cells expressing indicated shRNAs 
(n=10 per group, error bars ± SD). Xenografts 
were excised, scaled (a) and photographed (b). c, 
SUM185 cells expressing indicated shRNA were 
injected into mammary fat pads of female nude 
mice (n=10 per group, error bars ± SD). Tumor 
volume was measured with calipers at indicated 
time points. 
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Having previously shown that a monoclonal antibody which blocks PVRL4-driven cell 
clustering and anchorage-independent growth of TL-HMECs in vitro, we sought to determine 
whether this antibody would similarly alleviate SUM190 xenograft growth in an in vivo setting. 
To address this, we treated mice bearing ~50 mm
3
 SUM190-eGFP xenografts with four 
consecutive intravenous injections of either anti-PVRL4 monoclonal antibody or isotype control 
IgG at 15 mg/kg each. After the last treatment, we continued to monitor tumor growth for seven 
more days. Whereas tumor volumes in the control group steadily increased over time, the 
PVRL4 antibody-treated group displayed a remarkable stalling of tumor growth throughout the 
course of injection regimen (Figure 20a). Immunoblotting of tumor lysates revealed that PVRL4 
antibody treatment resulted in a precipitous decline of PVRL4 protein levels even after 7 days 
after the last antibody infusion, suggesting that high PVRL4-expressing cells were preferentially 
eliminated over the course of the treatment (Figure 20b). Dissection of excised xenografts 
revealed a softer, paste-like composition of PVRL4 antibody-treated tumors compared to the 
more solid consistency of control-treated samples. This latter observation was corroborated by 
histological analysis (Figure 20c), which revealed areas of widespread necrosis and, importantly, 
loss of cell contacts, in tumors with the strongest response to treatment (D-F) when compared to 
control IgG-treated tumors (A-C). Finally, examination of a three-dimensional tumor architecture 
in control- and anti-PVRL4 antibody-treated tumors by two-photon confocal microscopy 
revealed reduced cell-cell contacts in anti-PVRL4 antibody treated samples as compared to 
control (Figure 20d). Loss of cell contacts and necrosis observed in explanted tumors provides in 
vivo support to our model that PVRL4-driven ability to tolerate loss of anchorage by virtue of 
direct interaction between neighboring cells. 
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Figure 20. Antibodies against PVRL4 inhibit xenograft growth and reduce cell-to-cell 
adhesion within tumors. a, Female nude mice with ~50 mm
3 
SUM190-eGFP xenografts were 
randomized into two cohorts (N=7 per group) and injected with anti-PVRL4 monoclonal 
antibodies or control IgG at indicated days. Tumor volume was measured with calipers (error 
bars ± s.e.m.). b, Levels of PVRL4 protein were measured in tumor lysates from anti-PVRL4 
antibody or control-treated mice, seven days after the last treatment. c, Tumor sections from 
control IgG (A-C) or anti-PVRL4 antibody-treated (D-F) mice were stained with 
hematoxylin/eosin and photographed. Representative images are shown. d, Freshly explanted 
tumors from control IgG or anti-PVRL4 antibody-treated mice (N=3 per group) were visualized 
using multiphoton confocal microscope. Representative images are shown. 
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One possible explanation for the in vivo tumor inhibitory effect could be that the Fc-
region drove recruitment of components of innate immunity by the anti-PVRL4 antibody. To test 
this possibility, we asked whether the anti-PVRL4 antibody which we used, was capable of 
inducing ADCC (antibody-dependent cytotoxicity) in vitro. Specifically, we mixed SUM190 
cells with fresh human NK cells and measured the relative degree of cell lysis induced by either 
anti-PVRL4 antibody or control IgG. No increase in cell lysis was observed with anti-PVRL4 
antibody over isotype control-incubated cells, demonstrating that the Fc region of this antibody 
was inefficient at recruiting Fc receptor-containing cells. These data suggest that the observed 
tumor inhibitory effect is likely a 
consequence of a direct blockade of 
PVRL4 function (Figure 21). 
Taken together, these data 
suggest that targeting PVRL4-
driven tumors with a monoclonal 
antibody directed towards its 
extracellular region results in the 
dramatic inhibition of growth and 
disruption of cell-cell contacts, 
demonstrating a therapeutic efficacy 
of such approach. One caveat 
associated with targeting junctional 
proteins as an anticancer therapy 
strategy is that it may inadvertently 
Figure 21. Anti-PVRL4 antibodies do not trigger in 
vitro ADCC of SUM190 cells. Europium-labeled 
SUM190 cells were incubated with fresh human NK 
cells in presence of an isotype control or anti-PVRL4 
antibody, and the degree of lysis was measured by the 
DELFIA Europium assay. The maximum signal was 
determined by a complete lysis of labeled SUM190 
cells in DELFIA lysis buffer. As a positive control, 
hMB humanized mouse lymphoma cells were mixed 
with effector cells in presence of ADCC-competent 
anti-CD52 antibody. 
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induce an EMT phenotype and, while suppressing the primary tumor growth, concomitantly 
instigate metastasis. To test this, we measured levels of E-cadherin (an epithelial marker) and 
vimentin (a mesenchymal marker) in SUM190 xenografts treated with anti-PVRL4 antibody in 
vivo (Figure 22a), as well as in cultured SUM190 cells in which PVRL4 expression was inhibited 
by RNAi (Figure 22b). In each case, E-cadherin and vimentin protein levels remained 
unchanged, demonstrating that inhibiting PVRL4 in SUM190 cells does not cause EMT; neither 
does it select for cells with EMT-like characteristics in vivo. However, this analysis cannot rule 
out the possibility in which a small subset of cells undergo EMT as a result of treatment.   
 
Figure 22. PVRL4 inhibition does not trigger EMT in SUM190 cells. a, Tumor lysates from 
control antibody- or anti-PVRL4 antibody-treated mice were blotted for E-cadherin and 
vimentin. b, PVRL4 was stably depleted by two independent shRNAs in SUM190 cells and 
lysates were blotted for E-cadherin and vimentin. 
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Another safety concern associated 
with targeting PVRL4 with a monoclonal 
antibody is that such treatment has a 
potential for inducing damaging effects in 
tissues that normally expressing the antigen. 
Both human and mouse PVRL4 were 
strongly recognized by anti-PVRL4 antibody 
when expressed on the cell surface (Figure 
23). Among normal mouse tissues, PVRL4 
expression is strongest in cornea and skin 
epidermis [265]. Skin surface of mice 
treated with anti-PVRL4 antibodies was not 
visibly affected by treatment, and mice 
appeared healthy overall, demonstrating that 
targeted therapy against PVRL4 does not 
induce acute side effects in this organism, 
not ruling out, however, a potential side 
effects with the chronic exposure. Taken together with our findings that functionally link PVRL4 
to tumorigenesis, as well as with its widespread expression in multiple tumor types, these data 
validate, in a preclinical setting that PVRL4-driven cell-cell contacts can be targeted with 
antibodies as a potential therapeutic strategy directed against a broad spectrum of tumor types. 
  
Figure 23. Both mouse and human PVRL4 
are recognized by the anti-PVRL4 antibody. 
293T cells were transfected with empty 
pQCXIN (green line), pQCXIN-human PVRL4 
(blue line) or pCMV-SPORT6-mouse PVRL4 
(magenta line). Live-cell FACS was performed 
with mouse anti-human PVRL4 antibody 
followed by anti-mouse secondary antibody 
conjugated to Alexa Fluor 488 fluorophore. 
FITC-A fluorescent signal for three labeled cell 
populations is shown. 
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Materials and Methods 
Cell Culture. SUM190 and SUM185 cells (provided by K. Polyak) were cultured in 
SUM medium, which is a 1:1 mix of MEGM and F12:DMEM (Invitrogen), supplemented with 
5% FBS (Invitrogen). 293T cells were cultured in DMEM (Invitrogen), supplemented with 10% 
FBS. HMVEC-L cells (Lonza) were cultured in EGM-2 medium (Lonza). Retroviral infections 
were performed in presence of 8 ug/mL of polybrene (Sigma). For SUM190 and SUM185 
infections, cells were plated in 6-well dishes and centrifuged in presence of viral supernatant and 
polybrene for 1 hr at 2,000 r.p.m. Successful viral integrants were selected with puromycin (2 
ug/mL) or Geneticin (200 ug/mL for TL-HMECs, 750 ug/mL for SUM190). Mouse pSPORT6-
PVRL4 was purchased from Open Biosystems and transiently transfected into 293T cells 
following Mirus Bio's TransIT transfection protocol. 
Anchorage-independent colony formation assays. ECM-independent colony formation 
assays were performed as previously described [98] with minor modifications. Briefly, cells were 
suspended in SUM medium with 2% methylcellulose (Sigma) and plated on tissue culture dishes 
precoated with 0.6% Noble Agar (Sigma) in MEM (Invitrogen). For assays performed in 6 cm 
dishes, 4.5 x 10
4
 cells per dish were plated. For assays performed in 6-well plates, 1.2 x 10
4
 cells 
per well were plated. Colonies were counted after three weeks of growth. For each assay, an 
average of three replicates +/- SD is shown.  
Clonogenic Assays. For assaying clonogenic potential, 1.0 x 10
3
 SUM190 cells were 
seeded in 6 cm tissue culture-treated dishes. After 3 weeks of growth, resulting colonies were 
stained with 1% Methylene Blue and counted. For each assay, an average of three replicates +/- 
SD is shown. 
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Clustering Assays. Cells were gently detached off the tissue culture surface with 
enzyme-free cell dissociation buffer (Invitrogen) and washed once with complete medium. 1.0 x 
10
5
 cells were allowed to aggregate in 1 mL of complete medium in a 15-mL conical tube at 
room temperature. Tubes were gently flicked in the process to visually assess the progression of 
clustering. After 1-1.5 hr of incubation, cell suspension was poured into wells of 12-well dishes 
and allowed to attach to the bottom of the dish for 5-10 minutes. Cells were promptly visualized 
and photographed under phase contrast and fluorescent filters using AxioVert inverted 
microscope. When clustering assays were performed in the presence of antibodies, following 
antibodies were used: normal mouse IgG (MAB004, R&D Systems), mouse anti-human PVRL4 
IgG2B (MAB2659, R&D Systems). All antibodies were used at a concentration of 4 μg/mL. 
Western Blotting. Cells were lysed in NP-40 buffer (1% NP-40, 25 mM Tris-HCl 
pH=7.4, 150 mM NaCl, 1mM EDTA, 10% Glycerol) in the presence of protease and 
phosphatase inhibitor tablets (Roche). Adherent cells were lysed for 15 minutes on ice, followed 
by scraping into Eppendorf tubes and centrifugation at 14,000 rpm for 15 min at 4C. Protein 
concentration in supernatants was measured using BCA assay (Pierce) and lysates were brought 
to identical concentrations with lysis buffer. Samples were mixed 1:1 with 2X Laemmli buffer 
(125 mM Tris-HCl, pH = 6.8, 4% SDS, 20% Glycerol, 0.004% Bromophenol Blue) and DTT 
was added to final concentration of 25 mM. Samples were boiled for 8 minutes and loaded on 
Tris-Glycine 4-20% or 4-12% gradient gels (Invitrogen). Transfer/blotting were performed as 
described elsewhere. Western blotting was performed with the following antibodies: goat anti-
PVRL4 (AF2659, R&D Systems), goat anti-PVRL1 (AF2880, R&D Systems), mouse anti-
Vinculin (V9131, Sigma), mouse anti-RAN (610340, BD Biosciences). 
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Live–cell FACS analysis. 293T cells were gently detached off the adherent surface with 
enzyme-free cell dissociation buffer (Invitrogen) and washed once with serum-free DMEM. 
Cells were incubated with 10% normal goat serum (Invitrogen) for 10 min at room temperature, 
then with a primary antibody at 1:100 dilution in 5% goat serum for 30 min on ice, followed by a 
goat-anti-mouse secondary antibody coupled to Alexa Fluor 488 (Invitrogen) at 1:1000 dilution 
in PBS for 30 min on ice. Fluorescent signal was measured on LSR II FACS Analyzer and 
analyzed with FlowJo software. 
In vivo experiments. For subcutaneous xenograft assays with shRNA-transduced cells, 
nude mice (Taconic) were injected orthotopically into the mammary fat pad with 1.0 x 10
6
 
SUM190 or SUM185 cells in serum-free medium with 50% Matrigel (BD Biosciences), one 
injection site per mouse. Tumors were excised after four weeks of growth, scaled and 
photographed. For antibody treatment experiment, 15 mg/kg of anti-PVRL4 antibody or normal 
IgG control (R&D Systems) was injected 4 times at days 0, 1, 4 and 7. Treatment response was 
assessed by caliper measurements of the tumors in anesthetized mice. Mice were euthanized 15 
days post treatment initiation and tumors were harvested and representative parts subjected for 
paraffin embedding, western blot analysis and direct microscopy on an inverted Olympus 
Multiphoton Laser Scanning Confocal Microscope using a 25x objective. Images were analyzed 
by IMARIS software package. 
Antibody dependent cell-mediated cytotoxicity (ADCC) assay. PVRL4 antibody-
dependent cell-mediated cytotoxicity was assessed by using europium-labeled (DELFIA cell 
cytotoxicity assay, Perkin Elmer) SUM190 cells as target cells in a 96-well format. Primary 
human NK cells were isolated from a fresh buffy coat using a magnetic purification (EasySep 
Human CD56 positive selection Kit, StemCell Technologies). Cells were co-incubated at 1:1, 
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1:10 and 10:1 effector-to-target cell ratio. 25 µg/ml anti-PVRL4 antibody was added to 
respective wells. Cells were co-incubated for 4 hours and cell-free supernatants further subjected 
to time-lapsed fluorescence quantification using a TECAN Infinite 200 PRO plate reader. To 
determine maximal range of europium release, target cells were lysed in DELFIA lysis buffer. 
Levels of released europium are displayed as percentage values of maximum release determined 
by lysis. To control for NK cell effector functionality, ADCC assay was performed using the 
hMB lymphoma model [266] as a target cell line in presence of 25 µg/ml of anti-CD52 antibody 
(alemtuzumab). 
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Chapter V: The signaling mechanism of PVRL4 
Background and Rationale 
Interactions of cell adhesion molecules with signaling proteins 
Far from being passive intercellular “glue”, cell adhesion molecules (CAMs) are known 
to affect cell signaling in a number of ways. Even though CAMs, as a rule, lack catalytic 
domains themselves, they make use of their extracellular and cytoplasmic regions to recruit 
signaling-competent proteins. The surface of the cell and the subcellular region is densely 
populated with a variety of signaling-competent molecules. Among these molecules are receptors 
of intercellular signals – first and foremost, integrins and receptor tyrosine kinases, as well as 
non-receptor tyrosine kinases, signaling adaptor proteins and phosphatases. Various signaling 
proteins are known to physically associate with CAMs, which influences their downstream 
signaling. The great variety of the types of interaction between CAMs and other proteins can be 
divided into distinct categories with respect to directionality and the part of the molecule 
involved in interaction: (1) interactions of extracellular regions of CAMs with signaling 
receptors on neighboring cells; (2) interactions with intracellular proteins through cytoplasmic 
regions of CAMs and (3) lateral cis-interactions with transmembrane receptors (Figure 24). 
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A prototypical example of a trans-interaction of a CAM with another cell-surface signaling 
molecule (Figure 24-1A) is at the core of an immune synapse formation mechanism which is 
mediated via juxtacrine interactions of leukocyte-specific IgCAMs and integrins. Thus, a trans-
interaction between ICAM-1 on the surface of antigen-presenting cells and αLβ2 and αMβ2 
integrins on T cells promotes the immune synapse formation between these two cell types, 
followed by T-cell activation [267]. An additional layer of complexity to this mode of CAM 
action is added by the susceptibility of extracellular regions of some CAMs for becoming 
Figure 24. Cell adhesion molecules interact with other signaling proteins in a variety of 
ways. 1A, Trans-interaction between a CAM and a signaling receptor, such as integrin. 1B, 
Trans-interaction of a cleaved extracellular region of a CAM with a signaling receptor. 2A, 
Recruitment of signaling adaptors to the cytoplasmic region of a CAM. 2B, Nuclear translocation 
of cleaved cytoplasmic regions of CAMs and their participation in transcriptional regulation. 3, 
Lateral cis-interaction of CAMs with integrins and receptor tyrosine kinases. 
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cleaved by a class of metalloproteinases called sheddases. The release of an extracellular region 
of a CAM into the intercellular space allows it to engage with its respective receptor on cells at a 
distance (Figure 24-1B). For example, the interaction of cleaved extracellular region of L1CAM 
with αvβ5 integrin was shown to promote the migratory behavior in CHO cells, and this 
phenotype can be blocked by integrin-specific antibodies [203]. Importantly, various sheddases, 
such as ADAM17, become upregulated in cancer, raising an important possibility that such mode 
of CAM-mediated signaling can be selected for during the process of tumorigenesis [268]. 
Cytoplasmic regions of CAMs can bind a variety of signaling adaptors which may result 
in stimulation or, on the contrary, suppression of intracellular signaling (Figure 24-2A). As 
described previously, adherens junction-localized E-cadherin molecules sequester critical 
signaling adaptors β-catenin and p120-catenin, thus inhibiting Wnt- and small GTPase-
associated signaling. In other instances, cytoplasmic regions of CAMs can promote pro-survival 
signaling events. As an example, homotypic trans-interactions of NCAMs on juxtaposed 
neuronal cells trigger the recruitment of RPTPα phosphatases to C-termini of NCAM. This, in 
turn, activates a non-receptor tyrosine kinase Fyn, a member of the Src family of kinases, which 
triggers neurite outgrowth [269]. 
Not only extracellular, but cytoplasmic regions of CAMs as well are susceptible for 
cleavage by proteases, and resulting fragments can carry out autonomous functions (Figure 24-
2B). As an example, γ-secretase-cleaved C-terminal region of EpCAM, the cell adhesion 
molecule upregulated in a variety of tumors, translocates to the nucleus where it directly 
influences Wnt-regulated gene expression through forming a complex with FHL2, β-catenin and 
LEF [270]. 
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A third mode of cell adhesion molecule-influenced signaling is the lateral recruitment of 
transmembrane signaling molecules, such as integrins and receptor tyrosine kinases (Figure 24-
3). A well-studied example is a cis-interaction of NCAM and FGFR in neuronal cells, which 
facilitates FGFR activation independently of its ligand [271, 272]. Furthermore, as was described 
in chapter II, nectin-3, through its extracellular region, was shown to engage in lateral 
interactions with αvβ3 integrin, inhibiting its activation [253]. In addition, nectin-3 was shown to 
bind and activate PDGF receptor at sites of cell-cell junctions in MDCK cells in a manner that is 
dependent on its cytoplasmic binding partner, afadin [254]. 
In conclusion, cell adhesion molecules employ a variety of interaction modes, thereby 
influencing a wide range of signaling events. Some of the signaling events associated with 
CAMs are cell-cell adhesion-dependent and are thought to be further enhanced via formation of 
supramolecular chains of cis- and trans-interacting CAM dimers. As an example, formation of 
such supramolecular structures has been proposed for both homotypically trans-interacting 
CAMs, such as NCAM [273], as well as for heterotypically interacting SynCAM1 and 
SynCAM2 [274]. Yet other signaling events modulated by CAMs are independent from their 
participation in cell-cell contacts, being carried out by autonomously acting proteolytic 
fragments.  
Through structure-function characterization of PVRL4, we have demonstrated that, in 
normal mammary epithelial cells and in cancer cells alike, PVRL4 carries out its prosurvival 
action through its extracellular region. Importantly, a chimeric fusion of PVRL4 extracellular 
region and the transmembrane domain of CD8 protein is sufficient for driving cell-cell clustering 
and colony formation, whereas the extracellular region of PVRL4 that is not anchored to the 
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membrane fails to induce anchorage-independence in TL-HMECs. Thus, the extracellular region 
of PVRL4 must be tethered to the cell surface in order to exert its function.  
Integrin β4 - an atypical member of the integrin family 
In mammalian cells, the integrin family of adhesion molecules consists of 8 β and 18 α 
subunits, which associate into 24 distinct heterodimers. Both α and β subunits interact with the 
extracellular matrix, whereas intracellular interactions with actin filaments and signaling 
adaptors are carried out by β subunits [111]. 
Integrin β4 is a unique member of the integrin family. Whereas all of the other integrins 
have very short cytoplasmic regions (~50 amino acids), the cytoplasmic region of a β4 integrin is 
atypically long, consisting of 1017 amino acids. Integrin β4 forms heterodimers exclusively with 
α6 subunit, which determines its preference for laminin for a ligand. In further distinction from 
the rest of the integrin family, integrin β4 does not take part in forming canonical focal 
adhesions, but instead, creates attachment points for keratin-containing intermediate filaments in 
adherent cells, forming structures known as hemidesmosomes [275]. As opposed to other 
integrins, the C-terminus of integrin β4 does not bind FAK; however, it can activate Src family 
kinases (SFKs) in a FAK-independent manner via recruitment of SHP-2 phosphatase [276]. 
Activated SFKs, in turn, phosphorylate several key tyrosine residues in the C-terminus of β4 
integrin, creating docking sites for Shc adaptor, which drives the activation of Ras and PI-3 
kinase [277]. 
Originally identified as a tumor cell surface specific protein TSP180 [278], integrin β4 is 
upregulated in a variety of cancers and is functionally involved in tumorigenesis [275]. An 
extensive array of evidence functionally links integrin β4 to breast cancer. Similarly to PVRL4, 
integrin β4 expression is associated with poor prognosis and basal-like expression profile [279, 
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280]. Integrin β4-specific antibodies were shown to suppress anchorage-independent growth in a 
panel of breast cancer cell lines [281]. Integrin β4 interacts in cis- with a number of receptor 
tyrosine kinases, such as EGFR [282], c-Met [283] and HER2 [284], and C-terminal deletion 
mutant integrin β4 transgene causes delay of tumor onset and reduced invasiveness in the 
MMTV-HER2 mouse model of mammary tumorigenesis [284]. 
Due to its atypically long C-terminus which serves as an organizing scaffold for a number 
of downstream signaling effectors, integrin β4 is thought to exhibit a significant degree of ECM-
autonomous signaling. This signaling autonomy was convincingly demonstrated in a study 
utilizing chimeric constructs where extracellular and transmembrane regions of integrin β4 were 
substituted with those on the TrkB receptor tyrosine kinase. Dimerization of two such chimeric 
molecules on the cell surface by adding TrkB ligand, BDNF, was sufficient to trigger SFK 
activation in a manner which was dependent on SHP-2 phosphatase [285].  
In this chapter we use mass spectrometry analysis to identify novel binding partners of 
PVRL4 and identify integrin β4 as its cis-binding interactor. Next, we evaluate the relevance of 
this interaction as well as integrin β4-associated downstream signaling to PVRL4-driven 
transformation in TL-HMECs and SUM190 cells. 
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Results 
Identification of integrin β4 as a novel interacting partner of PVRL4 via mass spectrometry 
We have demonstrated that PVRL4-PVRL1 cell surface trans-interaction provides a 
survival advantage in anchorage-free conditions. As a next step, we sought to gain insight into 
the mechanism by which this interaction becomes sensed by a cell and interpreted as a 
prosurvival signal. Neither of two molecules possesses catalytic activity; in addition, our data 
show that transmembrane as well as cytoplasmic regions are dispensable for anchorage-
independence phenotype. Therefore, we considered a possibility that the assembly of a PVRL4-
PVRL1 interacting module on the interface of two neighboring cells triggers lateral recruitment 
and/or activation of cell surface-localized proteins, which, in turn, conveys a prosurvival signal.  
To identify cell surface-localized binding partners of PVRL4, we created a C-terminally 
HA/FLAG-tagged PVRL4 construct and verified that cell-cell clustering as well as anchorage-
independence phenotypes were not affected by the addition of a C-terminal tag (not shown). We 
then performed immunoprecipitations with anti-HA agarose beads from lysates of TL-HMECs 
induced to express either HA/FLAG-tagged PVRL4 or HA/FLAG-tagged GFP and subjected the 
eluates to tandem mass spectrometry analysis. Since only the extracellular regions of PVRL4 and 
PVRL1 are required for anchorage-independent colony formation, we searched the list of 
PVRL4 IP-specific peptides for those with at least three unique peptides that corresponded to cell 
surface-localized proteins, as classified by Gene Ontology.  
In particular, we have identified the transmembrane protein integrin β4 as specifically 
interacting with HA/FLAG-PVRL4 (Figure 25a). To validate the putative PVRL4-integrin β4 
interaction directly in cells under conditions of anchorage deprivation, we performed 
111 
 
immunoprecipitations with anti-HA beads from lysates of suspension-incubated TL-HMECs that 
expressed either HA/FLAG-tagged PVRL4 or HA/FLAG-tagged GFP. Immunoblotting for 
integrin β4 verified a specific association of integrin β4 with PVRL4 (Figure 25b). Reciprocally, 
PVRL4 was found to coprecipitate from suspension-incubated TL-HMECs subjected to 
immunoprecipitation with integrin β4-specific antibody but not with control IgG (Figure 25c). 
Similarly, we were able to coprecipitate endogenous PVRL4 from SUM190 cell lysates, when 
immunoprecipitations with integrin β4-specific antibody were performed (Figure 25d). 
In addition, we tested whether integrin β4-PVRL4 association was triggered by PVRL4-
PVRL1 cell-cell contact assembly. The amount of β4 integrin coprecipitating with HA/FLAG-
tagged PVRL4 was not affected by whether cells were incubated to allow assembly of clusters or 
lysed immediately; neither was it affected by RNAi-mediated depletion of PVRL1 (Figure 25e). 
These data point to a cis mode of association between PVRL4 and β4 integrin on cell membrane 
and that cell-cell clustering is unlikely to be influencing this association. 
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Figure 25. Interaction of PVRL4 with integrin β4. a, Cell surface-localized proteins interacting 
with HA/FLAG-tagged PVRL4, but not with HA/FLAG-tagged GFP, as determined by mass 
spectrometry. b, TL-HMECs expressing HA/FLAG tagged PVRL4 or HA/FLAG-tagged GFP 
were detached from adherent surface with the enzyme-free cell dissociation buffer and incubated 
in suspension for 1 hour. Immunopreciptiations were performed with HA beads, followed by 
Western blot with FLAG and integrin β4 antibody. c, Immunopreciptiations with anti-β4 integrin 
or control IgG were performed on lysates from suspension-incubated TL-HMECs stably 
expressing HA/FLAG-tagged PVRL4. Immunoprecipitates and input lysates were blotted with 
anti-integrin β4 and anti-FLAG antibodies. d, Immunopreciptiations with anti-β4 integrin or 
control IgG were performed on lysates from suspension-incubated SUM190 cells and blotted with 
anti-integrin β4 and anti-PVRL4 antibodies. e, Anti-HA beads were used to immunoprecipitate 
HA/FLAG-PVRL4 from indicated lysates. Immunoprecipitates were blotted with anti-integrin β4 
and anti-FLAG antibodies. 
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Integrin β4 is necessary for the PVRL4-driven anchorage-independence 
To ask whether PVRL4-β4 integrin association contributes to anchorage-independent 
colony formation phenotype, we stably depleted β4 integrin from TL-HMECs using two 
independent shRNA constructs (Figure 26a). Depletion of β4 integrin had no effect on TL-
HMEC attachment to tissue culture vessel or on proliferation in adherent conditions; neither did 
it affect cell cluster formation induced by PVRL4 (not shown). However, PVRL4-mediated 
anchorage-independent colony formation was markedly reduced in the presence of β4 integrin-
specific shRNAs (Figure 26b). Importantly, reliance on β4 integrin was specific to anchorage-
independent colony growth promoted by PVRL4, whereas PI3K-driven colony numbers were not 
affected by its depletion (Figure 26c). 
 
  
Figure 26. Integrin β4 is specifically required for PVRL4-driven anchorage-independent 
growth. a, TL-HMECs expressing vector control, PVRL4 or myr-PI3K were stably transduced 
with the indicated shRNA constructs and integrin β4 levels were assayed by Western blot. b, c, 
TL-HMECs from (a) were assayed for anchorage-independent colony formation induced by 
PVRL4 (b) and by myr-PI3K (c). Colony numbers were normalized to vector control sample. 
Assays were performed in triplicate (error bars ± SD). 
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PVRL4-driven cell-cell contact assembly enables sustained Src family kinase activation in 
anchorage-deprived cells 
In matrix-attached cells, ligation of integrins to ECM maintains a constitutive level of 
active Src family kinases (SFKs), whereas in cells that are deprived of anchorage, SFKs become 
inactivated. We hypothesized that PVRL4-
induced cell clusters are able to maintain 
SFK activity even in the absence of 
anchorage. To test this, we measured levels 
of autophosphorylated SFKs in TL-HMECs 
after 6-hour incubation in suspension 
(Figure 27a). Levels of activated SFK 
dropped precipitously in control cells but 
were markedly higher in PVRL4-
expressing cells, but not in PVRL4-
expressing, PVRL1-depleted cells. Also, 
addition of anti-PVRL4 antibody sufficient 
to partially block cell clustering also 
reduced the level of SFK 
autophosphorylation in suspension.  A 
similar effect was observed after a 1 hour-
long incubation of PVRL4-expressing TL-
HMECs in suspension (Figure 27b). 
Similarly, activated state of SFKs was 
Figure 27. Src kinases become activated in 
PVRL4-expressing cells in a clustering-
dependent manner. a, TL-HMECs were 
detached from the adherent surface and incubated 
in methylcellulose in suspension for 6 hours, or 
cultured on an adherent surface for 48 hours. b, 
PVRL4-expressing TL-HMEC cells transduced 
with control or anti-PVRL1 shRNA were 
incubated in suspension in conditions indicated. 
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maintained in cells that were allowed to form clusters but not in samples where clustering was 
blocked by either anti-PVRL4 antibody or by PVRL1 depletion. 
SFK activity is necessary for colony growth in TL-HMECs and SUM190 cells 
Having shown that PVRL4-driven cell-cell contact assembly could preserve SFK 
activation even in the absence of attachment, we next hypothesized that sustained activation of 
SFKs underlies the observed ability of PVRL4-expressing cells to survive and proliferate in the 
absence of attachment. In support of this, PVRL4-driven, but not PI3K-driven anchorage-
independent colony formation was abrogated in presence of PP2, a chemical inhibitor of SFK 
activity (Figure 28a, b). Similarly, clonogenic survival of SUM190 cells was strongly inhibited 
by PP2 (Figure 28c). 
 
Figure 28. Chemical inhibition of Src suppresses anchorage-independence in TL-HMECs 
and clonogenic survival in SUM190 cells. a, b, TL-HMECs stably expressing PVRL4 (a) or 
myr-PI3K (b) were assayed for anchorage-independent colony formation in presence of PP2 or 
vehicle control. Colony numbers were normalized to vector sample. Assays were performed in 
triplicate (error bars ± SD). c, Clonogenic growth of SUM190 cells was assayed in presence of 
varying concentrations of a Src inhibitor PP2. 
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Matrix-independent 
activation of SFKs by 
integrin β4 was previously 
shown to be carried out 
through SHP-2 
phosphatase. Since 
PVRL4-driven anchorage-
independent growth is 
inhibited by both integrin 
β4 depletion and by 
chemical inhibition of SFK 
activity, we reasoned that 
depletion of SHP-2 will 
have a similar effect. 
Indeed, two independent 
shRNAs against SHP-2 
completely abrogated 
PVRL4-driven colony 
formation in TL-HMECs 
(Figure 29a, b) and in 
SUM190 cells (Figure 29c, 
d). 
 
Figure 29. RNAi-mediated depletion of SHP-2 suppresses 
anchorage-independence in TL-HMECs and clonogenic 
survival in SUM190 cells. a, TL-HMECs expressing PVRL4 
were stably transduced with indicated shRNA constructs and 
assayed for anchorage-independence. Colony numbers were 
normalized to vector control sample. Assays were performed in 
triplicate (error bars ± SD). b, SHP-2 levels were assayed by 
Western blot in TL-HMEC lysates from (a). c, SUM190 cells 
were stably transduced with indicated shRNA constructs and 
assayed for clonogenic growth. d, SHP-2 levels were assayed by 
Western blot in SUM190 lysates from (c). 
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Taken together, these data suggest that PVRL4- potentiated cell survival relies upon 
activation of integrin β4/SHP-2/Src signaling pathway in a manner that is dependent on physical 
cell-cell interaction facilitated by PVRL4. This raises an interesting possibility that PVRL4 
potentiates colony formation through assembling cell-cell contacts which allows cells to 
maintain some critical aspects of matrix-dependent signaling even in the absence of matrix 
anchorage. 
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Materials and Methods 
Constructs and virus production. Stable RNAi-mediated depletion was performed with 
shRNAs expressed in either pMSCV-PM or pGIPZ vector in miR-30 context that were either 
picked from the Hannon-Elledge shRNA library (Open Biosystems) or designed de novo (design 
and cloning protocol described in [260]). 21-nt sense sequences of shRNAs used in this study are 
listed in Supplementary Table 2. Tandem HA/FLAG-tagged PVRL4 construct was obtained by 
Gateway recombination of PVRL4 entry clone into C-terminal iTAP vector (provided by W. 
Harper). Retro- and lentiviral supernatants were generated by transient transfection of 293T cells 
following Mirus Bio's TransIT transfection protocol and harvested 48 hrs later. 
Cell Culture. TL-HMECs expressing hTERT and SV40 Large T antigen [178] were 
cultured in MEGM (Lonza). SUM190 (provided by K. Polyak) were cultured in a 1:1 mix of 
MEGM and F12:DMEM (Invitrogen), supplemented with 5% FBS (Invitrogen). 293T cells were 
cultured in DMEM (Invitrogen), supplemented with 10% FBS. Retroviral infections were 
performed in presence of 8 ug/mL of polybrene (Sigma). For SUM190 and SUM185 infections, 
cells were plated in 6-well dishes and centrifuged in presence of viral supernatant and polybrene 
for 1 hr at 2,000 r.p.m. Successful viral integrants were selected with puromycin (2 ug/mL) or 
Geneticin (200 ug/mL for TL-HMECs, 750 ug/mL for SUM190). 
Anchorage-independent colony formation and anoikis assays. ECM-independent 
colony formation assays were performed as previously described [98] with minor modifications. 
Briefly, cells were suspended in reduced growth factor MEGM (containing 50% of kit-supplied 
BPA, Insulin, EGF and hydrocortisone) with 2% methylcellulose (Sigma) and plated on tissue 
culture dishes precoated with 0.6% Noble Agar (Sigma) in MEM (Invitrogen). For assays 
performed in 6 cm dishes, 4.5 x 10
4
 cells per dish were plated. For assays performed in 6-well 
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plates, 1.2 x 10
4
 cells per well were plated. Colonies were counted after three weeks of growth. 
For each assay, an average of three replicates +/- SD is shown. For ECM-independent colony 
formation assays in presence of PP2 inhibitor, PP2 (EMD/Millipore) was used at 10 μM final 
concentration. 
Clonogenic Assays. For assaying clonogenic potential, 1.0 x 10
3
 SUM190 cells were 
seeded in 6 cm tissue culture-treated dishes. After 3 weeks of growth, resulting colonies were 
stained with 1% Methylene Blue and counted. For each assay, an average of three replicates +/- 
SD is shown. 
Clustering Assays. For short-term culture of TL-HMECs in suspension, 4.0 x 10
5
 cells 
were allowed to aggregate in 1 mL of complete medium in a 15-mL conical tube at room 
temperature, mixed with 5 mL of 0.5% methylcellulose in reduced growth factor MEGM and 
incubated in wells of a 6-well ultra-low attachment dish (2 wells per sample) for indicated 
periods of time. 
Western Blotting. Cells were lysed in NP-40 buffer (1% NP-40, 25 mM Tris-HCl 
pH=7.4, 150 mM NaCl, 1mM EDTA, 10% Glycerol) in the presence of protease and 
phosphatase inhibitor tablets (Roche). Adherent cells were lysed for 15 minutes on ice, followed 
by scraping into Eppendorf tubes and centrifugation at 14,000 rpm for 15 min at 4C. Suspension-
cultured cells were washed once with cold PBS, followed by lysis and centrifugation. Protein 
concentration in supernatants was measured using BCA assay (Pierce) and lysates were brought 
to identical concentrations with lysis buffer. Samples were mixed 1:1 with 2X Laemmli buffer 
(125 mM Tris-HCl, pH = 6.8, 4% SDS, 20% Glycerol, 0.004% Bromophenol Blue) and DTT 
was added to final concentration of 25 mM. Samples were boiled for 8 minutes and loaded on 
Tris-Glycine 4-20% or 4-12% gradient gels (Invitrogen). Transfer/blotting were performed as 
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described elsewhere. Western blotting was performed with the following antibodies: goat anti-
PVRL4 (AF2659, R&D Systems), mouse anti-Vinculin (V9131, Sigma), mouse anti-RAN 
(610340, BD Biosciences), mouse anti-ITGB4 (611232, BD Biosciences), mouse anti-FLAG-
HRP (A8592, Sigma-Aldrich), rabbit anti-pY416 SFK (2101, Cell Signaling), mouse anti-SFK 
(2110, Cell Signaling), mouse anti-SHP-2 (610621, BD Biosciences) and mouse anti-α Tubulin 
(sc-8035, Santa Cruz). 
HA-pulldown. TL-HMECs expressing HA/FLAG-PVRL4 or HA/FLAG-GFP were 
gently detached off the tissue culture surface with enzyme-free cell dissociation buffer, washed 
and lysed for 30 min in MCLB lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40) in 
presence of protease and phosphatase inhibitors (Roche), followed by centrifugation at 14,000 
rpm at 4C. Lysates were precleared with protein A/G beads (sc-2003, Santa Cruz). Pulldowns 
were performed with anti-HA beads (A2095, Sigma Aldrich) overnight at 4C. Beads were 
washed 5 times with MCLB buffer, followed by 2 washes with elution buffer (50 mM Tris, pH 
7.5, 150 mM NaCl, 10% glycerol). Elutions were performed with 500 μg/mL of HA peptide 
(I2149, Sigma Aldrich) in elution buffer. Proteins were precipitated from this mixture with 20% 
trichloroacetic acid (TCA), and the resulting pellet was washed once with 10% TCA and four 
times with cold acetone. 
Mass Spectrometry. TCA-precipitated proteins were dissolved in 100mM ammonium 
bicarbonate (pH 8.0) with 10% acetonitrile and 10 ng/µL trypsin (Promega) and incubated at 
37C for 5 hours.  They were subsequently desalted, dissolved in 5% formic acid / 5% 
acetonitrile, and loaded onto a reversed phase microcapillary column (100 mm I.D.) packed with 
18 cm of Maccel C18AQ resin (3 mm, 200  , The Nest Group, Inc).  Peptides were eluted using 
a gradient of 4%–26% acetonitrile in 0.125% formic acid over 95 minutes and detected in a 
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hybrid linear ion trap-orbitrap mass spectrometer (LTQ-Orbitrap Discovery, ThermoFisher). 
Precursors selected for MS/MS fragmentation were corrected for errors in monoisotopic peak 
assignment, and tandem MS spectra were searched using the Sequest algorithm, with mass 
tolerance set to 25 ppm and two missed cleavages allowed.  False discovery rates were estimated 
with the target-decoy method [286], and linear discriminant analysis (LDA) was utilized to filter 
peptides to an initial 1% peptide-level FDR. Peptides were then assembled into proteins and 
further filtered to a protein-level FDR of 0.84% [287], resulting in a final peptide-level FDR of 
0.35%. 
Immunoprecipitations. Cells were lysed in IP lysis buffer (20 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 10% glycerol, 1% NP-40) in presence of protease 
and phosphatase inhibitors and centrifuged at 14,000 rpm at 4C. Immunoprecipitations were 
performed with anti-HA beads (A2095, Sigma Aldrich) for 2 hours or with anti-ITGB4 antibody 
(611232, BD Biosciences) for 2 hours, followed by protein A/G beads (sc-2003, Santa Cruz) for 
1 hour. Beads were washed 4 times with lysis buffer and boiled in Laemmli buffer with 25 mM 
DTT. 
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Chapter VI: Conclusions and Future Directions 
The utility of anchorage-independence screens for cancer gene discovery 
Genetic screening is a versatile tool for a high-throughput testing of thousands of genes 
for functional contribution, or lack thereof, to the biological phenotype of interest. Genetic 
screening had firmly established itself as an approach that is central to the discovery of genetic 
determinants of tumorigenesis. Thus, gain- and loss-of-function screens in normal and 
transformed mammalian cell lines had produced datasets of candidate genes functionally 
involved in a wide variety of phenotypes relevant to cancer cell biology. Among these 
phenotypes are increased rates of cell proliferation, sensitivities to select drugs and stressors, 
anchorage-independent growth, replicative and oncogene-induced senescence, a balance between 
stemness and differentiation as well as cellular motility and invasiveness. 
By staying anchored on the extracellular matrix, epithelial cells receive a sustained 
antiapoptotic message. Conversely, the cessation of this signal has to be compensated through 
acquisition of genetic changes associated with matrix-autonomous activation of various aspects 
of matrix adhesion-associated signaling. Anchorage-independent growth is a critical hallmark of 
epithelial cancers. To initiate and sustain tumor growth, cells must acquire some resistance to 
loss of matrix anchorage as early as at a stage of localized dysplasia, for example, at the ADH 
(atypical ductal hyperplasia), a precursor state to breast carcinoma in situ. Importantly, cancer 
cells remain addicted to anchorage-independence throughout the process of multistep 
tumorigenesis.  
Cell-matrix attachment does not simply elicit a singular flux through an isolated pathway; 
on the contrary, it profoundly affects diverse aspects of an epithelial cell physiology – among 
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which are cell cycle, apoptosis, cytoskeletal tension, various aspects of metabolism and cellular 
differentiation. Thus, it is conceivable that not a single oncogene, but large networks of 
interconnecting oncogenic changes contribute to a cancer cell’s resistance to anchorage loss. 
To decipher genetic changes that enable cell survival in the absence of matrix anchorage, 
sensitive in vitro models of anchorage-independent growth have been developed. TL-HMEC 
system in particular is a useful tool for testing genes that either enable or suppress anchorage-
independent growth in the context of a normal epithelial cell line. An important advantage of TL-
HMEC system is that it can be made anchorage-independent through ectopic introduction of a 
singular genetic change, such as a constitutively active catalytic subunit of PI-3 kinase or 
depletion of a lipid phosphatase PTEN. In other words, an upregulation or a downregulation of a 
single gene may be sufficient to induce a switch from anchorage-dependent to anchorage-
independent proliferation. This sensitivity makes TL-HMEC system a highly useful tool for 
discovery of novel genetic determinants of this phenotype.  
At the same time, one might argue that along with being an advantage, an obvious 
sensitivity of TL-HMECs for becoming anchorage-independent via potentiating PI-3 kinase 
signaling can also be perceived as a drawback. Thus, one might suggest that, instead of 
uncovering broad spectra of anchorage-independence drivers, screens performed in TL-HMECs 
will repeatedly yield sets of negative and positive regulators of PI-3 kinase pathway only. If this 
is indeed the case, the utility of this system as a tool for the discovery of broadly-acting 
anchorage-independence genes will be limited.  
However, if one is to examine the “track record” of validated ectopic genetic changes 
which, as our group has shown, can induce anchorage independence in TL-HMECs, they 
encompass a variety of genes that fall outside of spectrum of canonical PI-3 kinase pathway 
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signaling. Thus, among some of the validated genes that were discovered by our group as 
affecting anchorage-independence in TL-HMECs are (i) depletion of transcriptional repressor 
REST, which profoundly affects expression of a variety of protein-coding genes and non-coding 
RNAs [98], (ii) depletion of PTPN12 phosphatase, which affects activation states of a number of 
receptor tyrosine kinases [99], and (iii) depletion of TGF-β receptor II, a master regulator of a 
pathway known to be tumor-suppressive in epithelial cells [98]. Finally, as demonstrated in this 
work, expressing PVRL4 in TL-HMECs can sustain Src family kinase activity in the absence of 
matrix anchorage; and PVRL4-driven, but not PI-3 kinase-driven anchorage-independence, is 
sensitive to chemical inhibition of Src. Altogether, the broad spectra of genes discovered in 
anchorage-independence screens performed in TL-HMECs validate it as a sensitive tool for 
oncogene and tumor suppressor discovery, applicable for capturing the multifaceted nature of 
genetic determinants that converge upon the phenotype of anchorage-independent growth. 
We describe some of the additional steps we had taken in order to improve the sensitivity 
of TL-HMEC system as a tool for oncogene and tumor suppressor discovery. These steps include 
(1) isolating transformation-sensitive clones from a polyclonal population, and (2) decreasing 
non-autonomous drivers of growth factor signaling by reducing concentrations of growth factors 
in growth medium.  
Our observations provide some insight into additional aspects of TL-HMEC model which 
can be taken advantage of in order to facilitate cancer gene discovery. First, we demonstrate that 
distinct clones within the polyclonal TL-HMEC line exhibit profound differences in their 
susceptibility to transformation by PTEN shRNA. One intriguing hypothesis is that distinct 
clones of TL-HMECs may display distinct preferences with regard to what signaling pathways 
convey anchorage-independence phenotype upon them. For example, while some clones are 
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responsive to PI-3 kinase pathway stimulation, others might display sensitivity to activation of c-
Src, and yet others become anchorage-independent upon TGF-β pathway suppression. If this is 
indeed the case, anchorage-independence screens could be performed with an oligoclonal mix of 
TL-HMEC clones in which each clone with a distinct pathway tropism is uniquely barcoded for 
identification. An approach like this can uncover unexpected functional interactions and 
interchangeabilities between distinct functional modalities within cellular signaling networks.  
In addition, we observe that the number of spontaneously arising anchorage-independent 
colonies can be readily modulated by modifying growth medium composition. The sensitivity to 
paracrine environment can further be utilized for assessing interactions between various genetic 
and non-genetic factors and their combined contribution to the phenotype - for example, assaying 
anchorage independence in conditions when a certain growth factor or nutrient is limited.  
Yet another aspect that makes TL-HMEC system such a versatile tool for cancer gene 
discovery is a modular principle by which it is built. Thus, low-passage hTERT-HMECs require 
a combination of three elements – Large T, PI-3 kinase and exogenously introduced c-myc – for 
anchorage-independent growth. Thus, performing a screen for anchorage-independence in an 
HMEC line which expresses Large T and PI-3 kinase but not c-myc is likely to result in a 
different set of genes than a similar screen in TL-HMECs. Thus, such parallel approach would 
significantly broaden the spectrum of novel anchorage-independence driver discovery. 
The gain-of-function screen described in this work was performed with a library that (1) 
covers at least a third of a human protein coding genes, and (2) is not biased in favor of one or 
another functional group of genes. To the best of our knowledge, this is the most comprehensive 
screen for positive regulators of anchorage-independence that has been performed. Importantly, 
we were able to confirm that eleven candidate genes strongly stimulated anchorage-independent 
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colony formation when individually retested in TL-HMECs. Since the primary objective of 
performing a screen for drivers of anchorage-independence is to identify novel genes causally 
involved in tumorigenesis, we asked how many of our validated candidates are recurrently 
altered in tumors. Strikingly, eight out of eleven genes that strongly induced cell proliferation in 
the absence of anchorage were found to reside within statistically defined areas of copy number 
gain recurrently seen in solid tumors. Thus, our list is highly enriched for genes that are 
recurrently targeted for amplification in tumors, which lends an important proof-of-principle to 
the use of functional genetic screening approaches as a tool for novel cancer gene discovery. 
In addition to genetic screens for anchorage-independence inducers, we envision yet 
another promising direction that this conceptual framework can be taken into. This direction 
involves performing genetic screens for shRNAs which are synthetically lethal with growth of 
cells in anchorage-independence conditions. Specifically, libraries of shRNAs can be screened in 
cancer cell lines which are grown in the absence of attachment and, in parallel, in same cell lines 
grown in substratum-attached manner, thus identifying shRNAs that selectively target 
substratum-detached but not substratum-attached cells.  This type of a screening approach may 
lead to the discovery of some unexpected genetic interactions which are synthetically lethal with 
a growth condition uniquely experienced by a growing tumor. An approach like this has an 
appealing potential for yielding new potent and selective therapeutic ideas. 
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PVRL4 is a cell-cell adhesion-dependent driver of anchorage-independent growth  
A question of how different types of cell-cell adhesions contribute to tumorigenesis is 
complicated by the fact that mammalian genomes encode hundreds of cell adhesion proteins with 
strikingly diverse tropisms, adhesion strengths and signaling capabilities. In addition, many cell 
adhesion molecules can influence downstream signaling independently of their role in cell-cell 
attachment. For example, extracellular and cytoplasmic regions of some cell adhesion proteins 
may function in one capacity when they are anchored at the plasma membrane and acquire 
additional signaling capabilities after they are proteolythically cleaved and displaced from the 
membrane.  
Contributions of individual adhesion molecules to the process of tumorigenesis have been 
described and includes both tumor-suppressive functions, such as those mediated by E-cadherin, 
as well as tumor-promoting, such as those mediated by N-cadherin or EpCAM. Furthermore, 
antibody-based therapies against the latter two proteins have shown promising results in 
preclinical and clinical settings [200, 288]. It is worth noting that at least some of the prosurvival 
effects elicited by N-cadherin and EpCAM are independent of their role in cell adhesion [201, 
270].  
In this work, we identify the cell adhesion molecule PVRL4 as a potent functional 
contributor to tumorigenesis. PVRL4 promotes anchorage-independent growth of mammary 
epithelial cells, as well as anchorage-independent and clonogenic growth of breast cancer cells in 
vitro and xenograft formation in vivo. PVRL4 rapidly and potently induces cell-to-cell adhesion 
via engaging its counter-receptor PVRL1 on a juxtaposed cell, and our data strongly suggest that 
the interaction of PVRL4 with PVRL1 on the opposite cell is required for the observed 
prosurvival effect.  
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In addition to demonstrating the prosurvival role of PVRL4 and its ability to promote 
cell-to-cell attachment in various cell types, we find, unexpectedly, that the ectopic expression of 
some known oncogenic drivers in TL-HMECs, namely, RAS
V12
 mutant, constitutively active 
catalytic subunit of PI-3 kinase or stable depletion of PTEN, potently promotes cell-to-cell 
attachment phenotype as well. This observation suggests that activation of oncogenic signaling 
in a cell affect its cell surface adhesion molecule repertoire through unknown transcriptional or 
post-transcriptional mechanisms. We envision that the question of which cell adhesion molecules 
become induced in oncogene-expressing HMECs and whether they are functionally involved in 
promoting anchorage-independence is a promising direction in which this research could be 
taken. Because cell adhesion proteins are readily accessible by antibodies, identifying oncogene-
specific changes in cell surface adhesion molecule repertoire can foster novel therapeutic ideas. 
For example a monoclonal antibody targeted against a cell adhesion molecule that is specifically 
induced by hyperactive PI3K pathway can block a putative pro-survival action of this cell 
adhesion molecule, or it can trigger selective elimination of oncogene-expressing cells via 
antibody-mediated recruitment of NK cells and macrophages. 
In addition, we performed structure-function analyses of PVRL4 and PVRL1 in order to 
dissect which parts of the molecules are necessary and sufficient for anchorage-independence. 
Our analysis revealed that (1) a truncated extracellular region of PVRL4 fails to induce the 
anchorage-independence phenotype, (2) formation of a PVRL4-PVRL1 cell-to-cell attachment 
module is essential for anchorage-independence; (3) neither cytoplasmic nor transmembrane 
regions of PVRL4 and PVRL1 are required for anchorage-independence. An important question 
that still remains to be explored is whether a soluble extracellular region of PVRL1 can 
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substitute for PVRL1 depletion in PVRL4-expressing cells, or whether both molecules must be 
anchored on the membrane for promoting the survival phenotype. 
Cytoplasmic regions of all four nectins bind afadin, a large scaffold protein through 
which nectin-based intracellular signaling events are carried out. Interestingly, and in contrast to 
PVRL4, loss of afadin has been shown to be strongly associated with poor outcome in breast 
cancer patients in a number of studies [289, 290]. Whether afadin has negative or neutral effect 
on the stimulation of survival by PVRL4-PVRL1 interaction remains to be elucidated. 
Interestingly, we found that deleting four C-terminal amino acids of PVRL4 slightly yet 
reproducibly enhances its transforming ability which suggests that afadin binding might indeed 
mitigate some of the protumorigenic effects of PVRL4. 
We take further steps towards elucidating the mechanism by which PVRL4-PVRL1 cell-
surface trans-interaction enables the survival in the absence of anchorage. Specifically, we 
identify integrin β4 as a cis-binding partner of PVRL4 on the cell surface. Integrin β4 has 
previously been implicated in breast tumorigenesis; furthermore, at least some aspects of its 
downstream signaling can be activated by forced dimerization of individual integrin molecules 
on the cell surface. Our analysis of intracellular signaling reveals that clusters of PVRL4-
expressing TL-HMECs exhibit marked matrix-independent SFK activation, and that PVRL4-
driven anchorage-independence requires intact integrin β4/SHP-2/SFK signaling. How does 
PVRL4-driven cell clustering potentiate integrin β4 activation? One possibility is that PVRL4-
PVRL1 cell surface trans-interaction promotes clustering of isolated integrin β4 molecules at the 
site of cell-cell interaction. Indeed, preceding formation of a trans-interacting module between 
two juxtaposed cells, nectins reside on the cell surface in a form of cis-homodimers [236]. One 
may hypothesize that two cells coming into immediate proximity potentially trigger assembly of 
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long chains of alternating 
PVRL4 and PVRL1 cis-
homodimers, where each cis-
homodimer engages not one 
but two cis-homodimers on a 
cell opposite to it (Figure 30). 
Such mode of interaction has 
been proposed for a variety of 
cell adhesion molecules, such 
as SynCAM3 homotypic 
trans-interaction [291], as 
well as for trans-interaction of PVR and TIGIT cell adhesion molecules [292], with some 
support from crystal structure data. In case of PVRL4-PVRL1 interaction, assembly of such 
chains might drive individual integrin β4 molecules into proximity, activating SHP-2/SFK in a 
manner similar to one seen in artificial dimerization experiments. Further studies on PVRL4-
PVRL1-integrin β4-associated signaling, assisted by super-resolution microscopy methods such 
as TIRF (total internal reflection fluorescence) or STORM (stochastic optical reconstruction 
microscopy) and crystal structure analysis of PVRL1-PVRL4 interacting heterotetramers may 
shed more light at the supramolecular arrangement of these molecules at sites of cell-cell 
contacts. 
Intriguingly, PVRL4 is not the only nectin that was shown to physically interact with an 
integrin. Thus, a trans-interaction PVRL3 with PVR was shown to bring αVβ3 integrin to sites 
of de novo forming adherens junctions in adherent MDCK cells [252]. After a junction is 
Figure 30. Formation of supramolecular chains of cis-
interacting dimers at the site of cell-cell contact has been 
proposed for IgCAMs. 
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established, PVRL3 recruits PTPμ phosphatase which inhibits interaction of αVβ3 integrin with 
talin and prevents inappropriate levels of signaling downstream of integrin [253]. Interestingly, 
while all four nectins were shown to associate with PTPμ phosphatase in vitro, integrin β4 lacks 
binding sites for talin and other focal adhesion complex components. This, in turn, raises an 
interesting possibility that PVRL4-integrin β4 module may be free of PTPμ phosphatase-based 
negative feedback regulation mechanism, thus allowing continued potentiation of downstream 
signaling. 
Potential implications of PVRL4-driven anchorage-independence in relation to some 
aspects of tissue morphogenesis 
Even though the role of PVRL1, PVRL2 and PVRL3 in morphogenesis of various tissues 
has been described, little is known about where, and how, PVRL4 functions in normal tissues. 
Mutations of PVRL4 were identified in certain mild cases of ectodermal dysplasia [244-247]. In 
particular, patients with PVRL4 mutations have sparse fragile hair, syndactily and malformation 
of teeth. Immunohistochemical examination of PVRL4 distribution in skin epidermis and hair 
follicles from healthy donors revealed that protein expression was strongest in intermediate 
suprabasal layers, whereas little or no staining was seen in the topmost, terminally differentiated 
(cornified) layer as well as in the basal layer, which is least differentiated and is the only 
epidermal layer composed of cells directly anchored on the basement membrane [244]. Even 
though the skin of individuals with loss-of-function PVRL4 mutations was normal, perhaps as a 
result of another nectin being able to compensate for loss of PVRL4, their hair growth was 
profoundly affected. 
Considering the possibility that PVRL4 mode of action in tumorigenesis parallels its role 
in morphogenesis of normal tissue, one may hypothesize that in stratified epithelia, such as skin 
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epidermis and hair follicles, PVRL4-PVRL1 interaction on surface of neighboring cells may 
serve to protect suprabasal layers of stratified epithelia from premature physiologic anoikis, thus 
serving to instate and maintain the stratified architecture of skin and hair follicle. Intriguingly, 
mammary epithelial cells initiate a squamous-like differentiation program as an alternative form 
of anoikis in suspension [142], and we have demonstrated that expression of both full-length 
PVRL4 as well as cytoplasmic region deletion construct alleviates this phenotype.  
Interestingly, β4 integrin, paired with α6 subunit, is a major structural integrin in skin 
epidermis. Mutations in β4 integrin cause junctional epidermolysis bullosa, a severe skin 
blistering disorder [293]; and conversely, suprabasal overexpression of β4 integrin enhances 
chemical carcinogen-induced skin tumor formation in mice [294]. Taken together, it would be of 
particular interest to further explore the contribution of PVRL4 and, potentially, integrin 
β4/SHP-2/SFK axis to the process of morphogenesis of stratified epithelia via, potentially, 
delaying premature differentiation of suprabasal epidermal layers. 
PVRL4 shows promise as a therapy target in solid tumors 
Several lines of evidence obtained from breast, lung and ovarian tumors suggest that 
PVRL4 expression is upregulated in tumorigenesis and is strongly associated with adverse 
prognosis in patients suffering from breast and lung cancer. In breast cancer in particular, 
PVRL4 expression is associated with aggressive tumor characteristics - such as basal-like 
expression subtype and invasion of cancer cells into multiple lymph nodes. We used blocking 
antibodies against PVRL4 in a preclinical in vivo xenograft model and demonstrate that growth 
of PVRL4-dependent xenografts is potently inhibited by anti-PVRL4 antibody therapy. Our 
demonstration of the efficacy of anti-PVRL4 therapy lends a proof-of-principle to a novel 
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concept of using a therapeutic antibody to block a cancer-specific cell-to-cell attachment to 
suppress tumor growth. 
We also take steps to address three important caveats that arise from this experiment. 
First of all, we show, via in vitro ADCC assay, that PVRL4 antibody does not induce tumor lysis 
through recruitment of NK cells, supporting that the observed inhibitory effect may be a 
consequence of blocking PVRL4-PVRL1 interaction and signaling. Second, we show that even 
though PVRL4 antibody disrupts cell-cell contacts in treated SUM190 xenografts, the cell-cell 
contact disruption does not affect expression of key epithelial (E-cadherin) and mesenchymal 
(vimentin) markers, at least at the population level, even though SUM190 cell line is markedly 
E-cadherin-positive. Third, we show that PVRL4 antibody, though raised against a human 
epitope, recognizes mouse PVRL4 as well, yet does not trigger acute adverse effects in a mouse. 
Taken together, our work begins to address some aspects of both efficacy and safety of the 
proposed therapeutic principle. 
It remains to be investigated further, whether in PVRL4-dependent cancer cell lines, such 
as SUM190 and SUM185 cells, PVRL4 also acts by activating integrin β4/SHP-2/c-Src signaling 
axis. We began addressing this by demonstrating that the clonogenic growth of SUM190 cells is 
sensitive to both chemical inhibition of Src and RNAi-mediated depletion of SHP-2 phosphatase, 
which are key downstream effectors of integrin β4.  
It would be further important to explore the relationship between PVRL4 expression in 
tumors and their sensitivity to chemical inhibitors of c-Src. As gene expression and copy number 
analysis from human breast cancers suggests, both PVRL4 and integrin β4 expression is 
associated with a basal-like expression signature, which is characteristic for triple-negative breast 
cancers (TNBCs). Intriguingly, TNBC tumors display higher levels of activated c-Src in 
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comparison to other breast cancer subtypes [295]. Since we have shown that PVRL4-driven cell-
cell contacts facilitate Src activation it would be further interesting to explore whether positivity 
for PVRL4 could be a predictor for tumor sensitivity to Src inhibitors, such as dasatinib 
(Sprycel). Intriguingly, c-Src activation is a predominant mechanism of resistance of HER2-
positive breast tumors to trastuzumab therapy [296], which raises an interesting possibility that 
anti-PVRL4 therapy may be a viable option for treating trastuzumab-resistant tumors. 
In addition to treating primary tumors, another utility of PVRL4-targeted antibodies is in 
preventing metastatic dissemination or colonization by directly targeting circulating tumor cells. 
Indeed, circulating tumor cells are known to form clusters in the bloodstream as well as to attach 
to a variety of cell types in order to sustain their survival and promote metastasis. Multiple lines 
of evidence suggest that PVRL4 is overexpressed in a large fraction of breast tumors and is 
associated with metastasis; for example, one study showed that among breast cancer cases with 
1-3 cancer-positive lymph nodes, over 70% were PVRL4-positive, whereas those cases with four 
or more positive lymph nodes, 100% were positive for PVRL4. Furthermore, PVRL4 can induce 
cancer cell attachment to other cell types via PVRL1, as demonstrated by PVRL4-dependent 
attachment of SUM190 cells to primary human microvascular endothelial cells from the lung, an 
organ of primary tropism for breast cancer metastasis. Thus, the possibility that PVRL4 may be 
involved in enabling survival of cancer cells in lymphatic and blood circulation needs to be 
further explored, including its potential therapeutic implications. 
Using histology and two-photon microscopy imaging, we have observed a striking 
dissolution of cell-cell contacts in anti-PVRL4 antibody-treated tumors. We envision that, 
besides blocking the cell-matrix mimetic signaling that is associated with PVRL4-PVRL1 
interacting module, disrupting cell-cell contacts within a tumor can elicit a number of additional, 
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less-specific, but no less important, antitumor effects. For example, in the context of an anti-
PVRL4 therapy combined with another antitumor antibody or small molecule drug, disruption of 
cell-cell contacts may have an added benefit of improving the access of therapeutic agents deeper 
into the tumor core. Similarly, disruption of cell-cell contacts in tumors can allow entry of 
macrophages and T-cells into deeper areas of the tumor. Finally, cell-cell contact disruption can 
mitigate tumor hypoxia, acidic pH and interstitial fluid pressure within tumors, which are key 
contributors to angiogenesis, matrix remodeling and invasion, as well as resistance to therapies 
[297-299]. Thus, anti-PVRL4 therapy may serve the purpose of normalization of tumor 
microenvironment in susceptible tumors. 
In conclusion, our work uses interdisciplinary approaches, combining high-throughput 
mammalian cell genetics, analysis of genomic and expression data from human tumors, 
molecular structure-function studies, exploration of cellular signal transduction and the use of 
preclinical in vivo tumor models, to discover and characterize a novel driver of tumorigenesis, 
elucidate its mode of action and its effect on intracellular signaling and demonstrate its potential 
efficacy and safety as a target for antibody-based therapy of cancer. 
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Appendix I  
Supplementary Tables 
Supplementary Table 1. PVRL4 deletion series. 
Construct    Amino Acids 
Full-length    1-510 
4 aa C-terminal deletion  1-506 
Cytoplasmic region deletion  1-373 
Extracellular region   1-342 
Extracellular region deletion  341-510 
Cytoplasmic region   374-510 
 
Supplementary Table 2. Sequences of shRNAs used in the study. 
shRNA    Sense Sequence 
FF2 shRNA    CCGCCTGAAGTCTCTGATTAA 
PVRL1 shRNA-1   CCCAAGTCACTGGTGCAATAA 
PVRL1 shRNA-3   TCCCAGGTGGTCCAGGTGAAC 
PVRL4 shRNA-1   CACGGTGAGGGAGATAGAAA 
PVRL4 shRNA-3   CAGAGAAGGAGCTATGCTCAA 
PVRL4 shRNA-4   CAGGTCACTGTGGATGTTCTT 
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Supplementary Table 2 (Continued). 
shRNA    Sense Sequence 
PVRL4 shRNA-5   GTAGCTGCTCTGTGATGAGTGA 
PTEN shRNA-1   GAGGCGCTATGTGTATTATTA 
PTEN shRNA-2   TGCAGTATAGAGCGTGCAGAT 
ITGB4 shRNA-1   ACCTCCAAGATGTTCCAGAA 
ITGB4 shRNA-2   AGCACTGTCCTGGTGCACAA 
SHP-2 shRNA-1   CGCTCATGACTATACGCTA 
SHP-2 shRNA-2   GGCACGAATATACAAATAT 
 
Supplementary Table 3. Sequences of qPCR primers used in the study. 
Gene Name Left     Right     
PVRL4 CTGCATTCCCATCACACG GGCTCTCAGCCCTACACTCTC 
PVRL1 ACGGTCATCAGCCGCTAC AGGCCAAGGACTGCTGGT 
PTEN  GGGGAAGTAAGGACCAGAGA TCCAGATGATTCTTTAACAGGTAGC 
TGM1  GGAACTACGGCCAGTTTGAC GCCGGTCCAGGATGTATAAG 
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Appendix II 
List of candidate ORFs from anchorage-independence screen 
Gene Symbol   BC_NUM ORF_Length  Description      
ADCK5   BC031570 510  aarF domain containing kinase 5 
AKTIP   BC001134 879  fused toes homolog (mouse) 
ALDH1B1   BC001619 1554  aldehyde dehydrogenase 1 family, member B1 
ATP5H   BC032245 414  ATP synthase,mitochondrial F0 complex, subunit d 
ATPIF1   BC009677 321  ATPase inhibitory factor 1, transcript variant 1 
BET1    BC000899 357  BET1 homolog (S. cerevisiae) 
C10orf49   BC018068 465  chromosome 10 open reading frame 49 
C16orf52   BC027604 276  hypothetical protein LOC146174 
C17orf47   BC022189 1713  hypothetical protein FLJ40121 
CDC42SE1   BC012796 240  small protein effector 1 of Cdc42 
COCH    BC007230 1485  coagulation factor C homolog, cochlin 
CSTF2    BC017712 1734  cleavage stimulation factor, 3' pre-RNA, subunit 2 
CSTF3    BC009792 312  cleavage stimulation factor, 3' pre-RNA, subunit 3 
DCLRE1B   BC029687 1599  DNA cross-link repair 1B 
ELAVL2   BC030692 1041  ELAV-like 2 (Hu antigen B) 
ERGIC2   BC000887 1134  PTX1 protein 
EXOSC3   BC008880 828  exosome component 3 
GPR172A   BC002917 1338  putative G-protein coupled receptor GPCR41 
GPR177   BC007211 1326  putative NFkB activating protein 373 
HIST1H4E   BC012587 312  histone 1, H4e 
HSDL1   BC018084 993  steroid dehydrogenase-like 
KIAA1609   BC023251 1371  KIAA1609 protein 
LPCAT1   BC020166 1170  hypothetical protein FLJ12443 
MGC21675   BC013775 276  hypothetical protein MGC21675 
MRPS28   BC010150 564  mitochondrial ribosomal protein S28 
NPM1    BC002398 885  nucleophosmin (nucleolar phosphoprotein B23) 
NTRK3   BC013693 1839  neurotrophic tyrosine kinase, receptor, type 3 
PVRL3   BC017572 306  poliovirus receptor-related 3 
PVRL4   BC010423 1533  poliovirus receptor-related 4 
RAB14   BC006081 648  RAB14, member RAS oncogene family 
S100B    BC001766 279  S100 calcium binding protein, beta (neural) 
SCRG1   BC017583 180  scrapie responsive protein 1, mRNA 
SFRP2    BC008666 888  secreted frizzled-related protein 2 
SULF2   BC020962 450  sulfatase 2 
TAGLN2   BC009357 600  transgelin 2 
TM2D2   BC004878 450  TM2 domain containing 2, mRNA 
TMEM65   BC032396 537  hypothetical protein BC017881 
TRIP11   BC002656 243  thyroid hormone receptor interactor 11 
TRMT1   BC002492 1980  hypothetical protein FLJ20244 
UXT    BC000720 474  ubiquitously-expressed transcript 
139 
 
Appendix III: Exploration of potential effects of PVRL4 on 
antioxidant defense in conditions of anchorage deprivation 
Background and Rationale 
The understanding of the mechanism and significance of tumor-specific metabolic 
adaptations have been a focus of intense exploration in the field of cancer biology in the recent 
years (reviewed in [300]). Profound metabolic changes that tumors undergo include utilization of 
glucose via aerobic glycolysis (a phenomenon known as Warburg effect) as well as an increased 
flux through pentose phosphate pathway, a major provider of a cell’s NADPH pool. The 
increased ratio of NADPH to NADP is thought to benefit cancer cells in a number of ways. First, 
it provides antioxidant capacity to counteract the oxidative stress which is frequently 
encountered by tumor cells as they are being challenged by constitutively active oncogenes and 
hypoxic microenvironments. In addition, increased NADPH provides reducing equivalents for a 
number of complex anabolic processes that are required for proliferation, most notably, de novo 
lipid and cholesterol biosynthesis - molecules which are crucial for membrane formation. The 
unique metabolic state of cancer cells was shown to be driven by activated oncogenes and is 
therefore is thought to arise in response to an unchecked pro-growth signaling input experienced 
by a transformed cell.  
Interestingly, interaction of epithelial cells with the extracellular matrix has also been 
found to profoundly modulate cellular metabolism [131]. In particular, culturing normal 
mammary epithelial cells in the absence of substratum attachment not only suppressed their 
proliferation but also caused a profound defect in glucose uptake, reduced the flux through 
pentose phosphate pathway and decreased the cellular NADPH/NADH ratio. Moreover, 
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substratum-detached cells were found to contain higher levels of reactive oxygen species. 
Importantly, the observed defects were shown to be corrected by the ectopic expression of 
ERBB2 oncogene. Furthermore, supplementing the culture medium with antioxidant compounds 
such as N-acetylcysteine or Trolox (a vitamin E derivative) was found to be sufficient to rescue 
the proliferation defect induced by the substratum detachment. 
We asked whether TL-HMECs similarly accumulate high levels of reactive oxygen 
species when cultured in the absence of attachment. Furthermore, having shown that PVRL4 
enables colony formation of TL-HMECs in anchorage-independent conditions, we wanted to test 
a possibility that at least some aspects of PVRL4 action in anchorage-independence can be 
carried out through the modulation of oxidative stress and NADPH concentrations in a detached 
cell. 
Results 
We sought to assess the effect of PVRL4 expression on detachment-induced oxidative 
stress by staining live TL-HMECs with carboxy-H2DCF-DA, a cell-permeable ROS marker. 
Strikingly, ROS levels were decreased two-fold in PVRL4-expressing HMECs, as measured by 
carboxy-H2DCF-DA signal normalized to total protein concentration (Figure 31a, b). Similarly, 
PVRL4 depletion by RNAi increased ROS levels in SUM190 cell line in suspension (Figure 
31c). We next asked whether the observed differences in ROS levels were paralleled by changes 
in NADPH/NADP ratio, since NADPH is a major supplier of a cell’s antioxidant capacity, and 
NADPH/NADP ratio has been previously shown to be affected by the attachment deprivation. 
Indeed, we have found that the expression of PVRL4 in TL-HMECs potently increased both total 
NADP as well as NADPH/NADP ratio (Figure 31d), suggesting that PVRL4 may exert at least 
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some of its protective role on growth of cells in suspension via mitigating the metabolic defects 
experienced by epithelial cells upon their detachment from the matrix.  
However, restoring the antioxidant capacity of TL-HMECs via exogenous 
supplementation of medium with antioxidant compounds, NAC and Trolox, failed to protect TL-
HMECs from suspension-induced growth suppression (Figure 31e). This result suggests that 
restoring the antioxidant capacity of TL-HMECs alone is not sufficient for restoration of their 
proliferation in anchorage-deprived conditions, which is contrary to what has been previously 
observed in MCF10A cells. Further studies aimed at exploration of the significance of the effect 
of PVRL4 on cellular oxidative status and NADPH content, as well as the mechanism of this 
effect, are needed. Besides its role in maintaining the antioxidant capacity of the cell (such as 
through replenishing reduced glutathione), NADPH is also a molecule critical in biosynthesis of 
a number of macromolecules, and it would be of particular interest to explore whether PVRL4 
expression affects these anabolic processes inside the cell as well. 
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Figure 31. PVRL4 suppresses suspension culture-induced oxidative stress. a, TL-HMECs 
expressing PVRL4 or vector control were cultured in the absence of attachment for 96 hours. 
Cells were stained with carboxy-H2DCF-DA dye to measure reactive oxygen species (ROS) 
abundance. Dye fluorescence was quantified and normalized to total protein content. Values are 
expressed as relative to empty vector control. Assays were performed in triplicate (error bars ± 
SD). b, Carboxy-H2DCF-DA-stained cells from (a) were photographed to provide a visual 
representation of the ROS signal. c, SUM190 cells expressing anti-PVRL4 shRNA-3 and 
shRNA-4 or control shRNA were cultured as in (a) and relative ROS abundance was similarly 
determined. Values are expressed as relative to control shRNA sample. Assays were performed 
in triplicate (error bars ± SD). d, TL-HMECs expressing PVRL4 or vector control were cultured 
in the absence of attachment for 96 hours. Cell lysates were used for determining reduced 
NADPH and total NADP values for each sample. NADPH/NADP ratio was calculated using the 
following formula: NADPH/(total NADP – NADPH). e, TL-HMECs expressing PVRL4 or 
vector control in presence of solvent control or indicated antioxidants were assayed for viability 
under conditions of ECM deprivation by measuring total ATP content in cells cultured on ultra-
low attachment plates for 72 hours. Values were normalized to empty vector-transduced sample. 
Assays were performed in triplicate (error bars ± SD). 
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Figure 31 (Continued). 
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Materials and Methods 
ROS measurement. TL-HMEC or SUM190 cells transduced with indicated constructs 
were cultured on ultra-low attachment plates in their respective complete media with 1% 
methylcellulose (a thickening agent) for 96 hours. Cells were harvested and washed three times 
with cold PBS three times. A fraction of cells was used to determine total protein concentration 
via BCA assay (Pierce), and another fraction was labeled with carboxy-H2DCF-DA ROS sensor 
dye (C-400, Invitrogen). Carboxy-H2DCF-DA-stained cells were photographed and their 
fluorescence signal was measured with Victor X5 plate reader. A background fluorescence 
reading from “no cells” control was subtracted from the raw values, and the resulting numbers 
were normalized to total protein content. 
NADPH measurement. NADPH and total NADP levels from suspension-cultured TL-
HMEC lysates transduced with indicated constructs were determined using NADPH/NADP 
assay protocol (ab65349, Abcam) and normalized to protein content. NADPH/NADP ratio was 
calculated using the following formula: NADPH/(total NADP – NADPH).  
Anoikis assays in the presence of antioxidants. For anoikis assays, cells were cultured 
on ultra-low attachment plates (Corning) in reduced growth factor MEGM with 1% 
methylcellulose. Where indicated, 1 mM N-acetyl-cysteine (A7250, Sigma) or 50 μM Trolox 
(648471, EMD Biosiences) were added. Total ATP measurements were performed using 
CellTiterGLO reagent (Promega) according to the manufacturer’s protocol after 72 hours of 
growth in suspension, and luminescence values were read with Victor X5 plate reader. 
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Appendix IV: Alternative strategies for inducing TL-HMEC 
clustering and their effect on anchorage independent colony 
formation 
Background and Rationale 
We have discovered that PVRL4 drives anchorage independent growth of TL-HMECs in 
a manner that is dependent on its ability to potentiate cell-cell contacts via its counter-receptor 
PVRL1, whereas the transmembrane as well as cytoplasmic parts of the receptor and its counter-
receptor are dispensable and can be substituted by an unrelated transmembrane domain 
sequences. Furthermore, we have identified integrin β4 as an interacting partner of PVRL4. 
Importantly, RNAi against integrin β4 negatively affected (albeit not abolished) PVRL4-driven 
anchorage-independence, suggesting the functional relevance of integrin β4 –PVRL4 interaction 
to the observed phenotype. However, this finding does not rule out the possibility that PVRL4 
may affect cellular survival in a more than one way, in addition to recruiting integrin β4. 
Notably, as we also show, a number of distinct oncogenic perturbations induce cell-cell 
clustering. One intriguing possibility is the existence of a generalized prosurvival effect that the 
increased propensity for cell-to-cell attachment in suspension might convey. Such prosurvival 
effect can be mediated by, for example, local accumulation of growth factors, facilitation of 
extracellular matrix component deposition or creation of flattened surfaces in an otherwise 
rounded cells. To test whether the facilitation of cell-to-cell attachment by itself is sufficient for 
enhancing anchorage-independent survival, we sought alternative ways of potentiating cell 
clustering in TL-HMECs and assessed their effects on colony formation. 
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Results 
We tested two distinct strategies to induce cell-to-cell attachment. First, we used a 
monoclonal antibody against CD44 protein (clone H4C4) that was previously shown to induce 
self-aggregation of lymphocytes [301]. Similar to lymphocytes, TL-HMECs readily formed 
multicellular clusters in presence of H4C4 antibodies (Figure 32a). Plating a single-cell 
suspension of TL-HMECs into semi-solid medium in the presence of H4C4 resulted in a 
dramatic increase in anchorage-independent colony formation as compared to control IgG 
(Figure 32b). A caveat to this experiment is that CD44 protein itself can affect signaling events 
and therefore it is possible that H4C4 antibody perturbs cellular signaling in a manner that is not 
directly related to cell-cell clustering. Therefore, we decided to test whether a purely artificial 
inducer of cell-cell clustering will have an effect on anchorage-independence. We created a 
synthetic construct in which two tandem mutant FKBP dimerization domains (DmrD) with a 
propensity to form trans-dimers even in the absence of the ligand [302] were fused in frame into 
a construct with an N-terminal signal sequence and a C-terminal transmembrane domain derived 
from CD8 (Figure 32c). The DmrD-CD8tm construct was stably expressed in TL-HMECs and its 
membrane localization was confirmed by immunofluorescence (data not shown). DmrD-CD8tm 
promoted both cell clustering and anchorage-independent growth of TL-HMECs (Figure 32d, e), 
thus providing an additional demonstration that potentiation of cell-cell interaction is sufficient 
for inducing transformation. Taken together, these results suggest that the potentiation of cell-to-
cell attachment per se may be sufficient for at least some protection against suspension-induced 
death or growth arrest. 
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Figure 32. Alternative cell-cell clustering approaches and their effect on anchorage-
independent growth. a, TL-HMECs were assayed for cell-cell clustering in presence of H4C4 
(anti-CD44 mouse anti-human antibody (University of Iowa Developmental Studies Hybridoma 
Bank) antibody or control IgG at 4 μg/mL. Representative images are shown. b, Transformation 
of TL-HMECs was assayed in presence of H4C4 (anti-CD44) antibody or control IgG. Colony 
numbers were normalized to control sample. Transformation assays were performed in triplicate 
(error bars ± SD). c, A scheme depicting the DmrD-CD8tm construct design and binding 
strategy. d, TL-HMECs were transduced with empty vector or the DmrD-CD8tm construct and 
assayed for clustering. Representative images are shown. e, Transformation of TL-HMECs 
transduced with virus representing the empty vector, or virus expressing DmrD-CD8tm and 
PVRL4 was assayed as before. Colony numbers were normalized to the control sample. 
Transformation assays were performed in triplicate (error bars ± SD). 
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Materials and Methods 
To create a DmrD-CD8tm construct, a prHom-Nuc1 plasmid (iDimerize Reverse 
Dimerization System, Clontech) was used as a template in a PCR reaction with a forward primer 
containing CD8 signal sequence followed by a FLAG tag and a reverse primer containing CD8 
transmembrane domain sequence followed by a STOP codon. The resulting product was cloned 
into pQCXIN vector. 
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Appendix V: A whole genome loss-of-function genetic screen 
for suppressors of TL-HMEC transformation 
Background and Rationale 
In addition to gain-of-function screens, TL-HMEC transformation system can be used as 
a discovery tool for identifying negative regulators of transformation and, thus, potential tumor 
suppressors. Focused libraries of shRNAs have been successfully used by our group for 
identification of novel tumor suppressors REST [98] and PTPN12 [99] . We therefore set out to 
perform a whole-genome screen for negative regulators of anchorage-independent growth, taking 
advantage of an expanded, third-generation shRNA library in miR-30 context. This library 
provides a comprehensive coverage of 22,000 human genes with each gene targeted with 12 
individual shRNAs. The library is divided into 12 pools of equal complexity, each targeting 
approximately 1,800 genes. 
 
Results 
Each pool was screened separately in quadruplicate, with 100-fold library representation 
for each replicate and the multiplicity of infection of 0.2. For the high-throughput bioinformatic 
readout of shRNAs that become enriched among resulting colonies and thus are likely to be 
directed towards transformation suppressor, we took advantage of NextGen Illumina sequencing. 
To do this, we pooled all of the colonies that were formed within each of the four screen 
replicates and isolated total genomic DNA. To correct for the relative abundance of each shRNA 
in the starting material, we also isolated genomic DNA from the corresponding library-infected 
pools of cells prior to their plating into methylcellulose. For each genomic DNA sample, we 
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have recovered the antisense arm of the shRNA hairpin by PCR, followed by adding p5 and p7 
Illumina adapters in a second round of PCR (for the PCR strategy schematic, see Figure 33a). 
Resulting PCR products were then used as independent barcodes that we proceeded to sequence 
following the Illumina protocol (Figure 33b). 
For each of the four replicates of each of the twelve pools, we then calculated the 
enrichment score for each shRNA. Specifically, for each shRNA, we have determined the ratio 
of the number of sequencing reads in the end sample (represented by shRNAs recovered from 
anchorage-independent colonies) to the number of reads for the same shRNA in the start sample 
(represented by the library-infected cell population prior to introduction into anchorage-
independent conditions). As expected, a very small subset of shRNAs showed massive 
enrichment over the start sample, while the majority of shRNAs showed little or no enrichment. 
In order to be included on the list of potential candidates for the phenotypic validation, we have 
decided to apply a 10-fold enrichment cutoff for individual shRNAs recovered in each replicate. 
The reasoning behind this was that since each shRNA should be theoretically present in a 100 
cells in the start sample, a 10-fold enrichment in the end sample would correspond to a colony 
composed of 1000 or more cells. 
As a next step, for each gene from the library, we computed a so-called “gene score”, 
represented by the number of times each of the twelve shRNAs targeting a given gene appeared 
in four independent screen replicates plus the number of times any of the twelve shRNAs against 
this gene appearing across all four replicates. With this approach, we treated each of the twelve 
shRNAs as independent gene-specific events which allowed us to further expand the library 
representation and increase the discovery power of the screen. 
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We then have taken several further steps to refine the candidate list. First, we have 
performed expression profiling of TL-HMEC transcriptome in both attached and suspension 
cultures and excluding those genes that were not expressed in either condition from the candidate 
list. Second, we searched several publicly available copy-number, expression and mutation 
datasets for those genes from the list that had evidence of being altered in various tumors. 
Finally, we have performed literature searches to identify those genes that were previously 
shown to be involved in regulation of cellular growth and survival. In total, our list of putative 
candidate transformation regulated contained 697 candidate genes. 
We then began individual validations of the anchorage-independence phenotype with the 
candidate shRNAs that met the cutoff standards listed above. The absolute colony numbers from 
validation experiments that have been performed so far are shown in Figure 34. The current 
direction of this project is to carry out the individual validations of all the genes from the list of 
candidates with at least two shRNAs. 
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Figure 33. Illumina sequencing strategy. a, A schematic of a two-stage PCR protocol for the 
recovery of an antisense arm of an shRNA from genomic DNA of virus-transduced cells (PCR1) 
followed by the addition of p5 and p7 adaptor arms for Illumina sequencing (PCR2). b, A 
detailed structure of the PCR2 amplicon. The variable (antisense) part is highlighted in purple 
and the sequence to which Illumina sequencing primer miR-30-EcoRI anneals is highlighted in 
blue. 
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Figure 34. Validation of candidate anchorage-independence suppressors. Candidate shRNAs 
were de novo synthesized and subcloned into miR-30 context vector. TL-HMECs were 
transduced with indicated shRNAs or control shRNAs and their ability to form colonies in 2% 
methylcellulose was assayed exactly as before. 
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